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Summary 
I 
Summary 
Despite ongoing efforts, HIV-1 (the causative agent of AIDS) remains an unresolved health 
threat. Even though current therapy approaches efficiently block ongoing viral replication they 
cannot cure the infection due to the presence of a latent reservoir. It is of crucial importance to 
understand that this viral reservoir can fuel new rounds of viral replication and spread the 
infection. The viral reservoir is defined as cells (best-characterized are resting memory CD4+ 
T cells) harboring a replication-competent provirus while not producing new progeny virus, a 
state that can be reversed. Strategies to eradicate the viral reservoir include the so-called 
‘shock and kill’ approach, which is a two-step process, aiming in the first step to reactivate the 
latent reservoir, leading to the production of new viruses. In a second step, denoted as ‚kill’, 
death of those virus-producing cells is induced by specific cells of the immune system. The 
identification of host factors involved in HIV-1 latency formation and maintenance is therefore 
a crucial step to support this and also other strategies. 
This current study aimed at validating novel host factors involved in HIV-1 latency. For this, the 
results of a genome-wide siRNA screen performed in HEK293T cells infected with a single-
cycle HIV-1 reporter virus expressing luciferase (HIVluc), served as starting point. This model 
elucidates potential host factors important for HIV-1 transcriptional processes and is per se not 
a model for HIV-1 latency, as luciferase is constantly expressed from the viral promoter. 
Nevertheless, we hypothesize that there is a certain overlap in host factors, which not only 
have an influence on HIV-1 transcription but also on latency formation/maintenance. This 
assumption was confirmed by publications on two host factors, namely BRD4 and CYLD, which 
were reported to be important for the maintenance of HIV-1 latency but were also identified in 
the primary screen to influence HIV-1 luciferase expression. Two differential approaches were 
followed to choose and validate initial screening hits: For the first approach, follow-up hits were 
chosen based on their capability to bind and/or modify chromatin. This selection criterion is 
based on the importance of the chromatin environment for the formation and maintenance of 
HIV-1 latency. In a first set of experiments, the initial screening setup was recapitulated for a 
selection of hits and TRRAP, an adaptor protein found in multiprotein chromatin complexes 
and involved in epigenetic regulation of transcription, was reconfirmed as hit. Further 
experiments aimed to identify a potential role of TRRAP in HIV-1 latency. For this, J-Lat cells, 
a Jurkat derived latency cell model, were depleted of TRRAP by shRNA or siRNA and 
stimulated with various latency reversing agents (LRAs) to test for an additive effect on latency. 
Despite intensive testing, a clear involvement of TRRAP on latency could not be definitely 
determined. 
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In the second approach, follow-up hits were chosen based on the availability of commercially 
available compounds, which target the respective primary hits. This approach is here referred 
to as druggability. Several compounds were chosen and tested for their potential action on 
latency reversal alone or in combination with LRAs. Auranofin was identified to enhance 
reversal of latency when applied in combination with all tested LRAs, i.e. TNFα, prostratin, 
SAHA or sodium butyrate in J-Lat cells and in combination with SAHA and sodium butyrate 
when tested in U1 cells. Following the identification of auranofin, compounds affecting the 
same proposed targets, i.e. PRDX5, and its upstream pathway member, i.e. TXNRD1, involved 
in the thioredoxin pathway, were tested. Whereas none of the additional compounds 
recapitulated the exact effect of auranofin, diminazene was identified to also have an effect on 
latency reversal, which was most effective when applied in combination with either TNFα or 
prostratin. This effect was much stronger than the one seen for auranofin, but was cell line 
specific as the effect was only seen in J-Lat but not in U1 cells. Verification of auranofin’s (and 
diminazene’s) proposed targets was tested by siRNA-mediated silencing, demonstrating a 
marginal increase in latency reversal, pointing towards the involvement of the associated 
system in latency reversal. Based on literature, auranofin targets the thioredoxin system 
involved in reactive oxygen species (ROS) detoxification and reduction of oxidized proteins. 
This process is crucial for the integrity of the cell. Diminazene, on the other hand, is likely to 
target the polyamine homeostasis, which participates in a plethora of processes and 
interactions. An imbalance in polyamines might also lead to a higher level of oxidized products, 
potentially linking it to the cellular redox state. Whether those pathways are interconnected 
needs to be determined in future studies. Nevertheless, both the redox system and the 
polyamine homeostasis are of crucial importance for the cell with a wide range of possible 
consequences upon their perturbation, which are likely to affect the proviral state.  
In summary, in an unbiased systems-level approach, we identified two compounds that 
mediate latency reversal in combination with other LRAs. We propose further investigation of 
the two systems targeted by those compounds, which have not been (extensively) studied for 
an involvement in HIV-1 latency as they could support the targeting of the latent reservoir. 
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Zusammenfassung 
Trotz anhaltender Bemühungen bleibt HIV-1 (der Erreger von AIDS) eine ungelöste 
Gesundheitsbedrohung. Gegenwärtige Therapieansätze blockieren effizient den viralen 
Lebenszyklus, können die Infektion jedoch nicht heilen, aufgrund des Vorhandenseins eines 
latenten Reservoirs. Es ist von entscheidender Bedeutung zu verstehen, daß das latente 
Reservoir neue Runden viraler Replikation initiieren und damit die Infektion weiter verbreiten 
kann. Das latente Reservoir ist definiert als Zellen (am besten charakterisiert sind ruhende 
CD4+ T-Gedächtniszellen), die replikationskompetentes Provirus in ihrem Genom 
beherbergen können, ohne aktiv neue Viren zu produzieren, wobei dieser Zustand umkehrbar 
ist. Zu den Strategien der Reservoir Beseitigung gehört unter anderem der sogenannte "shock 
and kill" Ansatz, bei dem es sich um einen zweistufigen Prozess handelt, der im ersten Schritt 
darauf abzielt, das latente Reservoir zu reaktivieren und neue Viren zu produzieren. In einem 
zweiten Schritt, der als "kill" bezeichnet wird, wird der Tod dieser virusproduzierenden Zellen 
durch bestimmte Zellen des Immunsystems induziert. Die Identifikation von Wirtsfaktoren, die 
an der Etablierung und Aufrechterhaltung von HIV-1-Latenz beteiligt sind, ist daher ein 
entscheidender Schritt für diesen Therapieansatz (und andere). 
Diese Studie hatte zum Ziel, Wirtsfaktoren zu validieren, die an HIV-1-Latenz beteiligt sind. Als 
Ausgangspunkt dienten hierzu die Ergebnisse eines genomweiten siRNA-Screenings in 
HEK293T-Zellen, die infiziert waren mit einem HIV-1 Reportervirus das Luciferase exprimiert. 
Dieses Modell deckt Wirtsfaktoren auf, die potenziell an HIV-1 Transkription und Translation 
beteiligt sind, und ist an sich kein HIV-1 Latenzmodel, da Luciferase ständig vom viralen 
Promotor exprimiert wird. Dennoch gehen wir davon aus, dass es eine Überlappung von 
Wirtsfaktoren gibt, die nicht nur eine Rolle bei der HIV-1 Transkription spielen, sondern auch 
an der HIV-1 Latenz Etablierung/Beibehaltung. Diese Annahme wurde durch 
Veröffentlichungen von zwei Wirtsfaktoren bestätigt, nämlich BRD4 und CYLD, die Einfluss 
auf HIV-1-Latenz nehmen und ebenfalls im primären Screening identifiziert wurden. Für die 
Auswahl und Validierung primärer Screening-Treffer wurden zwei unterschiedliche Ansätze 
verfolgt: Für den ersten Ansatz wurden Folgetreffer auf der Grundlage ihrer Fähigkeit, 
Chromatin zu binden und/oder zu modifizieren, ausgewählt. Dieses Auswahlkriterium basiert 
auf der Bedeutung der Chromatinumgebung für die Bildung und Aufrechterhaltung der HIV-1 
Latenz. In einer ersten Reihe von Experimenten wurde das primäre Screening-Experiment 
rekapituliert und TRRAP, ein Adaptorprotein, das in Multiprotein Chromatinkomplexen 
vorkommt und an der epigenetischen Transkriptionsregulation beteiligt ist, wurde erneut als 
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Treffer bestätigt. Weitere Experimente zielten darauf ab, eine mögliche Rolle von TRRAP in 
der HIV-1-Latenz zu identifizieren. Dafür wurden J-Lat Zellen verwendet, ein von Jurkat-Zellen 
abstammendes Latenzmodel, die durch shRNA oder siRNA TRRAP depletiert wurden, gefolgt 
von Stimulierung mit verschiedenen latenzumkehrenden Wirkstoffen (LRAs), um einen 
additiven Effekt auf die Latenz zu testen. Trotz intensiver Tests konnte keine eindeutige 
Beteiligung von TRRAP an HIV-1-Latenz beobachtet werden. 
Im zweiten Ansatz wurden Folgetreffer ausgewählt, die durch kommerziell erhältliche 
chemische Substanzen, inhibiert werden können. Dieser Ansatz wird hier als „Druggability“ 
bezeichnet. Mehrere Substanzen wurden ausgewählt und auf ihren möglichen Einfluß auf die 
Latenz allein oder in Kombination mit LRAs getestet. Es wurde festgestellt, dass Auranofin die 
Umkehrung der Latenz erhöht, wenn es in Kombination mit allen getesteten LRAs, sprich 
TNFα, Prostratin, SAHA oder Natriumbutyrat, in J-Lat Zellen und in Kombination mit SAHA 
und Natriumbutyrat in U1 Zellen angewandt wird. Nach der Identifizierung von Auranofin 
wurden Substanzen, welche dieselben Wirtsfaktoren ansteuern, d.h. PRDX5 und sein 
übergeordneter Partner TXNRD1, die am Thioredoxin System beteiligt sind, getestet. Hierbei 
wurde keine Substanz gefunden, die den Effekt von Auranofin identisch rekapitulierte, aber 
Diminazen wurde identifiziert, die Latenz zu beeinflussen. Am wirksamsten war die 
Anwendung von Diminazen in Kombination mit TNFα oder Prostratin, der erzielte Effekt war 
wesentlich höher als der von Auranofin erzielte Effekt, war allerdings Zelllinien spezifisch, da 
dieser nur in J-Lat aber nicht in U1 Zellen gefunden wurde. Die Bestätigung des vermeintlichen 
Targets von Auranofin (und Diminazen) durch siRNA-Versuche zeigte einen kleinen Effekt und 
unterstützt die Vermutung, dass das assoziierte System wirklich das Ziel der Substanz(en) ist. 
Basierend auf Literaturangaben, beeinflußt Auranofin das Thiol-redoxin Sytem, welches an 
der Reduktion von reaktive Sauerstoffspezien und oxidierte Proteine beteiligt ist. Die 
Funktionalität dieses Prozesses ist von entscheidender Wichtigkeit für die Zelle. Diminazen, 
auf der anderen Seite, beeinträchtigt wohl das Polyamin Gleichgewicht, welches an einer Fülle 
von Prozessen und Interaktionen beteiligt ist. Ein Ungleichgewicht in der Polyamin 
Homöostase könnte den zellulären Redox Status beeinflussen. Dies könnte auf eine 
Verbindung zwischen den beiden Systemen hindeuten. Ob diese Systeme allerdings wirklich 
miteinander verbunden sind oder nicht, muß experimentell bestätigt werden. Nichtdestotrotz, 
sind beide Systeme von hoher Bedeutung für die Zelle mit weitreichenden Konsequenzen und 
somit ist auch ein potentieller Einfluss auf den Status des Provirus wahrscheinlich.  
Zusammenfassend läßt sich sagen, daß wir in einem unvoreingenommenen                      
System-basierenden Ansatz zwei Substanzen identifiziert haben, die eine Umkehrung der 
Latenz in Kombination mit anderen LRAs vermitteln. Wir schlagen vor, beide Systeme, die 
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Targets von diesen Substanzen sind, genauer zu untersuchen, da dies bis dato noch nicht 
(intensiv) getestet wurde hinsichtlich eines Einflusses auf HIV-1 Latenz. Das Targeting dieser 
Systeme könnte helfen das latente Reservoir angreifbar zu machen.
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1 Introduction 
1.1 HIV - the virus and its life cycle  
The human immunodeficiency virus (HIV) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS) (Weiss, 1993). Since the beginning of the current 
epidemic in mid- to late 1970s (Greene, 2007), HIV/AIDS caused more than 35 million of 
deaths. By the end of 2017, over 36.9 million people were infected with HIV 
(http://aidsinfo.unaids.org/). And despite ongoing efforts in preventing disease transmission, 
allowing access to medication, financing education and research, HIV still remains one of the 
major public health issues today.  
HIV originated from at least two independent zoonotic transmissions of the simian 
immunodeficiency virus (SIV) from chimpanzee (SIVcpz) and has diversified into several 
subtypes and clades (Gao et al., 1999). The HIV-1 M (major) group is the cause of the ongoing 
epidemic. The other type, HIV-2, has occurred via cross species transmission from SIV 
infected sooty mangabey monkeys (SIVsmm) (Sharp and Hahn, 2011). HIV-2 is geographically 
confined to western Africa, is less virulent and shows a lower level of transmission upon 
exposure when compared to HIV-1 (Berry et al., 2002; Popper et al., 2000). HIV-2 will be not 
further considered in this scientific work. 
HIV is member of the Retroviridae family and belongs to the genus Lentivirus. It is assigned to 
group VI of the Baltimore classification possessing two copies of a positive-sense single-
stranded RNA genome, which replicates via a DNA intermediate. The virus encodes for nine 
genes: three structural genes gag (group specific antigen), pol (polymerase, encoding the 
reverse transcriptase and integrase) and env (envelope glycoprotein), two regulatory genes 
tat and rev, and four accessory genes nef, vif, vpr, and vpu (and vpx in case of HIV-2) (Vogt, 
1997). A graphical scheme of the viral genome organization is shown in Figure 1A. 
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Figure 1: Genomic organization and virus composition of HIV-1. A) Organization of HIV-1 coding 
regions. B) Simplified presentation of HIV-1 particle. env= envelope, gag= group specific antigen, LTR= 
long terminal repeat, nef= negative regulatory factor, pol= polymerase, tat= transactivator of 
transcription, vif= viral infectivity factor, vpu= viral protein u, vpr= viral protein r. Adapted from Saliou et 
al., 2009. 
 
The viral RNA genome is associated with viral proteins and enclosed by a conical shaped 
capsid made from p24, i.e. product of multiple cleaved Gag protein. A scheme of an HIV-1 
virus is shown in Figure 1B. The capsid is further surrounded by matrix proteins and enveloped 
with cell derived lipid bilayer spiked with Env glycoprotein complexes, which mediate the first 
step in the viral life cycle, i.e. binding. A simplified graphical presentation of the life cycle is 
shown in Figure 2. Binding of the Env derived glycoprotein complex to its target receptor 
cluster of differentiation 4 (CD4), followed by co-receptor binding to either CC chemokine 
receptor 5 (CCR5) or CXC chemokine type 4 (CXCR4) (Wilen et al., 2012) leads to a 
conformational change in the glycoprotein and initiates fusion with the target cell membrane 
and release of the viral capsid into the cytoplasm. The viral RNA genome is reverse transcribed 
by the viral reverse transcriptase into double-stranded DNA (Hu and Hughes, 2012), 
transferred to the nucleus and integrated by the viral integrase into the host genome (Craigie 
and Bushman, 2012). The integrated virus is termed provirus. Upon integration, HIV-1 exploits 
the host transcription machinery. The preinitiation complex consisting of nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB), nuclear factor of activated T cells (NFAT), 
and specificity protein (Sp1) facilitates RNA polymerase II binding to the viral promoter, i.e.     
5’ LTR, leading to low levels of viral transcripts (Roebuck and Saifuddin, 1999). Those 
transcripts are enough to form the trans-activator of transcription (Tat). Tat greatly enhances 
viral transcription and viral full-length mRNA production by binding to the trans-activating 
response element (TAR), an RNA stem-loop structure, following the recruitment of the positive 
transcriptional elongation factor (P-TEFb) consisting of cyclin dependent kinase 9 (CDK9) and 
1A B 
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cyclin T1 (Nilson and Price, 2011). The viral mRNAs are exported into the cytoplasm, 
translation leads to viral protein formation, following assembly of immature virions including 
the packaging of the viral RNA genome and finally release via budding and maturation by viral 
protease.  
 
 
Figure 2: Simplified overview of the HIV-1 viral life cycle. The life cycle of HIV-1 follows defined 
steps, starting with attachment to the target cell, followed by entry, reverse transcription and integration 
into the host genome, synthesis of de novo viral proteins and assembly of those into new viral particles 
and their release. Possibilities to block the viral life cycle are indicated by red blocking lines RT= reverse 
transciptase. Adapted from Han et al., 2007. 
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1.2 HIV-1 disease progression and therapy 
An untreated HIV-1 infection will progress towards AIDS development within three stages over 
the course of years and disease progression can be correlated to the viral load and to the 
counts of HIV-1 target cells, i.e. CD4+ T lymphocyte counts (see Figure 3). The first stage, the 
acute infection phase, develops with flu-like symptoms within the first two to four weeks upon 
infection. During this time, the virus highly replicates and disseminates throughout the body, 
and CD4+ T lymphocyte counts decrease drastically. This picture partially reverses, the viral 
load drops and CD4+ T cell counts slightly recover (Perelson et al., 1997). This marks the 
beginning of the second phase. The second phase also known as the chronic phase, or 
asymptomatic phase, can last on average eight years and infected individuals do not show 
disease symptoms even though the viral load is slowly increasing while CD4+ T cells counts 
are slowly decreasing. The transition into the final phase, the symptomatic phase, is marked 
by the onset of diverse physical symptoms. The constant depletion of CD4+ T cells finally leads 
to an impaired immune system and opportunistic infections emerge. An untreated infected 
person will die due to the absence of an intact immune system (RKI-Ratgeber - HIV-
Infektion/AIDS). 
 
 
Figure 3: Overview of HIV-1 disease progression. Disease progression is measured by CD4+ T cells 
counts in blue (left y-axis) and by viral load in red (right y-axis) in dependency of time (Pantaleo et al., 
1993). 
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The first HIV-1 treatment was introduced as monotherapy in the late 1980s using 
azidothymidine (AZT) to block the reverse transcription step (Mitsuya et al., 1985), which is an 
essential step in the viral life cycle, but viral resistances quickly developed (Richman, 1990). 
Since the introduction of the highly active antiretroviral therapy (HAART, also known as the 
combined antiretroviral therapy (cART)) in 1995, disease progression towards AIDS can be 
halted (Egger et al., 1997; Palella et al., 1998; Perelson et al., 1997). Current recommendations 
for initial HAART regimens suggest a combination of three drugs, to effectively block the viral 
life cycle at various steps and to avoid the occurrence of viral resistances (“WHO | Updated 
recommendations on first-line and second-line antiretroviral regimens and post-exposure 
prophylaxis and recommendations on early infant diagnosis of HIV,” 2019). HAART adherence 
will lead to a decline in the viral load below the detection limit of clinical assays and in line with 
this the likelihood of HIV-1 transmission is drastically reduced (Baeten and Overbaugh, 2003). 
Further, the life expectancy of an HIV-1 infected person who adheres to therapy is comparable 
to the life expectancy of an HIV-1 negative person (Wandeler et al., 2016). Despite the 
treatment advances, HAART is not a cure as it only suppresses ongoing HIV-1 infection. 
Therefore, adherence to therapy is a prerequisite to keep the viral loads below detection limit, 
which comes at the price of a daily and lifelong medication intake, to potential toxicities due to 
the long-term intake and at high expenses. While interruption of HAART will lead to viral 
rebound, occurrence of viral escape mutants and disease progression (Davey et al., 1999; 
Wang et al., 2011). This phenomenon of HIV persistence can be explained by the presence of 
a latent reservoir, i.e. cells harboring an intact provirus without producing viral products. 
Latently infected cells are not recognized by the immune system due to the absence of viral 
products and persist within the body for decades (Margolis, 2010). But latency is a reversible 
process and previously latent cells can be induced to produce and release progeny viruses to 
fuel new rounds of infection and spread of infection and reseeding of the viral reservoir. 
Therefore, current HIV research efforts are focusing on the comprehensive understanding of 
the latent reservoir. It is important to stress that a cure from HIV-1 infection will be only 
achieved if this reservoir is targeted. 
In summary, the crux with HIV-1 infection is that it forms a latent reservoir, a tiny fraction of 
infected cells, which do not produce new viruses. But they can give rise to new progeny 
viruses, if latency is reversed and this in turn will start over the infection process. In the 
following sections the current understanding of latency establishment and reservoir formation 
are compiled, followed by the different current curing strategies. 
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1.3 Latency establishment - molecular mechanisms 
Successful full-length viral transcription is needed as initial step towards the production of 
progeny virus and viral spread. Reversely, impairment of viral transcription will support the 
formation of latency, which can be evoked by several mechanisms and orchestrated from 
several levels. Up to now, several host factors have been identified to directly or indirectly 
affect latency formation. The different levels, which can independently but also jointly 
contribute to latency formation and maintenance, are highlighted below. Nevertheless, it is 
important to keep in mind, that true latent cells are very rare. 
 
1.3.1 From the viral side - the presence of Tat 
From the viral side, the absence of sufficient levels of Tat can be regarded as driver of latency. 
It was experimentally shown that Tat expression in trans inhibits latency formation (Pearson et 
al., 2008). Tat is a master regulator of HIV-1 transcription, which exploits the host machinery 
to efficiently increase viral transcription, if Tat levels exceed its threshold (Das et al., 2011).  
 
1.3.2 Presence of transcription factors 
From the cellular side, the absence of key transcription factors as e.g. NFκB p65/p50 
heterodimers or NFAT impair initiation of transcription (Kinoshita et al., 1997; Nabel and 
Baltimore, 1987; Selliah et al., 2006; Yang et al., 1999). Those immediate acting transcription 
factors are usually kept in their inactive form or are sequestered but can be induced by external 
stimuli as e.g. by cytokines, growth factors, stress to viral and bacterial infections, without the 
need to be synthesized (Hiscott et al., 2001). Those transcription factors play a pivotal role in 
many cellular processes as cell differentiation, proliferation, immune responses and apoptosis. 
Due to this they are tightly regulated and constant activation of those has been linked to cancer 
development.  
NFκB is kept in the cytoplasm by its interaction with IκB. Upon activation of diverse signaling 
pathways, IκB is phosphorylated by IκB kinase (IKK) complex, freeing NFκB complex which 
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translocate into the nucleus and initiates transcription of target genes including the provirus 
(Thompson et al., 1995). Cylindromatosis (CYLD) is a deubiquitinase, which targets IκB, which 
in turn prevents phosphorylation of IκB by IKK and therefore inhibits NFκB translocation 
(Mathis et al., 2015; Sun, 2010). Knockdown of CYLD has been shown to support reversal of 
latency (Manganaro et al., 2014). CYLD has been identified as hit in the initial screening and 
will be used as positive control.  
 
1.3.3 Overcoming stalled RNA polymerase 
Beyond the need of those positive acting transcription factors as NFκB, also RNA polymerase 
II (RNA Pol II) proximal-promoter pausing needs to be overcome to allow full-length production 
of pre-mRNA (Core and Lis, 2008; Zhou et al., 2012). Pausing of RNA Pol II shortly after 
initiation is an essential step in regulating gene expression. The P-TEFb complex is a key 
player in releasing this block. P-TEFb modifies the DRB sensitivity factor (DSIF) (Bourgeois et 
al., 2002), which leads to the displacement of the negative elongation factors (NELF) (Pagano 
et al., 2014; Wenzel et al., 2008) and stalled RNA pol II is released. Also, HIV-1 Tat is 
dependent on P-TEFb for full-length proviral mRNA procession. Since P-TEFb is of crucial 
importance for successful transcription by RNA Pol II, it is not surprising that it is tightly 
regulated on various levels.  
Interestingly, P-TEFb is often found in association with bromodomain-containing protein 4 
(BRD4), which supports the recruitment of P-TEFb to genes and their successful transcription 
(Jang et al., 2005). The bromodomain of BRD4 is an acetyllysine-binding motive and been 
found to bind acetylated histones (Dey et al., 2003). In the case of HIV-1 transcription, Tat 
relies and binds P-TEFb complex to achieve full-length viral mRNA procession and is in direct 
competition with BRD4, as they share the same P-TEFb binding site (Bisgrove et al., 2007). 
Knockdown of BRD4 or its inhibition by JQ1 has been found to support reactivation of latent 
HIV (Bisgrove et al., 2007; Li et al., 2013). Also, BRD4 has been identified as hit in the initial 
screening and will be used as positive control. 
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1.3.4 Modulation of chromatin 
Changes in the chromatin i.e. epigenetic changes evoke another level of latency regulation 
and can support latency formation and maintenance. The DNA is spooled around 
nucleosomes, which form the basic building unit of chromatin and consist of DNA wrapped 
around a histone octamer, composed of each two proteins of H2A, H2B, H3 and H4 (Alberts 
et al., 2002; Luger et al., 1997). Histones are subjected to a variety of reversible modifications 
as methylation, acetylation, and phosphorylation among others (Luger and Richmond, 1998). 
The formation of densely packed chromatin, i.e. the formation of heterochromatin, can render 
whole regions transcriptionally silent, which can also affect the provirus. Even though it has 
been shown that HIV-1 preferentially integrates into intragenic regions of actively transcribed 
genes (Han et al., 2004; Lewinski et al., 2005). Nevertheless, the viral promoter has been 
found to be associated with two nucleosomes, i.e. Nuc-0 and Nuc-1 (Verdin et al., 1993), which 
is independent of its integration site. Nuc-1 is being situated around the proviral transcription 
start site and might impose a block to transcription. Those blocks can be derived from 
deacetylation of histone tails by a family of enzymes called histone deacetylases (HDACs), 
which leads to removal of acetyl groups from histone tails and with that to a spatial 
inaccessibility of transcription factors to the (viral) promoter (Yoshida et al., 2017). The action 
of HDACs can be reversed by histone acetyltransferase or by compound inhibition of HDACs. 
Also, histone methylation by histone methyltransferases (HMTs) as for example SUV39H1 (du 
Chéné et al., 2007), G9a (Imai et al., 2010) or EZH2 (Zhang et al., 2015) has been described 
to evoke a silencing effect by di- or tri-methylation of lysine residues on histones. Further, 
EZH2 is also being a partner in forming a repressive complex, which serves as binding platform 
for other chromatin remodelers and supporting by this heterochromatin formation (Friedman 
et al., 2011). The modification of histones is a reversible process and can be achieved e.g. by 
external stimuli which act for example by releasing NFκB heterodimer into the nucleus, which 
will in turn recruit co-activator complexes with histone acetyltransferase activity, leading to a 
remodeling of histones e.g. the proviral associated Nuc-1 and accessible DNA (Gerritsen et 
al., 1997; Perkins et al., 1997; Sheppard et al., 1999).  
Further, direct DNA methylation, i.e. the formation of CpG islands, at the transcription start site 
has been shown to repress viral gene transcription (Blazkova et al., 2009, 2012; Palacios et 
al., 2012). It shall be noted, that gene transcription is a complex process, which includes the 
recruitment of many different factors, which in turn either directly or indirectly bind DNA or 
histones and consequently allow gene transcription. This process is tightly regulated on many 
different levels. 
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1.3.5 Proviral integration site and orientation 
Another latency driving point is the integration site selection. HIV-1 predominately integrates 
into intronic regions of actively transcribed genes (Han et al., 2004; Schröder et al., 2002) with 
a preference for the open chromatin found in the outer shell of the nucleus, i.e. close to the 
nuclear membrane, and in close connection to nuclear pores (Marini et al., 2015). This is 
supported by findings showing that the components of the nuclear pore complex influence  
HIV-1 infection (König et al., 2008). In addition, also the viral integrase influences the choice 
of integration site, which needs to occur fast due to its short half-life (Manganaro et al., 2010). 
Further, also the orientation of provirus in relation to the host gene can influence latency 
establishment, as this may give rise to transcriptional interference. Known processes involve 
promoter occlusion and collision, which can give rise to read-through products or the absence 
of products (Greger et al., 1998; Han et al., 2008). 
 
1.3.6 Post-transcriptional regulation 
In addition, post-transcriptional regulation may also impact latency formation and maintenance, 
for example by retention of HIV-1 mRNA within the nucleus, or by regulation via host derived 
microRNAs (Huang et al., 2007; Van Lint et al., 2013) which can negatively impact on the 
newly formed viral mRNA or indirectly by affecting mRNAs levels of host factors needed 
(Ahluwalia et al., 2008). 
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1.4 HIV-1 target cells and reservoir formation 
The target cells of HIV express CD4 as well as one of the chemokine co-receptors, i.e. CCR5 
or CXCR4. Those surface receptors are found on CD4+ T cells as well as on monocytes/ 
macrophages and on other cell types, whereas CD4+ T cells are the major target of HIV-1. 
CD4+ T cells form a major part of the adaptive immunity orchestrating a panel of immune 
responses by e.g. supporting B cells in producing antibodies, activating macrophages, 
recruiting neutrophils and other immune cells through direct cell interaction or by the release 
of specific chemokines and cytokines (Zhu and Paul, 2008). They are originating in the bone 
marrow; transit to the thymus and further to the secondary lymphoid organs. Those cells are 
termed naïve CD4+ T cells since they have not encountered their specific antigen. Upon 
exposure to their specific antigen via professional antigen presenting cells (APCs), they 
become activated and turn into CD4+ T effector cells, which rapidly proliferate and activate 
other cells of the immune system in order to clear the body from the encountered antigen 
(Germain, 2002). The mounted immune response is stopped once the antigen is cleared and 
effector cells undergo apoptosis, while only a few will transition to become memory T cells. 
Those cells form a big part of the immunological memory and scan the environment for a 
reencounter with its specific antigen, being now able to mount an immune response faster and 
more efficient than upon its initial encounter (MacLeod et al., 2010). Since there are a broad 
range of CD4+ T effector cells, it is not surprising that there is also a heterogeneous population 
of CD4+ T memory cells, as e.g. TCM (central memory), TTM (transitional memory) and TEM 
(effector memory) among others (Sallusto et al., 2004). T cell differentiation and memory 
formation is only incompletely understood but interaction with other cells, antigen exposure 
time and cytokine environment play a critical function. The differentiation of subtypes was 
initially based on their cell surface receptor expression, but differentiation based on their 
effector T cell origin or their tissue migration pattern might help to better classify and to 
sophistically distinguish the different CD4+ memory T cells (Mahnke et al., 2013). Nevertheless, 
the shared feature of all memory T cells is their capability to persist in the body for years either 
by homeostatic proliferation or by low-level antigen-driven proliferation (Chomont et al., 2009). 
Those cells show lower levels of metabolism and RNA synthesis and are as well decreased in 
size when compared to effector CD4+ T cells.  
The CD4+ T memory cells are the main and best-characterized reservoir for latent HIV-1 
infection, which is experimentally supported as progeny virus can be recovered from those 
cells after stimulation (Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997). This reservoir 
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is seeded early during infection. Thus, early administration of HAART leads to a reduced and 
genetically less divergent reservoir but does not inhibit reservoir formation (Chun et al., 1998; 
Eriksson et al., 2013; Strain et al., 2005).  
Whether HIV-1 infects memory CD4+ T cells directly or infects effector CD4+ T cells which 
transition into memory CD4+ T cells is a matter of ongoing debate. It is generally accepted that 
effector CD4+ T cells are easily infected by HIV-1, which leads to a productive infection causing 
the formation and release of new infectious progeny viruses. When those cells become 
infected, most of them die within a short time due to the viral cytopathic effect or by cytotoxic 
T lymphocytes (CTL) induced cell death (Wei et al., 1995). The establishment of a latent 
infection in these cells might strictly depend on the right timing, i.e. the virus needs to infect 
the effector T cell at a moment when reverse transcription and integration can still happen 
while the cell is undergoing transition to become a memory T cell, a process which also 
involves chromatin rearrangement and differential gene expression, which also affects the 
provirus (Pace et al., 2011). One the other hand, ex vivo infection of primary CD4+ memory T 
cells has been experimentally shown. Even though this process is less efficient, as memory 
CD4+ T cells possess e.g. lower levels of CCR5 on their cell surface (Pierson et al., 2000) as 
well as lower dNTP levels (Baldauf et al., 2012; Goldstone et al., 2011) which negatively affects 
cell entry and reverse transcription. In any case, it shall be noted that latency formation is a 
rare process and one in one million memory T cells will carry a provirus that can be reactivated 
(Eriksson et al., 2013). The absence of viral products in latently infected cells renders those 
cells invisible to the immune system and so far, also no surrogate marker has been identified 
to allow direct targeting of infected cells. (Of note, CD32a, a member of the Fcγ receptor family, 
has been proposed as latency marker (Descours et al., 2017) while it could not been 
reproduced by others (Abdel-Mohsen et al., 2018; Badia et al., 2018)). On the other hand, 
activation of memory CD4+ T cells, by its cognate antigen, will likely induce proviral 
transcription. 
Of note, most studies on the latent reservoir have been carried out using CD4+ memory T cells 
isolated from patient blood, as it easy to sample. But it might not capture the complete picture 
as not all memory cells are circulating as seen for tissue resident memory CD4+ T cells (Wu et 
al., 2018). Further, HIV-1 positive cells can also be recovered from the lymph nodes, the                      
gut-associated lymphoid tissues and from the central nervous system. Here, a potential 
influence of the prevalent microenvironment in those tissues cannot be excluded.  
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In addition, the participation of other cells in supporting viral dissemination as e.g. proposed 
for dendritic cells, and serving as potential reservoir, as e.g. proposed for macrophages and 
microglial cells is not fully elucidated but might put an additional level of complexity on 
understanding HIV-1 persistence.  
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1.5 Curing HIV-1 - what approaches are considered? 
Finding a cure to HIV infection is the holy grail of ongoing research efforts and will only be 
achieved upon targeting of the latent reservoir. One differentiates between a sterilizing cure 
and a functional cure. In terms of sterilizing cure, no replication-competent proviruses will be 
found in a patient, the virus is eradicated from the patient (Xu et al., 2017). This type of cure 
will be difficult to achieve and even more difficult to prove due to limitations in e.g. the current 
HIV detection systems. A functional cure will be more likely achieved and can be described as 
remission, i.e. replication competent proviruses are present in the host, but no viral load can 
be detected, while HAART is not applied. Current curing efforts can be categorized in mainly 
four differential approaches (albeit more strategies will likely arise), as are stem cell 
transplants, genome editing, immune modulation and ‘shock and kill’, even though the 
categorization is not clearly defined and different strategies show overlap, share techniques or 
targets. In the following the main approaches are shortly summarized, but for this scientific 
work only the ‘shock and kill’ approach is of importance. 
 
1.5.1 Stem cell transplant 
The first person to be considered cured from HIV-1 was Timothy Brown, the so-called Berlin 
patient, and the achieved cure can be considered a sterilizing one. He received a stem cell 
transplant after chemotherapy failed to stop his leukemia. The transplant he received was from 
a donor carrying a homozygous ∆32 mutation in the CCR5 gene, which rendered the newly 
produced immune cells resistant to HIV-1 infection (Allers et al., 2011; Henrich et al., 2014; 
Hütter et al., 2009). The same approach was undertaken for the so-called London patient and 
the Dusseldorf patient, who are now considered patient two and three to be cured (Gupta et 
al., 2019). Of note, a similar approach has been undertaken for the so-called Boston patients, 
but resulted in viral rebound after prolonged remission, as the stem cell donors were not 
carrying the mutation in the CCR5 gene (Henrich et al., 2014). This highlights the importance 
for CCR5∆32 mutation in order to block viral entry. Further, while those examples show that 
an HIV cure is feasible, it needs to be kept in mind that a stem cell therapy approach is 
dangerous, costly and not broadly practicable as the frequency of an human leukocyte antigen 
(HLA) matching and homozygous CCR5∆32 donors is low. Besides this, not every HIV-1 
positive patient will develop leukemia, which would justify such drastic and risky treatment. 
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1.5.2 Genome editing 
Another approach investigated, comprises genome editing. Several targets are investigated 
and recent advances such as usage of CRISPR/Cas technology renders this approach 
feasible, as it allows the modification of the genome at a defined site. As examples, the 
knockdown of the CCR5 gene as well as double knockdown of both, CCR5 and CXCR4 genes, 
are investigated. If the vast majority of target cells were edited, then the cell entry of HIV would 
be impaired, and no new round of infection could be initiated (Tebas et al., 2014). It is also 
considered to use hematopoietic stem cells to introduce receptor knockouts; in this case the 
knockout would be transferred to daughter cells. Another investigated target is the virus itself. 
Targeting the incoming virus or the provirus by CRISPR/Cas could remove the virus from the 
host (Panfil et al., 2018). But also, this target is hard to reach, as reservoir cells may stay out 
of reach for sampling and due to the lack of a marker for latently infected cells, all HIV target 
cells would need to be edited. This highlights again the need for the identification of a specific 
latency marker, which would be a milestone in HIV latency research and would tremendously 
speed up the process of achieving a cure via genome editing (or other strategies). 
Nevertheless, up to now this technique is not fully developed to allow for highest efficiency by 
minimal off-target rate.  
 
1.5.3 Immune modulation 
Immune modulation aims to sustainably support/prime the immune system in fighting HIV 
better and more efficient. Examples include the modification of natural killer cells and CD8+ T 
cells by expressing artificial T-cell receptors (TCR) or chimeric antigen receptors (CAR), which 
specifically bind to HIV, to enhance recognition and killing of infected cells (Liu et al., 2015). 
Also, the application of selected broadly neutralizing antibodies against HIV is in development 
(Kuhlmann et al., 2018; Sok and Burton, 2018). Those antibodies are found in around a quarter 
of infected individuals and possess the ability to neutralize the virus. The identification of 
broadly neutralizing will also support therapeutic vaccination research. Major drawback of this 
strategy is founded in the high mutation rate of the virus. It will be therefore likely that escape 
viruses will occur, and new rounds of infection can be initiated.  
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1.5.4 Shock and kill 
This strategy comprises two critical steps. During the first step, denoted as ‘shock’, the latent 
reservoir is purged, i.e. proviral transcription is forced (Archin et al., 2014). Resulting viral 
products will render reactivated cells visible to the immune system. In the next step, denoted 
‘kill’, the immune system will clear those cells. New rounds of viral infection can be inhibited by 
the administration of HAART. If all replication competent proviruses are purged, followed by 
subsequent killing, a cure is feasible. This is up to now the most researched category, focusing 
on the identification of latency reversing agents (LRA) by screening them for their action in 
different latency cell models. Due to the availability of e.g. compound or host-factor RNA 
interference (RNAi) libraries and the implementation of high throughput screens, the 
elucidation of novel LRA candidates is facilitated and accelerated. Several LRAs have been 
extensively studied as well as tested in vivo, but so far none of the tested LRAs could decrease 
the latent reservoir size nor increase remission time, if HAART was suspended (Lee et al., 
2017; Rasmussen and Søgaard, 2018). The discovery of new LRAs (or host factors to be 
targeted) or the combination of two or more LRAs with distinct mechanistic actions presents a 
tool to reactivate the complete reservoir. Of note, there is accumulating evidence that the 
immune mediated killing of reactivated cells might be inefficient (Jones et al., 2014; Shan et 
al., 2012), this hurdle could be overcome by engineering the immune system (by strategies as 
immune modulation or others). 
LRAs comprise a large set of compounds, with distinct mechanistically actions. Further, they 
can be categorized in either T cell activating or non-activating compounds (Spivak and 
Planelles, 2018). It was found that T cell activation would also induce proviral transcription, but 
also leads to cytokine production and unspecific T cell proliferation (Clutton et al., 2016), which 
would negatively affect the size of the latent reservoir. An overall immune activation by 
administration of antiCD3 antibodies and IL-2β in vivo was tested, which led to toxic effects in 
individuals (Kulkosky et al., 2002; Prins et al., 1999). Due to this, an overall activation is 
generally avoided but some level of T cell activation might be still needed for efficient proviral 
transcription. 
In the following, examples of T cell activating and non-activating LRAs, which were used in this 
scientific work, will be listed including their proposed mechanisms of action. 
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1.5.4.1 T cell activating LRAs 
One example for a T cell activating LRA is prostratin, which is a non-tumor-promoting phorbol 
ester naturally occurring in some plants (Gustafson et al., 1992; Zayed et al., 1977). Prostratin 
evokes its action by mimicking diacylglycerol, which binds to protein kinase C (PKC) family 
members, i.e. acting as a PKC agonist. This family comprises a large set of threonine/serine 
kinases (McKernan et al., 2012). Binding of PKC initiates downstream activation of NFκB 
(Jiang and Dandekar, 2015). NFκB proteins are dimeric transcription factors, which regulate 
the expression of genes involved in a broad range of biological functions as e.g. innate and 
adaptive immunity, inflammation and stress response. In the classical NFκB pathway, NFκB 
proteins are kept inactive by IκB proteins, sequestered in the cytoplasm. The phosphorylation 
of IκB by PKC, leads subsequently to its proteasomal degradation, released NFκB dimers 
(p65/p50) translocate to the nucleus and initiate transcription of target genes including the 
provirus. Constituent NFκB activation has been linked to cancer development (Rayet and 
Gélinas, 1999). 
Another example of a T cell activating LRA is tumor necrosis factor alpha (TNFα). TNFα is an 
inflammatory cytokine, which regulates a wide range of biological processes. It is mainly 
produced by monocytes/ macrophages but also by other cells. TNFα evokes its action via TNF 
receptor engagement, which induces downstream signaling including NFκB activation via IκB 
phosphorylation (Sedger and McDermott, 2014). 
 
1.5.4.2 Non-activating LRAs 
As mentioned, there are also LRAs evoking their effect different from NFκB activation and 
therefore without overall cell activation. One intensely researched area is the inhibition of 
histone deacetylases (HDACs). HDACs comprise a group of enzymes, which can be divided 
in four classes (i.e. class I, II, III, and IV). HDACs catalyze the removal of acetyl groups from 
histones and other proteins. Acetylation and deacetylation are one mean of epigenetic control 
of gene expression. Blocking those enzymes by HDAC inhibitors (HDACi), leads to 
hyperacetylation of histones and to an ‘open’ chromatin conformation, rendering DNA 
accessible to transcription factors (Dokmanovic et al., 2007). Suberanilohydroxamic acid 
(SAHA; also known as vorinostat) is one prominent member of HDACi, as it blocks HDAC 
classes I, II, and IV (Xu et al., 2007) and is tested as an anti-cancer agent (Marks, 2007). 
Further, also sodium butyrate is an example of an HDACi acting on class I enzymes 
(Shirakawa et al., 2013). Sodium butyrate is a fatty acid derivative that can be found in some 
foods and is produced by bacteria from digestion of fibers in the large intestine (Li et al., 2012).  
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Another non-activating LRA is the recently identified JQ1. This compound inhibits 
bromodomain containing proteins, as e.g. bromodomain-containing protein 4 (BRD4). The 
inhibition of BRD4 leads to release of P-TEFb. Freed P-TEFb is hijacked by Tat and leads to 
increased proviral transcription. JQ1 has been shown to reverse latency when used in 
combination with e.g. prostratin in latency cell models (Li et al., 2013; Zhu et al., 2012).  
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1.6 How to measure the latent reservoir 
In order to evaluate the effectiveness of curing strategies, the size of the latent reservoir and 
changes within need to be exactly determined. Up until now, the quantitative viral outgrowth 
assay (qVOA) is used as the gold standard to determine the size of the latent reservoir (Finzi 
et al., 1997, 1999). For this, resting CD4+ T cells are isolated from HAART-treated HIV-1 
positive donor blood, plated in a limiting dilution series and are fully activated by 
phytohaemagglutinin (PHA) and co-cultured with allogenic CD8+ depleted peripheral blood 
mononuclear cells (PBMCs) from an HIV-1 negative donor. Reactivation of the latent reservoir 
followed by release of progeny virus and infection of bystander cells allows the amplification 
of virus and with this signal intensity. The detection is performed on culture supernatant by 
using standard p24 ELISA and the frequency of latently infected cells is calculated as infectious 
units per million cells (IUPM) (Norton et al., 2017). The advantage of this method is that it 
detects newly produced virus derived from reactivated reservoir cells, but it is time consuming, 
laborious and large quantities of cells (HIV-1 positive and allogenic PBMCs) are needed. 
Therefore, modifications have been implied to enhance the sensitivity and reproducibility of 
read-out and/or reducing the assay time by using e.g. HIV-1 permissive cell lines instead of 
allogenic PBMCs, ultra-sensitive p24 ELISA, or qPCR for viral RNA detection in the 
supernatant. Despite technical advances, it has been shown that not all replication-competent 
proviruses are reactivated upon stimulation and that multiple stimulations might be needed (Ho 
et al., 2013). Therefore, the qVOA is likely to underestimate the size of the latent reservoir.  
PCR-based approaches can also be used to determine the size of the latent reservoir. One 
prominent example is the Alu-PCR performed on genomic DNA (derived from HIV-1 positive 
PBMCs or CD4+ T cells). This approach uses primers which bind within a conserved region of 
the HIV-1 genome e.g. gag gene and within Alu elements of the host genome. Resulting 
fragments will be of varying size, depending on the distance of the provirus to the Alu element. 
A second (nested) PCR will be performed on top to amplify a fragment from the HIV-1 LTR. A 
standard containing a mix of cells with different HIV-1 integration sites is taken along to allow 
the calculation of the reservoir size. There are also other PCR-based approaches described, 
which e.g. directly amplify a fragment from the HIV-1 provirus with primers binding in highly 
conserved regions as e.g. LTR and gag gene, circumventing the need for a second PCR 
(Malnati et al., 2008). The general advantage of PCR-based approaches is that those are much 
faster in comparison to cell-culture based approaches (Henrich et al., 2017). The major 
drawback of PCR approaches is, however, that they cannot discriminate between replication-
competent and replication-incompetent proviruses. The proportion of defective proviruses is 
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believed to be as high as 90% (Bruner et al., 2016). Due to this the reservoir is easily 
overestimated, and also a reduction in reservoir size will be not easily discriminated. Of note, 
there is a recent report on an advanced droplet digital PCR approach which allows the 
discrimination of intact and defective proviruses and their precise quantification (Bruner et al., 
2019). The general implementation of this technique would allow to determine the reservoir 
size and to monitor it over time but requires designated equipment.  
Besides measuring the reservoir size, there are also various possibilities to measure 
reactivation of latent provirus. Measuring of e.g. multiple spliced transcripts, full-length viral 
mRNA, presence of Tat protein or other viral products as an indication for reactivation, but 
results need to be carefully evaluated as not all measured products might lead to the 
production of infectious progeny virus. 
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1.7 Latency cell models 
There have been many different latency models established, which aid to gain a more 
comprehensive understanding in latency formation and maintenance as well as to facilitate the 
discovery of host factors and/or compounds which can influence latency. Those latency 
models can be divided in cell line derived models, primary cell models and in vivo models. In 
the following the different models will be shortly summarized, with emphasis on cell line latency 
models utilized in this work. 
 
1.7.1 Cell line derived latency models 
Cell line derived latency models are easily cultivated, multiplied to high numbers and are not 
limited in their life span. Those cells are produced by transducing cell lines of interest with a 
commonly used HIV-1 laboratory strain, i.e. viruses that are well characterized and can be 
replication competent and may carry an additional reporter gene to allow facilitated detection. 
Those cell line derived latency models are a useful tool for a first-round evaluation of host 
targets or compounds for their potential effect to induce viral transcription. 
 
 
Figure 4: Graphical presentation of J-Lat cell production. Jurkat cells were infected with an HIV-1 
derived reporter virus (env deleted by frameshift mutation, nef replaced by gfp, VSV-G pseudotyped). 
Four days post infection cells were sorted for GFP negative cells. Those cells were stimulated with TNFα 
for 24h, followed by sorting of GFP positive cells and single cell expansion. Resulting cells are different 
J-Lat clones, which do not show GFP expression on their own but upon stimulation. Scheme according 
to description by Jordan, Bisgrove, & Verdin, 2003. 
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The so-called J-Lat cells were derived from the parental Jurkat cells. The Jurkat cell line was 
established from peripheral blood from a male patient with acute T cell leukemia (Weiss et al., 
1984). For the generation of J-Lat cells, the parental cells were transduced with an HIV-1 ∆env 
∆nef GFP-reporter construct. GFP negative cells were sorted followed by activation with TNFα 
and sorted for GFP positive cells. Single cells were expanded and GFP expression faded 
without stimulation. Several clones exist, which vary in their degree to respond to different 
stimuli, as measured by GFP induction as a mean of proviral activation (Jordan et al., 2003). 
A graphical overview on J-Lat cell production is shown in Figure 4.  
Another latency cell model tested are U1 cells, derived from the promonocytic U937 cell line. 
U1 cells were one of the first latency cell models established (Folks et al., 1987). This model 
possesses two copies of HIV-1 provirus, produces very low levels of viral mRNA under normal 
culture conditions and possesses mutations for the tat gene in both integrates (Emiliani et al., 
1998). Proviral transcription can be efficiently induced by several LRAs, whereas latency is 
likely maintained by the mutated form of Tat (Perkins et al., 2008). 
 
1.7.2 Primary latency models 
There are several primary latency cell systems available, which are superior over cell lines for 
the common concerns and regarding the diversity of integration sites in comparison to clonally 
expanded latency cell lines. Primary latency cell models employ CD4+ T cells (either with naïve 
or memory phenotype) isolated from uninfected PBMCs. Naïve CD4+ T cells are activated, 
followed by infection with a modified or wild type HIV-1 strain, and allowed to return to a resting 
state. In order to promote the survival of transduced CD4+ T cells the cultivation with feeder 
cells (Sahu et al., 2006), as well as the transduction with anti-apoptotic genes (Yang et al., 
2009) has been proposed. Other models directly infect resting CD4+ T cells and boost the 
number of infected cell by e.g. spin occulation (Swiggard et al., 2005) or the transduction with 
host factor antagonists’ known to pose a block to the viral life cycle (Coiras et al., 2016). Even 
though primary derived latency models might recapitulate the HIV-1 reservoir found in vivo 
more closely, they are labor extensive, tedious and hardly result in enough latently infected 
cells to allow broad range screening of LRAs. In addition, also primary latency models of non-
CD4+ T cell origin exist. An overview of the different primary models is summarized by 
Bonczkowski et al., 2016. 
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1.7.3 In vivo latency models 
In vivo models, as non-human primate (NHP) models or mouse models replenished with a 
human immune system, have been developed. The advantage of in vivo models is that they 
allow studying of a whole organisms and/or organs and with that the influence of different cell 
types and the microenvironment on pathogenesis, latency formation and reversal (Estes et al., 
2018). Disadvantages of non-human primate models include the usage of SIV for infection, 
and most SIV strains are resistant to non-nucleoside reverse transcriptase inhibitors and 
further possess the accessory protein Vpx, which supports infection of e.g. resting cells and 
macrophages (Evans and Silvestri, 2013). For humanized mouse models it needs to be 
considered that engraftment and colonization of human cells takes long and that the size of 
the model limits the number of cells, which can be subsequently tested (Brooks et al., 2003; 
Policicchio et al., 2016). 
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1.8 High throughput screenings - a method to identify host factors 
involved in latency 
The elucidation of novel host factors involved in latency can be challenging, but is 
indispensable for developing strategies, for instance, to reduce and/or to eradicate HIV 
reservoirs in patients. The implementation of high throughput screening (HTS) methods can 
propel the identification of novel factors. HTS are also commonly used in other research areas, 
for instance to identify novel cancer therapeutics. Prerequisite for performing an HTS are 
dedicated laboratory equipment like pipetting robotics. The experiment itself is run in an 
automated fashion with a throughput of thousands and more test substances, as e.g. 
compounds or biologicals, and therefore referred to as high throughput (Inglese and Auld, 
2008). At first, the experimental question, which is supposed to be answered, needs to be 
formulated. The choice of an adequate test system, e.g. the cell line, needs to be carefully 
chosen. This is followed by the choice of the library, e.g. compound or RNAi (RNA interference) 
library. Those libraries are commercially available, and effort is put in the verification of target 
specificity. This is especially of importance for an RNAi approach, in which host factors are 
targeted by shRNA or siRNA, generating a stable or transient knockdown on mRNA level. 
RNAi technologies are known for their potential off-target effects, which need to be considered 
when interpreting the results (Campeau and Gobeil, 2011). Further, also the implementation 
of suitable controls is of crucial importance, as those will allow the assessment of the assay 
performance and data reliability. The assay is typically run in 96, 384 or higher well plate 
formats with an appropriate plate design to avoid systematic errors e.g. including the same 
controls for each plate but at varying position. The read-out is usually conducted with 
automated microscopes or plate readers measuring luciferase, or changes in absorbance, 
among others. In a last step, the generated raw data need to be analyzed with a suitable test 
to identify primary hits. Special attention needs to be given to the included negative controls, 
as they will determine the background signal, which is optimally not subject to high variation. 
High variation in background noise could easily mask real hits. The statistical test chosen for 
data analysis is dependent on the experimental design and Z-score or signal-to-
noise/background have been proposed to discriminate hits (Caraus et al., 2015). Identified 
primary hits need to be further validated for example by (partial) repetition of the HTS, by a 
different approach or by a different test substance, e.g. shRNA instead of siRNA.  
In summary, HTS are a powerful tool, which allow the identification of cellular factors, including 
also unexpected ones, in a rapid fashion. The conduction of an HTS needs special equipment 
and trained staff. The usage of proper controls, repeated measurements and an appropriate 
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statistical test for data evaluation can increase the robustness of an HTS. The identified 
primary hits need to be further validated either by repetition or by a different approach. This 
scientific work uses the results of a genome-wide siRNA screen (screening approach detailed 
in section 3.1, identified primary hits Table S1, Appendix) for the validation of host factors 
involved in HIV-1 latency. 
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1.9 Aim  
The present study aims at the identification of host factors or compounds, which can support 
the reactivation of silent provirus as a first step in the ‘shock and kill’ approach. Starting point 
for this work are the primary hits derived from a genome-wide siRNA screen for host factors 
affecting transcription and (supposedly latency) of HIV-1 in HEK293T cells (detailed in     
Figure 5, primary hits identified Table S1, Appendix). Around 700 potential primary hits were 
identified, and some of those selected for follow-up experiments and validation. Two differential 
approaches will be pursued: I) identification of primary hits involved in chromatin 
binding/modification and testing whether these hits influence latency reversal alone or in 
combination with other known LRAs (TNFα, prostratin, SAHA, sodium butyrate) and II) 
identification of compounds that target primary hits (here referred to as druggability) and either 
reverse latency on their own or in combination with other known LRAs. As initial test systems 
HIV-1-infected HEK293T, J-Lat clones and U1 cell models are used to test for a potential effect 
upon host factor silencing or compound application. In a final setting, primary cells from HIV-1 
positive patients on long-term HAART are tested for the reversal of latency upon compound 
application. 
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2 Materials and Methods 
2.1 Materials  
2.1.1 Plasmids, siRNAs, Oligonucleotides 
2.1.1.1 Plasmids  
Plasmids Supplier Reference 
GIPZ CYLD shRNA_684    kind gift of L.Mangaro RHS4430-200203337 
GIPZ CYLD shRNA_685    kind gift of L.Mangaro RHS4430-200306163 
GIPZ CYLD shRNA_686    kind gift of L.Mangaro RHS4430-200173983 
GIPZ CYLD shRNA_687    kind gift of L.Mangaro RHS4430-200303048 
GIPZ CYLD shRNA_688    kind gift of L.Mangaro RMM4431-200333126 
GIPZ CYLD shRNA_689    kind gift of L.Mangaro RHS4430-200206310 
GIPZ non-silencing control   kind gift of K.Olivieri RHS4346 
pMD2.G (envelope expressing plasmid) Addgene #12259 
psPAX2 (lentiviral packaging plasmid) Addgene #12260 
TRIPZ BRD4 shRNA_004    kind gift of K.Olivieri RHS4696-201896257 
TRIPZ BRD4 shRNA_484    kind gift of K.Olivieri RHS4696-201905323 
TRIPZ BRD4 shRNA_487    kind gift of K.Olivieri RHS4696-201906445 
TRIPZ empty vector control    Dharmacon, Inc., Lafayette, US RHS4750 
TRIPZ TRRAP shRNA_538    Dharmacon, Inc., Lafayette, US RHS4696-200704208 
TRIPZ TRRAP shRNA_540    Dharmacon, Inc., Lafayette, US RHS4696-200706835 
TRIPZ TRRAP shRNA_543    Dharmacon, Inc., Lafayette, US RHS4696-200700889  
TRIPZ TRRAP shRNA_718    Dharmacon, Inc., Lafayette, US RHS4696-200761563 
TRIPZ TRRAP shRNA_720    Dharmacon, Inc., Lafayette, US RHS4696-200766616  
TRIPZ TRRAP shRNA_721    Dharmacon, Inc., Lafayette, US RHS4696-200759422  
 
2.1.1.2 Oligonucleotides 
Oligonucleotide Sequence (5' -> 3') Application 
ASXL3 fw TTGCTCCCAGAAGTGGATAG RT-qPCR 
ASXL3 rev CGTTGTTTGGTCCAGTAGTG RT-qPCR 
BRD4 fw CTCAGAGTGGTGCTCAAGAC RT-qPCR 
BRD4 rev AAGCGCTTCTTTATTGTTCC RT-qPCR 
CBX6 fw AGGGAGCGTGAGCTGTATGG RT-qPCR 
CBX6 rev GCTTCACCTTGCGGTTGATG RT-qPCR 
CCR5 fw ATGATTCCTGGGAGAGACGC qPCR 
CCR5 probe  VIC-AACACAGCCACCACCCAAGTGATCA qPCR 
CCR5 rev AGCCAGGACGGTCACCTT qPCR 
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Oligonucleotide Sequence (5' -> 3') Application 
CXXC1 fw CAACGAGGGTGACAGTGATG RT-qPCR 
CXXC1 rev CATTGCGCTCCTGCTCAAAC RT-qPCR 
CYLD fw GAGAGTGTGACGCAGGAAAG RT-qPCR 
CYLD rev GTGGTGAAGAACGGTCAAAG RT-qPCR 
GAG fw GACGCTCTCGCACCCATCTC RT-qPCR 
GAG rev CTGAAGCGCGCACGGCAA RT-qPCR 
GFP fw CCACAACGTCTATATCATGGC RT-qPCR 
GFP rev GATGTTGTGGCGGATCTTGA RT-qPCR 
HIV-1 M group fw TACTGACGCTCTCGCACC qPCR 
HIV-1 M group 
probe FAM-CTCTCTCCTTCTAGCCTC qPCR 
HIV-1 M group rev TCTCGACGCAGGACTCG qCR 
KAT6B fw AACGCGCTGTGAATAATGGG RT-qPCR 
KAT6B rev TACAGGCACTGCATGTCTTG RT-qPCR 
MSH6 fw ACCAAGAAGGGCTGTAAACG RT-qPCR 
MSH6 rev ACAGAATTACTGGGCGACAC RT-qPCR 
P1 fw GCGCTCTAGACGTATTACCGCCATGC PCR 
P2 rev CTCCTTGATCAGCTCGCTCATGGTGGCAGATCCTCTAGT
AGAG PCR 
P3 fw GCAAACTGGGGCACAGATAATGTACAAGTAGCGGCCGC PCR 
P4 rev GCGCCTCGAGCCTTCTGTTGGGTTAAC PCR 
P5 fw CTCTACTAGAGGATCTGCCACCATGGCGAGCTGATCAA
GGAG PCR 
P6 rev GCGGCCGCTACTTGTACATTATCTGTGCCCCAGTTTGC PCR 
P7 seq CGGCCGCATTAGTCTTCCAATTG sequencing 
PRDX5 fw GGGAATCGACGTCTCAAGAG RT-qPCR 
PRDX5 rev GGAGGGGTGGAGGAAGTAAT RT-qPCR 
RPL13A fw CCTGGAGGAGAAGAGGAAAGAGA RT-qPCR 
RPL13A rev TTGAGGACCTCTGTGTATTTGTCAA RT-qPCR 
RPS11 fw GCCGAGACTATCTGCACTAC RT-qPCR 
RPS11 rev ATGTCCAGCCTCAGAACTTC RT-qPCR 
SETD3 fw CTGCGCTAGGGGAAGC RT-qPCR 
SETD3 rev TCACTGGTCAGGTTCAAGAT RT-qPCR 
SMYD2 fw AGCAAGGATTCTGGCCAAAC RT-qPCR 
SMYD2 rev TCCTCTCCCGGCTTGATTTC RT-qPCR 
TRRAP fw AGGAGCGACGGAAACGAAA RT-qPCR 
TRRAP rev CCTCAAACTGACAGAATGGAGACA RT-qPCR 
TXNRD1 fw GTTGGAGCATCCTATGTCGC RT-qPCR 
TXNRD1 rev ATGCCATGTTCTTCCATGTGT RT-qPCR 
TXNRD2 fw TCCACCCTAGGTCTGAAGG RT-qPCR 
TXNRD2 rev ACCACCAGGAGATCATAGTC RT-qPCR 
USP22 fw GCGAGGGCAACGTGGTAAAC RT-qPCR 
USP22 rev TGCTGGAGGCCATGAAAGGG RT-qPCR 
All oligonucleotides were purchased from Eurofins MWG Operon, Ebersberg, Germany. fw= 
forward, seq= sequencing, rev=reverse 
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2.1.1.3 siRNAs 
Oligonucleotide Sequence Supplier Reference 
all star proprietary Qiagen, Hilden, Germany SI03650318 
ASXL3 #1 UCAGAAGGCUCUAGAAAUA Dharmacon, Inc., Lafayette, 
US 
D-023422-01 
ASXL3 #2 CCAAUUAGCUGCUCAGAAA Dharmacon, Inc., Lafayette, 
US 
D-023422-02 
ASXL3 #3 GGACACAGCCAGCCAUUUA Dharmacon, Inc., Lafayette, 
US 
D-023422-03 
ASXL3 #4 AAACUGAACAUGCCAACUA Dharmacon, Inc., Lafayette, 
US 
D-023422-04 
CBX6 #1 GAAAGGGACGCAUCGAGUA Dharmacon, Inc., Lafayette, 
US 
D-009555-01 
CBX6 #2 ACACAGAUCCGCCACAUGA Dharmacon, Inc., Lafayette, 
US 
D-009555-02 
CBX6 #3 GGCCGAAUCCAUCAUCAAA Dharmacon, Inc., Lafayette, 
US 
D-009555-03 
CBX6 #4 GAUGUGCAUUUCUCUGUCA Dharmacon, Inc., Lafayette, 
US 
D-009555-04 
CXXC1 #1 ACACAGACCUGCAGAUCUU Dharmacon, Inc., Lafayette, 
US 
D-008545-01 
CXXC1 #2 GGAAAUGGAACGCCGAUUC Dharmacon, Inc., Lafayette, 
US 
D-008545-02 
CXXC1 #3 CAGCCCAGCUCCAAGUAUU Dharmacon, Inc., Lafayette, 
US 
D-008545-03 
CXXC1 #4 CCAACAAGAUCCGGCAGAA Dharmacon, Inc., Lafayette, 
US 
D-008545-04 
Hs_CYLD #2 AAGGGTAGAACCTTTGCTAAA Qiagen, Hilden, Germany SI00110082 
Hs_CYLD #3 AAAGAACGATGTAGAATATTA Qiagen, Hilden, Germany SI00110089 
Hs_CYLD #4 AAGGTTCATCCAGTCATAATA Qiagen, Hilden, Germany SI00110096 
Hs_CYLD #5 CACCAAGATGCCCAATACCAA Qiagen, Hilden, Germany SI03059649 
Hs_PRDX5 #1 CAGCCAGGAGGCGGAGTGGAA Qiagen, Hilden, Germany SI00096971 
Hs_PRDX5 #2 CACCTGCAGCCTGGCACCCAA Qiagen, Hilden, Germany SI02638888 
Hs_PRDX5 #5 TGGGAAGGAGACAGACTTATT Qiagen, Hilden, Germany SI03120712 
Hs_PRDX5 #7 TGGGCCAGATTACTTCCTCCA Qiagen, Hilden, Germany SI05113248 
Hs_TRRAP #1 CTGGCGCACATTATCGCCAAA Qiagen, Hilden, Germany SI00052591 
Hs_TRRAP #3 CAGCACCTTTGTAACAAGTGTA Qiagen, Hilden, Germany SI00052598 
Hs_TRRAP #3 AAGATTCGACAGCAAGTTAAA Qiagen, Hilden, Germany SI00052584 
Hs_TRRAP #8 TTCCTGGTAGTTTGCGTGTAA Qiagen, Hilden, Germany SI05092605 
Hs_TXNRD1 #1 CTGCAAGACTCTCGAAATTAT Qiagen, Hilden, Germany SI00050876  
Hs_TXNRD1 #2 TGGCATCAAGTTTATAAGACA Qiagen, Hilden, Germany SI00050883 
Hs_TXNRD1 #3 CCGACTCAGAGTAGTAGCTCA Qiagen, Hilden, Germany SI00050890  
Hs_TXNRD1 #4 TGCCTGGCATTTGGTAGTATA Qiagen, Hilden, Germany SI00050897 
Hs_TXNRD2 #1 ACGGTTTGCGGCGTTGCCAAA Qiagen, Hilden, Germany SI03090038 
Hs_TXNRD2 #3 AACGCAGGCGAAGTTACTCAA Qiagen, Hilden, Germany SI03040527 
Hs_TXNRD2 #5 ACCGTGGGTATCCATCCCACA Qiagen, Hilden, Germany SI00088494 
Hs_TXNRD2 #6 CTCCGCGGCTTCGACCAGCAA Qiagen, Hilden, Germany SI00088480 
KAT6B #1 GAACAUGGCUGCAUCAAAU Dharmacon, Inc., Lafayette, 
US 
D-019563-01 
KAT6B #2 GCAGUUAACUAAUACACUU Dharmacon, Inc., Lafayette, 
US 
 
D-019563-02 
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Oligonucleotide Sequence Supplier Reference 
KAT6B #3 GAGGUGAAAUUAUAGACUU Dharmacon, Inc., Lafayette, 
US 
D-019563-03 
KAT6B #4 GCAUAUUGGAAGAGCGUCA Dharmacon, Inc., Lafayette, 
US 
D-019563-17 
Luciferase GL2 proprietary Dharmacon, Inc., Lafayette, 
US 
D-001100-01-
20 
Luciferase GL3 proprietary Dharmacon, Inc., Lafayette, 
US 
D-001400-01-
20 
MSH6 #1 GUAGAAAGAUGGCACAUAU Dharmacon, Inc., Lafayette, 
US 
D-019287-01 
MSH6 #2 CGAAGUAGCCGCCAAAUAA Dharmacon, Inc., Lafayette, 
US 
D-019287-02 
MSH6 #3 GAACAGAGCCUCCUGGAAU Dharmacon, Inc., Lafayette, 
US 
D-019287-03 
MSH6 #4 GCUCUGAUGUGGAAUUUAA Dharmacon, Inc., Lafayette, 
US 
D-019287-04 
negative con. proprietary Qiagen, Hilden, Germany SI03650325 
non-targeting #1 proprietary Dharmacon, Inc., Lafayette, 
US 
D-001210-01 
non-targeting #3 proprietary Dharmacon, Inc., Lafayette, 
US 
D-001210-03 
RPS27a  AAGCTGGAAGATGGACGTACT Qiagen, Hilden, Germany Custom siRNA 
scramble 403 AAGGCCGTATCGTAATACTTC Qiagen, Hilden, Germany Custom siRNA 
scramble 5701 AAGCCGCTTAGTAGTCTCGTA Qiagen, Hilden, Germany Custom siRNA 
scramble 6105 AAGTAAGCTCGTGCGACGTAT Qiagen, Hilden, Germany Custom siRNA 
scramble 984 AAGTAGCGAGTAATAGCCGCT Qiagen, Hilden, Germany Custom siRNA 
scramble177 AAGGTAATTGCGCGTGCAACT Qiagen, Hilden, Germany Custom siRNA 
scramble1777 AAGCGTTCGTCCTATGATCGA Qiagen, Hilden, Germany Custom siRNA 
SETD3 #1 AAACACAGCUCGACAGUAC Dharmacon, Inc., Lafayette, 
US 
D-014808-01 
SETD3 #2 GGUAAGAAGAGUCGAGUAA Dharmacon, Inc., Lafayette, 
US 
D-014808-02 
SETD3 #3 CCAACAAACUACCCUUGAA Dharmacon, Inc., Lafayette, 
US 
D-014808-03 
SETD3 #4 CCACACAAGCUAUACAUGA Dharmacon, Inc., Lafayette, 
US 
D-014808-04 
SMYD2 #1 GCAAAGAUCAUCCAUAUAU Dharmacon, Inc., Lafayette, 
US 
D-020291-01 
SMYD2 #2 GAAAUGACCGGUUAAGAGA Dharmacon, Inc., Lafayette, 
US 
D-020291-02 
SMYD2 #3 GACAGUAACGUGUACAUGU Dharmacon, Inc., Lafayette, 
US 
D-020291-03 
SMYD2 #4 GCACGCAACGUCAUUGAAG Dharmacon, Inc., Lafayette, 
US 
D-020291-04 
TRRAP #1 GGACUUAACUGGAGAGGUU Dharmacon, Inc., Lafayette, 
US 
D-005394-01 
TRRAP #2 GAAAGGAGCUUCUGAUUGC Dharmacon, Inc., Lafayette, 
US 
D-005394-02 
TRRAP #3 CAAUGUAGCUCUGGAUAUA Dharmacon, Inc., Lafayette, 
US 
D-005394-03 
TRRAP #4 CCUGGUAGUUUGCGUGUAA Dharmacon, Inc., Lafayette, 
US 
D-005394-19 
USP22 #1 GGAGAAAGAUCACCUCGAA Dharmacon, Inc., Lafayette, 
US 
D-006072-01 
USP22 #2 CAAAGCAGCUCACUAUGAA Dharmacon, Inc., Lafayette, 
US 
D-006072-02 
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Oligonucleotide Sequence Supplier Reference 
USP22 #3 GGAAGAUCACCACGUAUGU Dharmacon, Inc., Lafayette, 
US 
D-006072-04 
USP22 #4 CCUUUAGUCUCAAGAGCGA Dharmacon, Inc., Lafayette, 
US 
D-006072-17 
 
2.1.2 Antibodies  
Antibody Conju- gate 
Species, 
Clonality 
Appli- 
cation Dilution Supplier 
Refer- 
ence 
antiCD28  - mouse, mc cell activ.  2µg/ml Miltenyi Biotec, Bergisch 
Gladbach, Germany 
130-093-
375 
antiCD3  - mouse, mc cell activ. 2µg/ml Miltenyi Biotec, Bergisch 
Gladbach, Germany 
130-093-
387 
antiGAPDH  - rabbit, mc WB 1: 5,000 Cell Signaling Technology, 
Inc., Danvers, US 
#2118 
anti p24 
(AG3.0) 
 - mouse, mc WB 1:500 kind gift from Dr. S. Norley  -  
antiPRDX5  - rabbit, pc WB 1:1,000 Thermo Fisher Scientific 
Inc., Waltham, US 
PA5-
79864 
antiTRRAP  - rabbit, pc WB 1:1,000 Cell Signaling Technology, 
Inc., Danvers, US 
#3966 
antiTubulin  - mouse, mc WB 1:3,000 Sigma Aldrich Corporation, 
St.Louis, US 
T4026 
antiTXNRD1  - rabbit, mc WB 1:1,000 Cell Signaling Technology, 
Inc., Danvers, US 
#15140 
antiTXNRD2  - mouse, mc WB 1:1,000 Cell Signaling Technology, 
Inc., Danvers, US 
#12029 
antiCD4 FITC mouse, mc FC 1:20 BioLegend®, San Diego, 
US 
317407 
antiCD25 PE mouse, mc cell iso., 
FC 
1:11 Miltenyi Biotec, Bergisch 
Gladbach, Germany 
130-091-
024 
antiCD69 PE mouse, mc cell iso., 
FC 
1:11 Miltenyi Biotec, Bergisch 
Gladbach, Germany 
130-092-
160 
antiHLA-DR PE mouse, mc cell iso., 
FC 
1:11 Miltenyi Biotec, Bergisch 
Gladbach, Germany 
130-095-
298 
anti mouse 
IgG 
HRP goat, pc WB 1:10,000 Cell Signaling Technology, 
Inc., Danvers, US 
#7076 
anti rabbit IgG HRP goat, pc WB 1:10,000 Cell Signaling Technology, 
Inc., Danvers, US 
#7074 
anti rabbit IgG HRP goat, pc ELISA 1:100,000 Jackson ImmunoResearch 
Ltd., Ely, UK 
111-035-
045 
 
activ.= activation, ELISA= enzyme-linked immuno assay, FC= flow cytometry, FITC= fluorescein 
isothiocyanate, HRP= horseradish peroxidase, iso.= isolation, mc= monoclonal, pc= polyclonal, PE= 
phycoerythrin, WB= Western blot 
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2.1.3 Cell lines and bacterial strains 
2.1.3.1 Cell lines 
Cell line Origin Properties RRID Reference 
HEK293T human embryonic 
kidney 
adherent cells CVCL_
0063 
DuBridge 
et al., 1987 
HEK293T/17 human embryonic 
kidney, clone 17 
adherent cells CVCL_
1926 
Pear, 
Nolan, 
Scott, & 
Baltimore, 
1993 
U1                  
HIV-1 infected 
U937 cell 
human leukemic 
monocyte lymphoma 
suspension cells, express show 
minimal constitutive expression of 
virus 
CVCL_
M769 
Folks et 
al., 1987 
J-Lat 8.4        
HIV-1 (GFP+, E-) 
Jurkat cell 
T acute lymphoblastic 
leukemia 
suspension cells, upon stimulation 
express incomplete viral particles, 
possess gfp in place of nef  
CVCL_
8284 
Jordan et 
al., 2003 
J-Lat 6.3       
HIV-1 (GFP+, E-) 
Jurkat cell 
T acute lymphoblastic 
leukemia 
suspension cells, upon stimulation 
express incomplete viral particles, 
possess gfp in place of nef  
CVCL_
8280 
Jordan et 
al., 2003 
 
2.1.3.2 Bacterial strains 
Bacteria Properties and genotype Supplier 
MAX Efficiency™ 
DH5α™ Competent 
Cells 
F– Φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rk–, mk+) phoA supE44 λ– thi-1 
gyrA96 relA1  
Thermo Fisher 
Scientific Inc., 
Waltham, US 
One Shot™ Stbl3™ 
Chemically Competent 
E. coli 
F-mcrB mrrhsdS20(rB-, mB-) recA13 supE44 ara-14 
galK2 lacY1 proA2 rpsL20(StrR) xyl-5 λ-leumtl-1 
Thermo Fisher 
Scientific Inc., 
Waltham, US 
 
2.1.4 Compounds, solutions and general chemicals 
2.1.4.1 Compounds 
Compound Stock solution Solvent Supplier 
Catalogue 
number 
4hydroxynonenal 80mM C2H5OH Santa Cruz Biotechnology, Inc., Dallas, US sc-202019 
Auranofin 20mM DMSO Tocris® a BioTechne® brand, Ltd., 
Minneapolis, US 
4600 
AZ505 5mM DMSO APExBIO, Houston, US B1255 
Benzoic Acid 500mM C2H5OH Sigma Aldrich Corporation, St.Louis, US 242381 
Diminazene 0.5g/ml H2O Sigma Aldrich Corporation, St.Louis, US D7770 
Docetaxel 10mM DMSO Sigma Aldrich Corporation, St.Louis, US 1885 
Estramustine 250mM DMSO Santa Cruz Biotechnology, Inc., Dallas, US sc-353281 
Fotemustine 10mM H2O Sigma Aldrich Corporation, St.Louis, US F7307 
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Compound Stock solution Solvent Supplier 
Catalogue 
number 
HOE140 750µM H2O Tocris® a BioTechne® brand, Ltd., 
Minneapolis, US 
3014 
JQ1 20mM DMSO Sigma Aldrich Corporation, St.Louis, US SML1524  
Marimastat 50mM DMSO Sigma Aldrich Corporation, St.Louis, US M2699 
Mimosine 500mM 1M 
NH4OH 
Sigma Aldrich Corporation, St.Louis, US M0253  
Pazopanib 60mM DMSO Santa Cruz Biotechnology, Inc., Dallas, US SC-396318 
Prostratin 5mM DMSO Sigma Aldrich Corporation, St.Louis, US P0077  
SAHA 2.5mM DMSO Sigma Aldrich Corporation, St.Louis, US SML0061 
Sodium Butyrate 500mM H2O Sigma Aldrich Corporation, St.Louis, US B5887 
Terameprocol 25mM DMSO Sigma Aldrich Corporation, St.Louis, US T3455 
TNFα 100µg/ml H2O Miltenyi Biotec, Bergisch Gladbach, 
Germany 
130-094-
022 
Vitamin B1 1M H2O Santa Cruz Biotechnology, Inc., Dallas, US SC-338735 
Zonisamide 
solution 
4.7mM CH3OH Cerillant® by Sigma Aldrich Corporation, 
St.Louis, US 
Z-005 
 
2.1.4.2 Media, buffers and solutions 
Media, Buffers & 
Solutions Formulation 
2% paraform-
aldehyde (PFA) 
20g Formaldehyde, add 1X PBS to 1L final volume, sterile filtrated, aliquoted 
and stored at -20°C 
20X Tris-Acetate-
EDTA (TAE) Buffer 
800 mM Tris-HCl, 2.3% (v/v) acetic acid, 40mM EDTA, add H2O to 1L final 
volume 
Coomassie de-
staining solution  
40% (v/v) methanol, 7% (v/v) acetic acid, add H2O to 1L final volume 
Coomassie staining 
solution 
0.5% (w/v) Coomassie® Brilliant Blue G-250, 40% (v/v) methanol, 7% (v/v) 
acetic acid, add H2O to 1L final volume 
MOPS buffer 50mM MOPS, 50 mM Tris, 0.1% (w/v) SDS, 1.025 mM EDTA Titriplex II 
Phosphate-buffered 
saline (PBS) without 
Ca2+Mg2+  
137mM NaCl, 2.7mM KCl, 1.47mM KH2PO4, 8.1mM Na2HPO4 
RIPA complete lysis 
buffer 
12.5ml Tris 1M pH 8 (25mM), 13.7ml NaCl 5 M (137mM), 5ml Glycerol (1% 
(v/v)), 0.5g SDS (0.1 % (w/v)), 2.5g Na-deoxycholate DOC (0.5% (w/v)), 5ml 
NP40 (1% (v/v)), 2ml EDTA 0.5M pH 8 (2mM) add H2O to 500ml final volume  
Tris-buffered saline 
with 1% (v/v) 
Tween 20 (TBS-T) 
10mM Tris-HCl pH 8.0, 150mM NaCl, 0.05% (v/v) Tween-20, add H2O to 1L 
final volume 
Tris-EDTA (TE) 
buffer, pH 8.0 
10mM Tris-HCl, 1mM EDTA Titriplex III 
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2.1.5 Equipment and Consumables 
2.1.5.1 General laboratory equipment 
General laboratory 
equipment Supplier 
Agarose gel 
electrophoresis apparatus 
Mini-Sub Cell® GT System/ Sub-Cell® GT System, Bio-Rad Laboratories 
GmbH, Munich, Germany 
Biological safety cabinet HERAsafe, Thermo Fisher Scientific Inc., Waltham, US  
SterilGARD® III Advance, The Baker Company, Sanford, US 
Blotting pads Novex®, Life Technologies™, brand of Thermo Fisher Scientific Inc., 
Waltham, US 
Centrifuges Centrifuge 5810 R, Eppendorf AG, Hamburg, Germany  
Fresco 17 Microcentrifuge, Heraeus, Thermo Fisher Scientific Inc., 
Waltham, US  
Fresco 21 Microcentrifuge, Heraeus, Thermo Fisher Scientific Inc., 
Waltham, US  
Megafuge 40R, Heraeus, Thermo Fisher Scientific Inc., Waltham, US  
MiniSpin®, Eppendorf AG, Hamburg, Germany  
RC26 Plus, Sorvall, Thermo Fisher Scientific Inc., Waltham, US 
CO2 incubators BBD 6220, Heraeus, Thermo Fisher Scientific Inc., Waltham, US  
HERAcell 240i, Thermo Fisher Scientific Inc., Waltham, US 
Counting chamber Neubauer-improved, Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany 
Gel blotting module XCell II™ Blot Module, Novex®, Life Technologies™, brand of Thermo 
Fisher Scientific Inc., Waltham, US 
Incubator shaker Innova 4200/ 4230, New Brunswick Scientific, Eppendorf AG, Hamburg, 
Germany 
Pipette (0.1-2.5µl, 0.5-
10µL, 10-100µL, 
50-200µL, 100-1000µL) 
Eppendorf Reference®/ Eppendorf Research® plus, Eppendorf AG, 
Hamburg, Germany 
Pipette filler Pipetus®, Hirschmann Laborgeräte GmbH & Co. KG, Eberstadt, 
Germany 
Platform shaker Polymax 1040, Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany 
Polyacrylamide gel 
electrophoresis Apparatus 
XCell SureLock® Mini, Novex®, Thermo Fisher Scientific Inc., Waltham, 
US 
Power supply EV202, Consort bvba, Turnhout, Belgium  
PowerPac™ HC, Bio-Rad Laboratories, Inc., Hercules, US 
Multichannel electronic 
pipettor (0.5-12.5 µL, 2-
125 µL, 15-1250 µL) 
Matrix Multichannel Electronic Pipettors, Thermo Fisher Scientific Inc., 
Waltham, US 
Microscopes Eclipse TS100, Nikon GmbH, Düsseldorf, Germany  
Leica DM IL, Leica Microsystems GmbH, Wetzlar, Germany 
Scale BP211D, Sartorius AG, Göttingen, Germany 
Thermomixer Eppendorf Thermomixer 5436, Eppendorf AG, Hamburg, Germany 
UV/Vis spectrophotometer GeneQuant pro, Amersham™, GE Healthcare GmbH, Solingen, 
Germany 
Vortex mixer Vortex-Genie 2, Scientific Industries, Inc., Bohemia, US 
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2.1.5.2 Consumables  
 
2.1.6 Databases 
 
General consumables Source 
Autoradiography film Super RX, Fujifilm Europe GmbH, Düsseldorf, Germany 
Cell culture flasks (25 cm2,        
75 cm2, 175 cm2) 
CELLSTAR® Filter Cap Cell Culture Flasks, Greiner Bio-One 
GmbH, Frickenhausen, Germany 
Cryogenic storage vials Cryo.sTM, Greiner Bio-One GmbH, Frickenhausen,Germany 
Culture tube, with push cap Sarstedt AG & Co., Nümbrecht, Germany 
Cuvettes Rotilabo®-disposable cuvettes, Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
Filter paper (Whatman paper) GE Healthcare GmbH, Solingen, Germany 
Filter unit (0.45µm) Millex-HV Filter, Millipore, Merck KGaA, Darmstadt, Germany 
Inoculating loops L 200 - Ino-Loop™, Simport Scientific, Beloeil, Belgium 
Microcentrifuge tubes (1 ml, 2 
ml) 
Sarstedt AG & Co., Nümbrecht, Germany 
Microplate, transparent, 96 well, 
(F-bottom, U-bottom, V-bottom) 
Greiner Bio-One GmbH, Frickenhausen,Germany 
Microplate, white (96 well, 384 
well) 
Greiner Bio-One GmbH, Frickenhausen,Germany 
Multidishes (6 well, 12 well, 24 
well, 96 well) 
Nunc Multidishes Nunclon™∆, Nunc GmbH & Co. KG, 
Langenselbold, Germany 
Pipette tips, with filter (10µl, 
100µl, 300µl, 1000µl) 
Biosphere® Pipette Tips, Sarstedt AG & Co., Nümbrecht, Germany 
Pipette tips, with filter for 
multichannel electronic 
pipettors (12.5µl, 125µl, 1250µl) 
Thermo Fisher Scientific Inc., Waltham, US 
Pipettes, with filter (5ml, 10ml, 
25ml) 
Serological Pipettes, Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Pipettes, without filter  Aspirating Pipettes, Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Polypropylene tubes, conical 
(15ml, 50ml) 
Greiner Bio-One GmbH, Frickenhausen, Germany 
Database Application Source 
DGIbd - Mining the 
Druggable Genome 
Drug-Gene Interaction database http://dgidb.genome.wustl.edu/ 
(Cotto et al., 2018) 
DrugBank Target/compound details https://www.drugbank.ca/ 
(Law et al., 2014) 
Genego Target/compound details proprietary 
Primer-BLAST Primer design https://www.ncbi.nlm.nih.gov/tools
/primer-blast/ 
PubMed Information on host factors https://www.ncbi.nlm.nih.gov/pub
med/ 
The Human Protein 
Atlas 
Expression levels of host factors in 
different tissues 
http://www.proteinatlas.org/ 
(Uhlén et al., 2015) 
Therapeutic Target 
Database (TTD) 
Target/compound details http://bidd.nus.edu.sg/group/cjttd/ 
(Li et al., 2018) 
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2.1.7 Software  
Software Description Supplier 
FCS Express 4.0 FACS data processing De Novo Software, Suite, US 
Graph Pad Prism 7 Data processing GraphPad Software, Inc. 
Microsoft Office 
2010 
Basic writing and 
presentation programs 
Microsoft Corporation, Washington, US 
SDS v2.4 RT-qPCR data processing Applied Biosystems, brand of Thermo Fisher 
Scientific Inc., Waltham, US 
SnapGene Viewer 
3.3.4 
Cloning and plasmid 
organization system 
GSL Biotech LLC, Chicago, US 
Vector NTI 
Advance(R) 11.5.2  
Cloning and plasmid 
organization system 
Invitrogen, brand of Thermo Fisher Scientific Inc., 
Waltham, US 
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2.2 Methods  
2.2.1 Molecular techniques  
2.2.1.1 DNA amplification by PCR 
For the generation of a new constant shRNA expressing backbone, PCR was used to 
specifically amplify fragments. 
In short, primers were designed to allow amplification of the sequence of interest (in silico 
primer design with vector NTI software). A PCR master mix was set up (Table 1) and a PCR 
run under the indicated cycling conditions (Table 2) according to the KOD polymerase manual 
using TProfessional Thermocycler (Biometra GmbH, Göttingen, Germany). The annealing 
temperature of the primers was determined by vector NTI and is mentioned in the respective 
result paragraph. Successful amplification of PCR fragments was confirmed by fragment 
visualization after gel electrophoresis and by sequencing.  
 
Table 1: Formulation of PCR mix for fragment amplification. 
Component Volume 
KOD polymerase 2.5U/µl (Millipore, Merck KGaA, Darmstadt, Germany) 1.0µl 
MgSO4 (25mM) 3.0µl 
dNTPs (2mM each) 5.0µl 
template DNA (10ng) Xµl 
primer fw 10µM 1.5µl 
primer rev 10µM 1.5µl 
10X KOD buffer 5.0µl 
add nuclease free H2O to a final volume of  50.0µl 
 
Table 2: Overview over PCR cycling conditions. 
Step Temperature Time  
Polymerase activation 95°C 2min  
Denaturation 95°C 20s  
Annealing variable 10s repeat 30x 
Extension 70°C 20s/kb  
Final extension 70°C 5min  
On hold 4°C ∞  
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2.2.1.2 Restriction digestion of plasmids or PCR amplified fragments 
Digestion of DNA sequences or plasmids with restriction enzymes produces blunt or unique 
sticky ends, which allows for exchange, deletion or insertion of fragments. Compatible ends 
can be ligated into a backbone, generating a modified plasmid. In general, a restriction digest 
was set up (Table 3) with two restriction enzymes in the correct buffer and incubated for 1h/1µg 
template at 37°C. 
Purified PCR fragments for the generation of a new shRNA expressing backbone were 
restriction digested with XbaI and XhoI in diluted10X Buffer 4 (all New England Biolabs GmbH, 
Frankfurt am Main, Germany).  
Cloning of shRNA sequences from the pGIPZ to the pTRIPZ backbone and further to the 
pRIPZ backbone was done by restriction digest of backbone and shRNA containing plasmid 
with the same restriction enzymes to produce compatible ends, which were joined by ligation. 
The moving of shRNA was done according to the manual using FastDigest MluI and FastDigest 
XhoI in diluted 10X Fast Digest Green buffer (all Thermo Fisher Scientific Inc., Waltham, US).  
 
Table 3: Formulation of restriction digest. 
Component Volume 
10X buffer 5µl 
PCR fragment/DNA sample (≤ 5µg) Xµl 
Enzyme 1  1µl 
Enzyme 2  1µl 
add nuclease free H2O up to a final volume of 50µl 
 
2.2.1.3 Agarose gel electrophoresis 
Gel electrophoresis was carried out in order to visualize and separate digested DNA fragments 
and PCR products. 
For this, 0.4g – 0.75g LE agarose (Biozym Scientific GmbH, Hessisch Oldendorf, Germany) 
was weighed and mixed in 50ml 1X TAE buffer, yielding a 0.8% - 1.5% (w/v) agarose solution 
(lower agarose percentages for large fragments for restriction-digested backbones and higher 
agarose percentages for small fragments). The mixture was heated in a microwave oven until 
the agarose completely dissolved. 1:10,000 diluted Gel Red Nucleic Acid Stain (Biotium Inc., 
Fremont, US) was added, the gel was casted and allowed to solidify at room temperature. The 
gel electrophoresis chamber was assembled and filled with 1X TAE buffer. The sample was 
mixed with 1:6 diluted Gel Loading Dye (New England Biolabs GmbH, Frankfurt am Main, 
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Germany) and loaded on the gel along with 7µl of GeneRuler™ 1kb Plus DNA Ladder (Thermo 
Fisher Scientific Inc., Waltham, US). The applied voltage was 80V for preparative digestions, 
or 120V for analytical ones. The gel was visualized on a UV transilluminator (INTAS Science 
Imaging Instruments GmbH, Göttingen, Germany). For preparative digestions, samples were 
cut from the gel and used further. 
 
2.2.1.4 Isolation of DNA fragments from agarose gel 
After separation of DNA fragments by gel electrophoresis, the fragments were isolated from 
agarose. Using Nucleo® Gel and PCR Clean-up kit (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany), the DNA fragment isolation was performed according to the manufacturer’s 
protocol. The agarose piece was weighed, and 200µl NTI Binding Buffer per 100mg agarose 
was added. The mixture was heated to 50°C, incubated until agarose completely melted, 
loaded onto the provided column, and centrifuged for 30s at 11,000g. The column was washed 
twice with NT3 wash buffer by centrifugation for 30s at 11,000g, and then dried by 
centrifugation for 2min at 11,000g. 15-30µl (depending on fragment amount isolated) of 
prewarmed NE Elution Buffer (50°C) was added to the dried column, which was incubated for 
3min and centrifuged for 1min at 11,000g. The concentration of the eluted DNA was 
determined by a UV/Vis spectrophotometer (NanoDrop 2000™, Thermo Fisher Scientific Inc., 
Waltham, US).  
 
2.2.1.5 DNA ligation 
In order to obtain circular plasmids, a ligation reaction was set up, containing the digested and 
cleaned DNA fragment, backbone and T4 ligase (New England Biolabs GmbH, Frankfurt am 
Main, Germany) in the appropriate buffer (Table 4). The molar ratio of backbone to insert used 
was 1:5, with 100ng of backbone. The reaction was incubated for 1h at room temperature. In 
addition, for each ligation setup also a backbone only ligation (without insert) was performed, 
which allowed the estimation of incomplete backbone digestion.  
 
Table 4: Formulation of ligation mix. 
Component Volume 
T4 ligase (New England Biolabs GmbH, Frankfurt am Main, Germany) 1µl 
10X T4 ligase buffer (New England Biolabs GmbH, Frankfurt am Main, Germany 2µl 
DNA insert) Xµl 
DNA backbone (100ng)  Xµl 
add nuclease free H2O to final volume of 20µl 
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2.2.1.6 Transformation 
Amplification of plasmids was performed using One Shot™ Stbl3™ Chemically Competent E. 
coli. A 50µl aliquot/transformation was thawed on ice, and 2µl ligation mixture or 0.5µg plasmid 
was added. This mixture was incubated on ice for 30min, heat-shocked at 42°C for 25s, and 
incubated on ice for 2min. 500µl prewarmed super optimal broth with catabolite repression 
(SOC) medium (PEI media kitchen) was added, the mixture was gently shaken at 37°C for 1h, 
and 100µl of bacteria solution plated on LB agar plates containing 100µg/ml Ampicillin and 
25µg/ml Zeocin™ (PEI media kitchen). The plates were incubated at 37°C overnight, and 
single colonies were picked. 
 
2.2.1.7 Plasmid amplification 
Single colonies of transformed E. coli were picked and inoculated in 8ml LB medium 
(containing the selecting antibiotics). Those single colony cultures are hereinafter referred to 
as precultures. Precultures were cultivated under gentle shaking at 37°C overnight. To isolate 
small volumes of plasmid, as for sequencing purposes, 3ml of preculture was harvested, and 
plasmids were isolated with the QIAprep Spin Miniprep Kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s protocol. To isolate large volumes of plasmid, as for 
transfection and lentiviral particle production, 5ml of preculture was added to 200ml of LB 
medium containing the selecting antibiotics and cultivated under gentle shaking at 37°C 
overnight, and plasmids were isolated by NucleoBond® Xtra Midi Kit (Macherey-Nagel GmbH 
& Co. KG, Düren, Germany) according to the manufacturer’s protocol. Isolated plasmids were 
dissolved in TE buffer, and DNA concentration was determined by a UV/Vis 
spectrophotometer. 
 
2.2.2 qPCR and associated techniques 
2.2.2.1 Isolation of nucleic acids 
2.2.2.1.1 RNA isolation and DNase digestion  
In order to determine knockdown efficiency of host factors or the reversal of latency in J-Lat 
clones and U1 cells reverse transcriptase quantitative PCR (RT-qPCR) was performed. For 
this, RNA was isolated with the NucleoSpin® RNA Plus (Macherey-Nagel GmbH & Co. KG, 
Düren, Germany) according to the manufacturer’s protocol. In short, samples were collected, 
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the supernatant discarded, and cells resuspended in 200µl of LBP lysis buffer per well of a 96 
well format. RNA isolation was either directly continued or samples stored at -80°C. The lysed 
cells were loaded onto genomic DNA (gDNA) removal column, centrifuged at 11,000g for 30s. 
The flow-through was mixed with Binding Solution, loaded to on the RNA binding column, 
washed with WB1, centrifuged at 11,000g for 30s. The column was transferred into a new tube 
and washed with WB2 twice and column dried by centrifugation at 11,000g for 2min. The 
column with bound RNA was transferred into a new tube, 15µl of H2O was added onto the 
column, incubated for 1min and centrifuged at 11,000g for 1min. The elution step was 
repeated, yielding 30µl purified RNA.  
For quantification of gag or gfp mRNA from J-Lat clones or U1 cells, samples were DNase 
treated to avoid amplification from genomic DNA. For this 30µl of RNA were digested with the 
TURBO DNA-free™ kit (Invitrogen™, brand of Thermo Fisher Scientific Inc., Waltham, US) 
according to Table 5. In short, RNA samples were mixed with Turbo DNase in the appropriate 
buffer, including recombinant RNasin® Ribonuclease inhibitor (Promega Corporation, 
Fitchburg, US). The mixture was incubated for 20min at 37°C, then inactivated by adding 3.5µl 
inactivation reagent, incubated for 5min at RT and centrifuged at full speed for 5min. The 
supernatant containing the DNA-free RNA was transferred into a new tube and either used 
directly for RT-qPCR or stored at -80°C. 
 
Table 5: Formulation of DNase digest for RNA samples. 
Component Volume  
RNA sample 30.0µl  
Turbo DNase buffer 10x 3.5µl 
recombinant RNasin® Ribonuclease inhibitor 0.5µl 
add DNase free H2O to a final volume of 35.0µl 
 
2.2.2.1.2 Genomic DNA isolation from primary HIV-1 positive PBMCs 
Genomic DNA (gDNA) was isolated using the QIAamp DNA Mini Kit (51304, Qiagen, Hilden, 
Germany) following the instructions of the manufacturer, all solutions used were provided with 
the kit. In short, one million PBMCs were diluted in PBS up to a final volume of 200µl. 20µl 
Proteinase K solution was added, followed by 200µl AL buffer. The samples were pulse 
vortexed and incubated at 56°C for 10min. 200µl 100% ethanol was added, the mixture applied 
to a spin column and centrifuged at 6,000g for 1min. The spin column was placed into a new 
collection tube and 500µl AW1 buffer was added, followed by centrifugation at 6,000g for 1min. 
The flow-through with the collection tube was discarded. The spin column was placed into a 
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new collection tube and washed with 500µl AW2 buffer, followed by centrifugation at full speed 
for 3min. The spin column was placed into a 1.5ml elution tube and 100µl of AE buffer was 
added. After 3min of incubation the DNA was eluted by centrifugation at 6,000g for 1min. The 
genomic DNA was stored at -20°C until further used for HIV copies determination. 
 
2.2.2.2 qPCR 
2.2.2.2.1 HIV copy number determination by qPCR on gDNA 
To determine the absolute numbers of HIV integrates per million PBMCs, a duplex qPCR was 
performed amplifying a HIV-1 fragment and a CCR5 gene fragment in parallel (the 
experimental conditions follow a publication for HIV-1 viral load quantification (Malnati et al., 
2008). The qPCR was set up with the Agilent Brilliant II MM (Agilent Technologies, Inc., Santa 
Clara, US) according to the manufacturer’s protocol. In short, a master mix was set up      
(Table 6) excluding the DNA template and 17μl/well distributed to the designated wells. 
Afterwards 8μl of DNA or H2O, serving as non-template control, were added. The qPCR was 
performed on the Mx3000P® qPCR system (Agilent Technologies, Inc., Santa Clara, US) in a 
96 well format, each sample was run in five replicates and the plasmid standard dilution series 
in triplicates. The cycling conditions were according to Table 7. Analysis of the raw data was 
performed using MxPro QPCR Software (Agilent Technologies, Inc., Santa Clara, US). 
Absolute copy numbers were determined with the help of the plasmid standard dilution series 
with known copy numbers of both reference plasmids. Further, CCR5 results were used to 
determine the number of tested cells in order to calculate the number of HIV-1 integrates per 
one million PBMCs (Malnati et al., 2008).  
 
Table 6: Formulation of qPCR mix for HIV-1 provirus quantification. 
Component Volume  
2x Agilent Brilliant II MM 12.5µl 
HIV-1 forward primer (10µM) 0.75µl 
HIV-1 reverse primer (10µM) 0.75µl 
HIV-1 probe FAM (10µM) 0.3µl 
CCR5 forward primer (10µM) 0.5µl 
CCR5 reverse primer (10µM) 0.5µl 
CCR5 probe HEX (10µM) 0.5µl 
ROX dye (2µM) 0.375µl 
template DNA 8.0µl 
add DNase free H2O to a final volume of 25.0µl 
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Table 7: Cycling conditions for qPCR on HIV-1 provirus quantification. 
Step Temperature Time  
Polymerase activation 95°C 10min  
Denaturation 95°C 30s  
Annealing and extension 60°C 1min repeat 45x 
On hold 4°C ∞  
 
2.2.2.2.2 One-step RT-qPCR relative quantification of mRNA levels 
To determine the relative mRNA levels of genes of interest RT-qPCR was performed. For this, 
the isolated samples were measured by an UV/Vis spectrophotometer and equal 
concentrations of total RNA (usually 20ng/well) were tested. The RT-qPCR was set up with 
the QuantiTect® SYBR® Green RT-PCR kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. In short, a master mix was set up excluding the RNA template     
(Table 8) and distributed in to the designated wells. Afterwards the RNA samples were added 
to the wells. A no template control was included which allowed primer dimer detection. For 
DNase-digested samples, a no RT control for each sample was included which gave a signal 
if DNA digestion was incomplete. The RT-qPCR was performed on the 7900HT Fast Real-
Time PCR System cycler (Applied Biosystems, brand of Thermo Fisher Scientific Inc., 
Waltham, US) in a 384 well plate format, each sample was run in technical triplicates. The 
cycling conditions were according to Table 9. Analysis of the raw data was performed using 
SDS2.4 software. For this, the threshold of each primer pair was set, the CT values 
extrapolated and the relative expression levels determined by 2^-(CT ‘gene of interest’ – CT 
‘reference gene’). 
 
Table 8: Formulation of one-step RT-qPCR mix for relative RNA quantification. 
Component Volume 
2X QuantiTect SYBR Green RT-PCR Master Mix 5.0µl 
QuantiTect RT Mix 0.1µl 
Template RNA (30ng) 3.0µl 
primer fw (5mM) 0.1µl 
primer rev (5mM) 0.1µl 
add RNase free H2O to a final volume of 10.0µl 
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Table 9: Cycling conditions for one-step RT-qPCR on RNA samples. 
Step Time Temperature  
Reverse transcription 30min 50°C  
Polymerase activation 15min 95°C  
Denaturation 15s 94°C   
Annealing 30s 56°C repeat 45x 
Extension 30s 72°C   
denaturation 15s 95°C  
annealing  15s 60°C  
 
2.2.3 Cell-associated techniques 
2.2.3.1 Culture of cell lines 
All cells were grown at 37°C, 95% humidity and 5% CO2 in T75 cell culture flasks, if not stated 
otherwise. All procedures were performed under sterile conditions and cells regularly checked 
for being mycoplasma negative. Cell lines were cultivated up to passage number 40, and then 
discarded and a new vial thawed.  
Suspension cells were cultured in supplemented RPMI1640 (Sigma Aldrich Corporation, St. 
Louis, US) (10% heat inactivated FCS (Biowest, Nuaillé, France), 1% L-glutamine (Biochrom 
GmbH, Berlin, Germany)) and split 1:5 for J-Lat cells and 1:10 for U1 cells three times a week. 
Adherent cells as HEK293T and HIVluc HEK293T were grown in supplemented Dulbecco’s 
modified eagle medium (DMEM) (Lonza Group AG, Basel, Switzerland) (10% heat inactivated 
FCS and 1% L-glutamine). Cells were split 1:12 twice a week. For this, medium was discarded, 
cells were rinsed once with PBS, 2ml trypsin solution was added and incubated until cells 
detached from the flask. 10ml of supplemented DMEM was added, the cells singularized by 
pipetting up and down several times. 1ml was used for continuous culturing.  
 
2.2.3.2 Cell counting 
In order to determine to cell number, a Neubauer chamber was used. For this 10µl of cell 
suspension was mixed with 90µl of 0.1% Trypan blue solution (in PBS, PEI media kitchen) and 
10µl transferred to the counting chamber. Four squares were counted, the mean was formed, 
multiplied by 10,000 and by 10 (dilution with Trypan blue), resulting in the number of cells per 
ml. 
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Primary cells were counted using an automated cell counter (Coulter® Counter Z2™, Beckman 
Coulter, Inc., Indianapolis, US). For this 100µl cell suspension was added to 10ml degassed 
Casey ton (OLS® OMNI Life Science, Bremen, Germany) and measured with the appropriate 
settings. 
 
2.2.3.3 Cell thawing and freezing 
Frozen cells were stored for short-term storage at -80°C and for long-term storage in liquid 
nitrogen. Cells were thawed by warming the cryovial until cell suspension liquefied. Cells were 
transferred to a 50ml Falcon tube and 4ml of medium added. Cells were centrifuged at 100g 
for 5min, the supernatant was discarded, and the cells carefully resuspended in 5ml of medium 
and transferred to a T25 flask. For the different assays, cells were expanded in T75 flasks. 
For freezing cells, the cells were counted and a minimum of two million cells/cryovial frozen. 
The cells were centrifuged at 100g for 5min, the supernatant was discarded, and cells 
resuspended in 1ml of cold freezing medium (90% FCS, 10% DMSO (Sigma Aldrich 
Corporation, St. Louis, US)). The cryovials were transferred into a freezing container, 
Nalgene® Mr. Frosty (Sigma Aldrich Corporation, St. Louis, US), and stored at -80°C for 24h 
before being transferred into liquid nitrogen. 
 
2.2.3.4 Transfection of adherent cells (siRNA) 
For transient knockdown of host factors in adherent cells, Lipofectamine™ RNAiMAX 
Transfection Reagent (Thermo Fisher Scientific Inc., Waltham, US) was used to transfer siRNA 
into cells. A reverse transfection approach was chosen and performed according to the 
manufacturer’s protocol. All surfaces and equipment were cleaned with RNase AWAY 
beforehand. In short, the siRNA stock was diluted in fresh OPTI-MEM™ to a final concentration 
of 0.1pmol/µl (for details refer to Table 10) and added to the wells. Lipofectamine™ RNAiMAX 
Transfection Reagent was prediluted in OPTI-MEM™ and added to the diluted siRNA and 
incubated for 20min at room temperature. Meanwhile, the cells were counted and diluted to a 
final concentration of one million cells/6ml medium containing 20% FCS and then seeded onto 
the transfection mix. The cells were incubated at 37°C ≤72h before harvest or read-out was 
performed. 
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Table 10: Ratio of siRNA to transfection reagent to cell number in dependence of well format.  
 µl/well (96 well) µl/well (384 well) 
siRNA in OPTI-MEM™ (0.1pmol/µl) 30µl 10µl 
1:200 diluted Lipofectamine™ RNAiMAX in OPTI-MEM™ 30µl 10µl 
cells/well seeded 3333/20µl 10000/60µl 
 
2.2.3.5 Transfection of suspension cells (siRNA) 
For transient knockdown of host factors in suspension cells, transfection by electroporation 
was chosen to transfer siRNA into cells. For this, the cell specific electroporation kits, i.e. Cell 
Line Nucleofector® Kit V for J-Lat clones and Cell Line Nucleofector® Kit C for U1 (both Lonza 
Group AG, Basel, Switzerland), were used, and the instruction of the manufacturer followed. 
In short, cells were counted and centrifuged at 100g for 10min, the supernatant was completely 
discarded and two million cells per sample were resuspended in nucleofector solution and 2µl 
of 20µM siRNA was added. The suspension was transferred into a cuvette. The cells were 
electroporated with the appropriate program with a Nucleofector™ 2b device (Lonza Group 
AG, Basel, Switzerland). The cells were transferred into a well of a 12 well plate, containing 
1ml of prewarmed RPMI1640. If electroporated cells were further stimulated, the cells were 
split over three wells and a stimulus was added for 24h.  
 
2.2.3.6 Lentiviral particle production 
Lentiviral particles were produced in HEK293T/17 cells, seeded at 0.75 million cells well in a 6 
well plate. 24h post seeding, the medium was replaced with 1ml OPTI-MEM™. The DNA mix 
was prepared (according to Table 11) in 500µI OPTI-MEM™ and 5µl Lipofectamine® 2000 
Transfection Reagent (Thermo Fisher Scientific Inc., Waltham, US) prediluted in 500µl OPTI-
MEM™ were added to the DNA, followed by incubation for 20min at room temperature. The 
plasmid DNA transfection mix was added drop wise to the cells followed by overnight 
incubation. The next day, medium was replaced by supplemented DMEM. On the two following 
days, the lentiviral particle containing supernatant was collected on ice, filtered through a 
0.42µm filter, aliquoted in 1ml aliquots and stored at -80°C.  
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Table 11: Formulation of DNA ratios for lentiviral particle production. 
Component Amount 
pAX2  1.0µg 
pCMV-VSV-G 0.5µg 
shRNA containing plasmid 2.0µg 
filled up with OPTI-MEM™ to final volume of 500.0µl 
 
2.2.3.7 Transduction of adherent cells (stable cell lines) 
Production of stable HEK293T cells, expressing luciferase from HIV promoter, was performed 
by transducing cells with lentiviral particles containing a modified version of pNL4.3 (pNL4.3 
env deleted by frameshift mutation, nef replaced by firefly luciferase) in a ratio of one particle 
per cell. The cells were seeded and allowed to attach before viral particles were added. The 
next day, medium was changed, and cells cultivated over twenty passages before being 
checked for expression of luciferase and testing. Those produced cells were denoted HIVluc 
HEK293T in all further experiments. 
 
2.2.3.8 Transduction of suspension cells (stable cell lines) 
Production of stable suspension cell lines was achieved by transduction of target cells with 
lentiviral particles. For this, 0.75 million cells/well were seeded in 1.5ml supplemented 
RPMI1640 in a 6 well plate format. 1ml of lentiviral particles was added to the cells and then 
spin occulated at 300g for 90min at 30°C. The next day, medium was exchanged with 
supplemented RPMI1640. Two days after spin occulation, puromycin (InvivoGen, San Diego, 
US) was added to the medium at a final concentration of 1µg/ml to start the selection process. 
For each round of transduction, a non-transduced control was taken along. During the first 
week of puromycin selection the cells and the non-transduced control were closely monitored, 
and medium was regularly changed. One week after selection, cells were expanded and 
experimentally tested. For suspension cells containing pTRIPZ derived integrates a further 
induction of shRNA by doxycycline (InvivoGen, San Diego, US) was initiated before these cells 
were tested.  
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2.2.4 Primary cells 
2.2.4.1 Origin of patient material 
Primary material was obtained from follow-up blood samples of participants of the 
‘seroconverter’ study (RKI - HIV-Serokonverterstudie). This study is ongoing in Germany since 
1997 and collects data on the long-term disease progression and the overall survival time 
within the study cohort as well as observes trends in HIV mutations and subtypes. Study 
participants included are ≥18 years, HIV-1 positive with an acute or documented 
seroconversion (<3 years) and provided written consent. The Robert Koch Institute is 
conducting this study and receives 20ml of EDTA blood at least once per year from each 
participant. The blood plasma is used for further analysis and the remainders, which are not 
used for any further testing, were used for the isolation of CD4+ T cells. All experiments on 
primary CD4+ T cells were conducted at the Robert Koch Institute within a 2.5-month period.  
 
2.2.4.2 PBMC isolation from HIV-1 positive study participants 
HIV-1 positive full blood was diluted with two parts of PBS and carefully layered on 11ml 
Histopaque®-1077 (Sigma Aldrich Corporation, St.Louis, US) in a 50ml tube. The sample was 
centrifuged for 25min at 900g without brake and acceleration. The formed lymphocyte ring was 
carefully aspirated and transferred into a new tube, which was filled up to a final volume of 
50ml with PBS and then centrifuged at 600g for 10min with brake and acceleration, as all 
centrifugation steps from here on. The supernatant was discarded, and the cell pellet 
resuspended in 10ml 0.87% NH4CL for 5min under occasional swirling to allow lysis of 
remaining erythrocytes. After incubation, PBS was added to a final volume of 50ml and 
centrifuged at 300g for 10min. The supernatant was discarded, and the cell pellet was 
resuspended twice more in PBS and centrifuged at 300g for 10min. The supernatant was 
discarded, and the cell pellet was resuspended in 5ml PBS and cell numbers determined.  
 
2.2.4.3 Isolation of CD4+ T cells from PBMCs 
For the further isolation of CD4+ T cells from the PBMCs, the CD4+ T Cell Isolation Kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany) was used and the instructions of the manufacturer 
followed. For all washing and resuspension steps, sterile-filtered PBS with 5% BSA and 2mM 
EDTA was used, which is in the following assigned as MACS buffer. All steps were performed 
with pre-cooled solutions. Volumes of MACS buffer, antibodies and microbeads used were 
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calculated based on the cell numbers. All centrifugation steps were carried out at 300g for 
10min, unless stated differently. 
In short, cells were centrifuged, the supernatant was discarded, and cells resuspended in 40µl 
MACS buffer per 1x107 cells. All non-CD4+ T cells were labeled by addition of 10µl of biotin-
antibody cocktail (containing antibodies against the following surface markers: CD8, CD14, 
CD15, CD16, CD19, CD36, CD56, CD123, TCR γ/δ, and CD235a) per 1x107 cells total and 
incubated for 5min in the fridge. Another 30µl MACS buffer was added to the cells followed by 
20µl microbead cocktail (microbeads conjugated to anti-biotin antibodies) per 1x107 cells total. 
The mixture was incubated for another 10min in the fridge, before applied onto LS columns 
set under a strong magnetic field (Midi MACS separator and MACS Multistand, both Miltenyi 
Biotec, Bergisch Gladbach, Germany). The cell suspension was applied to the column and the 
flow-through containing the unlabeled CD4+ T cells was collected, while the labeled unwanted 
cells were retained in the magnetic field. The cell number was determined with the Coulter 
Counter Z2. 
 
2.2.4.4 Isolation of non-activated CD4+ T cells from CD4+ T cells  
In a final isolation step, untouched CD4+ T cells were isolated for non-activated CD4+ T cells, 
i.e. cells that do not express the activation markers HLA-DR, CD69, and CD25 on the cell 
surface. For this, cells were centrifuged and resuspended in 100µl MACS buffer per 1x107 
cells. The CD4+ T cell population was mixed with 10µl of each PE-coupled antibody solution 
directed against HLA-DR, CD69 and CD25 per 1x107 cells and cells incubated for 10min in the 
fridge. After addition of 1ml MACS buffer, the cell suspension was centrifuged, and the 
supernatant discarded. The cells were resuspended in 80µl MACS buffer per 1x107 cells and 
20µl anti-PE conjugated microbead solution (Miltenyi Biotec, Bergisch Gladbach, Germany) 
was added. The mixture was incubated for 15min in the fridge, 1ml MACS buffer was added 
and the cells centrifuged. The supernatant was discarded, the cells resuspended in 500µl 
MACS buffer and then applied to a LD column (Miltenyi Biotec, Bergisch Gladbach, Germany) 
set under a strong magnetic field. The flow-through was collected containing the unlabeled and 
non-activated CD4+ T cells. The cell number was determined with the CASY cell counter. 
 
2.2.4.5 Primary T cell stimulation 
For stimulation of primary CD4+ T cells, 5x105 cells per condition were seeded in RPMI1640 
supplemented with 20% FCS and 1% L-glutamine in a 48 well plate in a final volume of 500µl 
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per well. Cells were treated with compound, LRAs, a combination of both, antiCD3/antiCD28 
(both Miltenyi Biotec, Bergisch Gladbach, Germany) as positive control or with only medium 
as negative control. Cells were treated for initially six days, with treatment replacement on day 
three (and later onwards treated for three days only). Cells were transferred into a 1.5ml 
collection tube and centrifuged at 300g for 10min. 110µl of supernatant was collected for p24 
ELISA and the leftover kept for optional RT-qPCR of viral RNA. The cell pellet was 
resuspended in 0.5ml of TRIzol™ reagent (Thermo Fisher Scientific Inc., Waltham, US) and 
stored for subsequent isolation of RNA and DNA at -20°C.  
 
2.2.5 Protein associated techniques 
2.2.5.1 p24 ELISA on cell line supernatant 
In order to determine p24 levels, the HIV-1 p24CA antigen capture assay (via the material 
transfer agreement from Frederick National Laboratory for Cancer Research) was acquired 
and performed according to the manufacturer’s protocol. 200µl of supernatant of treated U1 
cells was collected and mixed with 20µl of lysis buffer (10% Triton X-100 (Sigma Aldrich 
Corporation, St.Louis, US) in H2O), incubated for 2h at 37°C before being stored at -80°C until 
further used.  
The ELISA was performed in a 96-flat well plate and all incubations were performed at room 
temperature unless stated differently. 24h prior to the ELISA, the capture antibody was diluted 
1:1440 in PBS and 100µl per well distributed. The coated wells were sealed and stored 
overnight at 4°C. The next day, the capture antibody solution was discarded, and the wells 
were blocked with 300µl blocking solution (1% BSA in PBS) for 30min at room temperature. 
The wells were washed five times with 1X wash buffer (1:10 diluted ELISA plate wash 10X 
(Perkin Elmer, Inc., Waltham, US)). 100µl of lysed supernatant or standard dilution series was 
added and incubated for 2h. The wells were washed five times with 1X wash buffer. 100µl of 
primary antibody solution (sterile filtered 10% FCS, 2% NMS in RPMI1640 + primary antibody 
anti-HIV-1 p24) was added and incubated for 1h. The wells were washed five times with 1X 
wash buffer. 100µl of secondary antibody solution (sterile filtered 2% NMS, 5% NGS, 0.01% 
Tween 20 in RPMI1640 + 1:100,000 diluted HRP-conjugated goat-anti-rabbit) was added and 
incubated for 1h. The plates were washed five times with 1X wash buffer. 100µl of TMB 
Peroxidase substrate was added and incubated for 30min. The reaction was stopped by the 
addition of 100µl 1M HCl. The wells were read with a microplate reader (PHERAstar FSX, 
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BMG Labtech, Ortenberg, Germany) at 450nm and 650nm background wavelength. The 
background results were subtracted from the raw data. A sigmoidal fit was performed 
(GraphPad Prism 7) using the values given by the standard dilution series and the pg/ml p24 
calculated from it. 
 
2.2.5.2 Sensitive p24 ELISA on primary cells 
In order to detect reactivation of latent HIV-1 provirus on protein level a highly sensitive and 
commercially available p24 ELISA (Innotest® HIV antigen mAb kit 80564, Fujirebio, Inc., 
Malvern, US) was chosen, which allows the detection of small amounts of p24 of all HIV strains 
within short time. The instructions of manufacturer were followed. In short, 100µl conjugate 
working solution I was mixed with 100µl supernatant, added to the pre-coated 8-well strips and 
incubated at 37°C for 1h. The supernatant was discarded, and the wells washed five times 
with 300µl of 1X washing solution by addition and removal via inversion and gentle tapping on 
absorbing cloth. 200µl of conjugate working solution II was added to the wells, incubated at 
37°C for 30min. After incubation the wells were washed five times as before. 200µl of substrate 
working solution was added to the wells and incubated at RT for 30min and the strips gently 
tapped to allow mixing. Then 50µl of 25% sulfuric acid were added to the wells, incubated for 
5min and the wells read at 450/620nm (Spark® TECAN Group Ltd., Mannedorf, Switzerland) 
absorbance with a plate reader. A standard dilution series of was run along with the samples, 
a sigmoidal curve fit was applied to the standard dilution series allowing the extrapolation of 
p24 concentrations of the tested supernatants.  
 
2.2.5.3 Protein lysate preparation  
Protein lysate of treated J-Lat 8.4 cells or U1 cells was prepared from ≥0.5 million cells. For 
this, cells were transferred to a 1.5ml collection tube and centrifuged in a precooled centrifuge 
(4°C) at 300g for 5min. The supernatant was discarded, the cells washed once with 1ml cooled 
PBS, and centrifuged as before. The supernatant was completely discarded, the cell pellet 
resuspended in 30µl RIPA buffer containing protease inhibitor (cOmplete Protease Inhibitor 
Cocktail, Roche Holding AG, Basel, Switzerland), and incubated for 30min on ice. The lysed 
cells were centrifuged in a precooled (4°C) centrifuge at full speed for 30min. Afterwards the 
supernatant was transferred to a new collection tube and either stored at -20°C or directly used 
to further determine the protein concentration. 
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2.2.5.4 Protein concentration determination by Bradford 
The protein concentration of the lysates was determined with the Bradford Protein Assay (Bio-
Rad Laboratories, Inc., Hercules, US), based on a color change of Coomassie brilliant blue   
G-250 dye due to its binding affinity to basic and aromatic residues present on other proteins 
(Bradford, 1976). 
The Bradford reagent was diluted 1:5 in H2O and transferred into a cuvette, 5µl of 1:5 diluted 
lysates or BSA standard was added, mixed well, incubated for 5min, and the absorption 
measured in a UV/VIS-spectrometer. Due to the known concentration of the standard and the 
measured absorbance, a standard curved was compiled, and the concentration of the samples 
was calculated. 
 
2.2.5.5 Polyacrylamide gel electrophoresis 
To separate proteins according to their size SDS polyacrylamide gel electrophoresis (SDS-
PAGE) was applied. The gel chamber was assembled, the inner and outer chamber were filled 
with MOPS running buffer. 500µl Antioxidant (Life Technologies™, brand of Thermo Fisher 
Scientific Inc., Waltham, US) was added to the inner chamber in addition. The samples were 
prepared according to Table 12, incubated at 70°C for 10min and loaded on a pre-cast 15 well 
4% - 12% NuPAGE® Bis-Tris gradient gel (Life Technologies™, brand of Thermo Fisher 
Scientific Inc., Waltham, US) along with 5µl protein marker/ladder XXL DeLuxe (GeneON 
GmbH, Ludwigshafen, Germany). 160V were applied to the samples for 110min.  
 
Table 12: Formulation of protein samples for SDS-PAGE. 
Component Volume 
Protein lysate (20µg) Xµl 
4X NuPAGE® Sample buffer 6.0µl 
10X NuPAGE® Sample Reducing Agent 2.4µl 
add H2O to a final volume of 24.0µl 
 
2.2.5.6 Protein blotting and detection 
The size-separated proteins were transferred onto Amersham Hybond P 0.45 PVDF 
membrane (GE Healthcare GmbH, Solingen, Germany) using the Semi-Wet-Blotting Module 
Novex® (Life Technologies™, brand of Thermo Fisher Scientific Inc., Waltham, US). For this, 
500ml transfer buffer was prepared (NuPAGE® Transfer buffer 20X (Life Technologies™, 
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brand of Thermo Fisher Scientific Inc., Waltham, US), 20% methanol, 500µl Antioxidant (Life 
Technologies™, brand of Thermo Fisher Scientific Inc., Waltham, US) in H2O). The blotting 
chamber, the cut to size Whatman papers and sponges were soaked in transfer buffer. The 
cut to size PVDF membrane was incubated first in methanol for 20s, in H2O for 20s before also 
soaked in transfer buffer. The blotting chamber was assembled with sponges and Whatman 
paper sandwiching the gel and the membrane. 35V were applied for 1h. After blotting the 
membrane was blocked in blocking buffer (5% BSA solved in 1X TBS-T) for ≥1h at room 
temperature under gentle shaking. In addition, the gel was stained with Coomassie staining 
solution for 1h and destained in Coomassie de-staining solution. This served as quality control 
for successful protein separation. After blocking, the membrane was incubated with the first 
antibody in blocking buffer overnight at 4°C. The membrane was washed three times in 1X 
TBS-T for 10min, followed by incubation with the secondary HRP-labeled antibody in blocking 
buffer for 1h at room temperature. The membrane washed three times as before. The 
membrane was incubated with ECL Prime (GE Healthcare GmbH, Solingen, Germany) 
according to the manufacturer instructions for 5min and transferred into a light tight film 
cassette. Autoradiography films were exposed to the membrane and developed with an 
autoradiography film developer (Agfa Healthcare N.V., Mortsel, Belgium). 
 
2.2.6 Compound preparation and read-out associated techniques 
2.2.6.1 Flow cytometric sample preparation 
J-Lat and U1 cells were analyzed by flow cytometry for viability (and GFP) after treatment. For 
this, a minimum of 80,000 cells per sample was used. Cells were pelleted by centrifugation at 
300g for 5min. The supernatant was discarded, and cells washed twice with 200µl PBS. The 
cells were resuspended in Fixable Viability Dye eFluor® 450 (eBioscience, brand of Thermo 
Fisher Scientific Inc., Waltham, US) diluted 1:2000 in PBS and incubated at 4°C for 30min in 
the dark. Then cells were washed twice in 200µl PBS and fixed in 2% PFA for 30min. Samples 
were measured using the MACSQuant® Analyzer 10 (Miltenyi Biotec, Bergisch Gladbach, 
Germany) or the BD™ LSR II SORP (BD Biosciences, Franklin Lakes, US) and analyzed using 
FCS Express V4 software.  
Primary cells were analyzed by flow cytometry for purity and viability. A minimum of 30,000 
cells was stained. The cells were transferred into a 96 U well plate, centrifuged at 300g for 
10min and the supernatant discarded. The cell pellet was resuspended in 200µl PBS and again 
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centrifuged at 300g for 10min. The supernatant was discarded, and the cells resuspended in 
50µl of 1:11 diluted anti-HLA-DR, anti-CD69, anti-CD25 or in 1:20 diluted anti-CD4. Samples 
were incubated at 4°C in the dark for 15min. 150µl of PBS was added to the samples, 
centrifuged at 300g for 10min and the supernatant discarded. The washing step was repeated. 
The samples were finally resuspended in 80µl of PBS.  
Determination of viability in primary was done as stated above using the Fixable Viability Dye 
eFluor ®780 (eBioscience, brand of Thermo Fisher Scientific Inc., Waltham, US). Samples 
were measured with the BD FACSCalibur™ (BD Biosciences, Franklin Lakes, US) flow 
cytometer. Analysis of data was done with FCS Express 4.0 software.  
 
2.2.6.2 Gating strategy 
For flow cytometric analysis, the cells were first gated for the cell population, excluding cell 
debris, followed by exclusion of duplets. Then the singlets were gated for viable cells excluding 
stained dead cells. In the case of J-Lat cells, singlets were also gated for GFP positivity, which 
as a measure to determine the level of latency reversal. In case of stable suspension cell lines 
containing pTRIPZ or pRIPZ derived shRNA integrates, RFP was measured in addition, 
whereas RFP served as measure for shRNA-derived knockdown of host factors tested. 
 
2.2.6.3 Luminescence read-out 
Luciferase activity in HEK293T cells after treatment was assessed by adding Britelite™ 
substrate (Perkin Elmer, Inc., Waltham, US) to the cells and incubation for 5min at room 
temperature. Luciferase activity was determined using a microplate reader (PHERAstar FSX, 
BMG Labtech, Ortenberg, Germany). 
Viability of adherent HEK293T cells after treatment was assessed by adding ATPlite™ 1 step 
substrate (Perkin Elmer, Inc., Waltham, US) to the cells followed by 5min of incubation at room 
temperature and read with a microplate reader (PHERAstar FSX, BMG Labtech, Ortenberg, 
Germany). 
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2.2.7 Statistical analysis 
For the statistical analysis of compounds with LRA in comparison to LRA only a Kruskal-Wallis 
test was chosen. This test is non-parametric one and allows comparing more than two groups 
(Daniel, 1990). The choice of test was in accordance with the bioinformatic department of the 
Paul-Ehrlich-Institut. Statistical significance was calculated by GraphPad Prism software and 
is indicated by * on the group itself in comparison to the control group, whereas * indicates the 
p-value (also known as probability value) < 0.05, **<0.01, ***<0.001, ****<0.0001. 
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3 Results  
3.1 The initial screening - starting point 
In the following, the initial screening setup will be explained. The primary hits of a genome-
wide siRNA screen served as starting point to choose and follow-up candidate factors, whereas 
the screen itself, its execution, analysis and primary hit discrimination are not part of this 
scientific work.  
A genome-wide siRNA screen was performed in HEK293T, which had been transduced with 
an HIV-1 derived reporter virus (pNL4.3 expressing luciferase instead of nef, env deleted by 
frameshift mutation and VSV-G pseudotyped). After transduction, the cells were cultured over 
several weeks and expressed baseline luciferase levels from the HIV -1 LTR promoter. As env 
was deleted neither complete viral particles could form nor could be released. This transduced 
cell line was then used for a genome-wide siRNA screen. The screen was performed in a 384 
well format, using two siRNAs per target in a pooled approach, i.e. both siRNAs were applied 
simultaneously in the same well, and two wells per target were transfected. The luciferase        
read-out was performed 72h post siRNA transfection. Upon substrate addition the production 
of luciferin was measured (a graphical overview of the experimental procedure is shown in         
Figure 5). The Z-score was calculated for all values and served as a measure on how far a 
specific value deviates from the normal distribution. Hits were considered if their Z-score was 
either ≤ -2 or ≥ +2, reflecting either a decreased or an increased luciferase signal beyond the 
baseline luciferase signal derived from negative (non-targeting) controls. Increased luciferase 
values point towards a restrictive ability of the given factor, whereas decreased luciferase 
values point towards a supportive role of the factor on HIV-1 transcription.  
The identified primary hits (Table S1, Appendix) potentially play a role in HIV-1 transcriptional 
processes. Further, those primary hits may also play a role in HIV-1 latency. This assumption 
is supported by two published examples, namely BRD4 and CYLD (Manganaro et al., 2014; 
Zhu et al., 2012), both host factors support latency maintenance and have been identified by 
the primary screening as restrictive hits, i.e. increased luciferase signal upon their knockdown. 
This also underlines the suitability of the primary screening hits as a starting point to (chose 
and) validate follow-up hits.  
Nevertheless, some general considerations concerning the initial screening need to be kept in 
mind. The usage of VSV-G pseudotyped viral particles allows for one or more infections per 
cell. In this regard, the infected cell line is non-homogenous for the number of proviruses 
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present per cell and also in regard to diverse integration sites. Further, the cells express a 
luciferase baseline level; therefore, this model is strictly speaking not a latency cell model.  
 
 
Figure 5: Graphical overview on the HIV-1 derived reporter virus and the initial screening setup.       
A) Genomic organization of the HIV-1 reporter virus used for the initial screening and for the re-testing 
of follow-up candidates. The reporter construct was derived from pNL4.3 being env deleted by frameshift 
mutation and possessing luciferase gene in place of nef. B) HEK293T cells were transduced with an 
HIV-1 reporter construct (genomic composition described in A). Transduced cells were cultured several 
weeks before host-factors were knocked down by siRNA. 72h post knockdown luciferase substrate was 
added and luciferin production was assessed. Increases or decreases in luciferase signal beyond 
baseline can be correlated to a potential supportive or restrictive effect of the host factor on HIV           
transcriptional processes. 
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3.2 Two differential approaches to identify novel LRAs 
The hits of a genome-wide siRNA screen, as detailed in 3.1, served as basis for the selection 
of follow-up hits to be tested for their impact on latency reversal. A schematic overview of the 
initial screening is shown in Figure 5B. For the follow-up hit selection two differential strategies 
were applied and a graphical scheme is shown in Figure 6. For the approach I (left arm), the 
selection of follow-up hits was based on their potential to bind and/or modify chromatin. The 
selected candidates were then retested in the initial screening test system, followed by 
validation in a latency cell line model. A follow-up on validated factors would be done in primary 
HIV-1 cells. For the approach II, follow-up hits were based on their property to be druggable 
and are known targets of available compounds, here referred to as druggability. The idea 
behind this approach is to repurpose licensed drugs for new medical indications, also known 
as ‘drug repurposing’. Chosen compounds were directly tested in different latency cell lines, 
followed by siRNA knockdown of host factor to verify the compound target and finally testing 
potential compounds in primary HIV-1 cells. 
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Figure 6: Graphical scheme on hit selection and follow-up strategies to identify novel candidates. 
Left arm) Selection of hits based on the presence of chromatin binding/modifying domains and their 
verification strategy. Right arm) Selection of hits based on their druggability (here referred to as hits, 
which can be inhibited by available compounds) and their verification strategy. 
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3.3 Approach I: Chromatin targets 
3.3.1 Test of target hits in the initial screening system 
For the first approach, the initial 706 primary screening hits were checked against publications 
listing chromatin associated proteins (Arrowsmith et al., 2012; Bottomley, 2004; de la Cruz et 
al., 2005; Patel and Wang, 2013; Talbert and Henikoff, 2010). The selection criteria for the first 
approach followed the assumption that chromatin modifications and involved factors can 
influence proviral latency. 10 hits were found to possess domains known to interact with 
chromatin, as shown in Table 13, even though this number likely underestimated the actual 
number of hits meeting these criteria. The selected hits were followed up on. The experimental 
setup followed the initial screening setup with the difference that four independent siRNAs per 
candidate host factor were tested individually. Staying in line with the initial screening, an 
increase in luciferase signal as derived from increased luciferase expression from the HIV-1 
LTR promotor upon knockdown of a host factor would point towards its potential restrictive 
capacity on HIV-1 transcriptional processes. The results are shown in Figure 7.  
 
Table 13: Screening hits identified to possess chromatin binding and/or modification properties. 
Z-score 
NCBI-
official 
symbol 
NCBI-official full name Protein domains reported HIV interactions 
4.588 BRD4 bromodomain containing 4 bromo among others Li et al., 2013; 
Mbonye et al., 2013; Taube & 
Peterlin, 2013 
4.4118 MSH6 mutS homolog 6 PWWP not announced 
4.2379 SMYD2 SET and MYND domain 
containing 2 
HMT not announced 
2.8281 SETD3 SET domain containing 3 HMT not announced 
2.4388 TRRAP transformation/transcription 
domain-associated protein 
others Brès et al., 2009; Gautier et al., 
2009 
2.3053 CXXC1 CXXC finger protein 1 PHD Gautier et al., 2009 
2.2635 CBX6 chromobox homolog 6 chromo not announced 
2.1472 KAT6B lysine acetyltransferase 6B HAT Gautier et al., 2009 
2.058 ASXL3 additional sex combs like 3 
(Drosophila) 
PHD Zhou et al., 2008 
2.0267 USP22 ubiquitin specific peptidase 22 others not announced 
bromo: bromodomain, chromo: chromodomain, HAT: histone acetyltransferase, HMT: histone 
methyltransferase, PHD: plant homeodomain, PWWP: proline-tryptophan-tryptophan-proline containing 
domain. 
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Luciferase signal was measured in HIVluc HEK293T (env deleted by frameshift mutation, 
luciferase in place of nef) 72h post-knockdown, determining the potential influence of the host 
factor on HIV-1 transcription processes Figure 7A). A panel of non-targeting siRNAs was 
transfected, the luciferase counts were set to 100% for the negative controls and the results of 
all other siRNAs were normalized to them. As an internal control, a siRNA targeting luciferase 
was transfected (designated si luciferase), leading to a decrease in signal by ~90% and 
thereby validating the assay functionality. As positive controls, siRNAs targeting either BRD4 
or CYLD were used, leading to an increase of luciferase signal beyond the negative control. 
Of note, CYLD is not chromatin associated but evokes its effect by indirectly regulating NFκB. 
An increase in luciferase signal, comparable to the results for the BRD4 knockdown, was 
detected upon silencing of the transformation/transcription domain-associated protein 
(TRRAP) (Figure 7A). This result led to further testing of TRRAP regarding its potential 
influence in HIV-1 latency. 
In order to validate the luciferase results, the same panel of siRNAs was transfected 
simultaneously in HEK293T cells. This allowed the identification of a potential effect on cell 
viability (Figure 7B) measured by ATPlite. The panel of non-targeting siRNAs was set to 100% 
and all other results normalized to it. As internal control, validating the assay functionality, a 
siRNA targeting the ribosomal protein 27 (designated as ‘si tox control’), which is essential for 
cell survival, was transfected. The knockdown of this internal control resulted in a decrease of 
viability by around 90%. All other tested siRNAs resulted in a decrease of maximally 30%, 
suggesting that RNAi silencing only minimally influenced cell viability (except siCYLD #2). 
In a final setting, the knockdown efficiency of each tested siRNA was determined by RT-qPCR 
(Figure 7C). For this, HEK293T cells were transfected with siRNA, samples were harvested 
after 48h and total RNA was isolated for each sample. Each gene of interest was internally 
normalized to GAPDH, serving as housekeeping gene. Furthermore, a fold change for each 
tested host factor was determined with the averaged non-targeting controls. Most siRNAs 
efficiently silenced their targets.  
In summary, silencing of host factors by siRNA has led in some cases to an increase in 
luciferase signal. This increase was specific for the knockdown of the given factor. This was 
further confirmed by viability testing, in which no tested siRNA led to a toxic effect, which could 
bias the luciferase read-out. In addition, the specific targeting of host factor by siRNA was 
confirmed on mRNA level. TRRAP was confirmed as hit and chosen for further testing in J-Lat 
clone 8.4 latency model. 
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Figure 7: siRNA knockdown results of chosen hits. A) Luciferase read-out in HIVluc HEK293T cells 
and (B) viability read-out in HEK293T cells 72h post siRNA transfection. Four individual siRNA per host 
factor were tested individually and in quadruplicates in a 384 well plate setting. The results for all applied 
non-targeting siRNA controls were averaged, set to 100% and all other values normalized to the control. 
The combined results of three independent experiments are shown including standard deviation.            
B 
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C) Fold change of host factor knockdown on mRNA level tested in HEK293T cells 48h post siRNA 
transfection as measured by RT-qPCR. Each siRNA was tested individually in triplicates in a 96 well 
plate setting. 
 
3.3.2 Establishment of J-Lat 8.4 induction 
In order to determine the optimal stimulus concentration and time point of read-out, J-Lat (clone 
8.4) cells were treated with four different LRAs, i.e. TNFα, prostratin, SAHA or sodium butyrate. 
The LRAs were applied at different concentration for either 24h or 48h followed by flow 
cytometric analysis for viable cells and GFP positive cells, to determine the optimal 
concentration to induce reversal of latency (as measured by GFP positive cells) without 
inducing cell toxicity. The results are shown in Figure 8 and a scheme on how J-Lat cells were 
generated (Jordan et al., 2003) and work is provided in Figure 4.  
High concentrations (up to 270ng/ml) of TNFα, a T cell activating LRA, did not negatively affect 
cell viability. TNFα concentration, as low as 1.11ng/ml, could induce minimal GFP expression.      
J-Lat 8.4 cells showed up to 20% of GFP positive cells after 24h of stimulation, which increased 
up to 30% of GFP positive cells after 48h at the highest concentration applied (Figure 8A). 
Prostratin (also a T cell activating LRA) treatment showed 20% reduction in viability when the 
highest concentration of 135µM was applied. This decrease in viability was even more drastic 
upon 48h of treatment leading to a cell death greater than 50%. The minimum concentration 
to induce GFP positive cells in this assay system was determined to be at 1.67µM. The highest 
concentration of prostratin could induce almost 30% of GFP positive cells after 24h, and less 
after 48h that was accounted to the high toxicity of prolonged prostratin exposure (Figure 8B). 
SAHA (an HDACi and non-T cell activating LRA) treatment resulted in 20% reduction of viability 
after 24h when used at high concentrations. Prolonged treatment for 48h showed high toxicity. 
2.5µM SAHA was seen to induce minimal GFP expression. The highest percentage of GFP, 
of almost 20%, was induced at a concentration of 22.5µM after 24h, which did not increase 
further after 48h of treatment (Figure 8C). 
The results for sodium butyrate were comparable to the results of SAHA, the other tested 
HDACi. 125mM, the highest concentration tested, of sodium butyrate led to a drastic decrease 
(up to 40%) in cell viability after 24h and to almost 100% after 48h. At 15mM the maximum of 
30% GFP induction was reached after 24h. Prolonged sodium butyrate treatment did not lead 
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to an increase in GFP positive cells, which was accounted to its high toxicity. A concentration 
of 1.667mM was determined to induce minimal GFP expression (Figure 8D).  
In summary, all tested stimuli could induce GFP expression in J-Lat 8.4 cells to a various 
degree. The influence on cell viability was more pronounced after 48h of LRA treatment, while 
less after 24h. Due to this, the assay duration was set to 24h for all further experiments. The 
concentrations were chosen to be 10ng/ml TNFα, 5µM prostratin, 2.5µM SAHA, and 5mM 
sodium butyrate. Those concentrations led to GFP induction without reaching the maximum, 
which allows the detection of additional effects. In addition, the concentrations are in line with 
publications using the same model (Blazkova et al., 2009; Zhu et al., 2012). 
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Figure 8: Reversal of latency in J-Lat 8.4 cells in dependence of stimulus concentration. J-Lat 8.4 
cells were treated with different concentrations of TNFα (A), prostratin (B), SAHA (C) or sodium butyrate 
(D) for 24h and 48h. % Viability (right y-axis) in grey and %GFP positive cells (left y-axis) in black were 
assessed by flow cytometry. Each point was measured in technical duplicates and standard deviation 
was indicated. 
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3.3.3 Inducible shRNA encoding J-Lat 8.4 cells - establishment of 
experimental system 
TRRAP is a highly conserved adapter protein, which is found in multiprotein complexes with 
HAT activity without possessing HAT activity on its own. It recruits HATs to facilitate acetylation 
of histones and by this supports transcription. TRRAP is further involved in cell cycle 
progression and DNA repair (Ard et al., 2002; Ikura et al., 2000; McMahon et al., 1998, 2000). 
To verify TRRAP involvement in latency reversal, stable J-Lat 8.4 cells were generated that 
contained vectors where TRRAP silencing could be elicited including negative and positive 
control cells, i.e. encoding shRNAs against no cellular target or against BRD4, respectively. 
For this, the so-called TRIPZ system was chosen, i.e. those vectors encode an shRNA against 
a cellular target, along with a rfp gene under a tetracycline depend promoter. Knockdown of 
host factors is only achieved in the presence of doxycycline and can be monitored by RFP 
expression, while reversal of latency in J-Lat cells can be measured by expression of GFP. 
This test system allowed for determination of double positive cells. For this, cells were 
transduced with lentiviral particles, then selected with puromycin over five days, followed by 
doxycycline induction of the shRNA along with RFP (being expressed from the same 
tetracycline-dependent promoter). The doxycycline induction was tested in two control cell 
lines encoding either a non-silencing shRNA or no shRNA. Two different concentration of 
doxycycline, either 1µg/ml or 2µg/ml, respectively, were tested for induction of shRNA along 
with RFP. Doxycycline was replenished every 24h. As seen in Figure 9A, 1µg/ml doxycycline 
treatment for 96h led to the same level of RFP induction as 2µg/ml, the maximum level of RFP 
expression was found to be around 60%. For all further experiments, 1µg/ml of doxycycline 
was applied for induction of the TRIPZ constructs.  
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Figure 9: Establishment of TRIPZ derived stable J-Lat cells. A) RFP induction in dependence of 
doxycycline concentration determined by flow cytometry after 96h of induction. B) Determination of RFP 
levels in dependence of doxycycline duration measured after 48h and 96h. C) Determination of 
knockdown on mRNA level by RT-qPCR (same samples as in (B), standard deviation derived from the 
two negative controls which were averaged and set to one, and all other values normalized to those. 
 
In the next step, the optimal duration of doxycycline induction was tested. For this, the control 
cell lines as well as the three generated cell lines containing different shRNA targeting BRD4 
(as positive control) were tested for RFP induction by flow cytometry and for knockdown of 
BRD4 by qRT-PCR at either 48h or 96h after induction. The results are shown in Figure 9B 
and C. A prolonged doxycycline treatment resulted in higher RFP levels (Figure 9B) and led 
to a better knockdown (Figure 9C). Of note, even though all stable cell lines could be induced 
with doxycycline to a varying degree, the knockdown capacity of each shRNA varied greatly.  
In a final experiment, the doxycycline induced stable cell lines were exposed to prostratin 
stimulation for 24h and the cells analyzed for double positive cells, whereas RFP correlated to 
the knockdown of host factor targeted and GFP correlated to reactivation of latency (as 
determined by flow cytometry). The results are shown in Figure 10. Medium treatment led to 
average 5% of double positive cells. The stable cell line encoding TRIPZ shBRD4 004 showed 
even around 10% of double positive cells without additional stimulation. Upon treatment with 
prostratin, an increase in double positive cells was seen for all tested cell lines. The induction 
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capacity was greatest for the control cell line. The TRIPZ shBRD4 004 cell line showed a slight 
increase in double positive cells over the negative control cell line, whereas TRIPZ shBRD4 
484 and 487 did not. The results did not well correlate to the knockdown results (determined 
in Figure 9C at 96h), as the knockdown with TRIPZ shBRD4 484 was not as efficient as the 
knockdown for TRIPZ shBRD4 487, but both showed comparable numbers of double positive 
cells with and without stimulation. 
  
Figure 10: Determination of double positive J-Lat cells upon induction and stimulation. Stable 
inducible J-Lat 8.4 cells containing either shRNA encoding against the cellular target BRD4 or non-target 
encoding (controls) were stimulated for 24h with prostratin (dark squares) or medium (grey circles). 
Percentage of double positive cells was determined by flow cytometry. GFP determined the level of 
latency reversal and RFP served as measure for targeted knockdown. The experiment was measured 
in technical duplicates and standard deviation was indicated. 
 
In summary, the TRIPZ knockdown approach led to a reduction of host factor of about 2.5-fold 
on mRNA level and to maximum RFP expression of 60%. This approach needs induction of 
shRNA and RFP by doxycycline for prolonged period including the replenishment of the 
antibiotic due to its short half-life. In addition, the background reactivation was considered 
rather high. Due to this, we decided to change to a more efficient system. The RIPZ approach, 
as from here on referred to, allowed the expression of shRNA and RFP from a constant active 
promoter. 
 
10 
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3.3.4 RIPZ plasmid generation - cloning of non-inducible shRNAs 
Since the induction of pTRIPZ stable cell lines did not result in high percentage of RFP positive 
cells, an approach was chosen without the need for doxycycline induction. For this, the GFP 
gene from the pGIPZ backbone was replaced with the RFP gene from the pTRIPZ backbone, 
resulting in a construct, which expresses the shRNA and RFP gene under a constant active 
promoter, the new construct was designated pRIPZ.  
As there were no compatible restriction sites present in both constructs, a fusion PCR 
approach was chosen, which is illustrated in Figure 11. For this, three fragments were 
amplified by PCR. Two fragments from the pGIPZ backbone were amplified, resulting in a 
634bp fragment (referred to as fragment I, primer P1 and P2, annealing temperature 52°C) 
with an XbaI restriction site and an overhang identical to the beginning of the RFP gene and a 
695bp fragment (referred to as fragment III, primer P3 and P4, annealing temperature 54°C) 
containing an XhoI site and an end identical to the end of the RFP gene. Additionally, one 
fragment was amplified from the pTRIPZ backbone, spanning the 1308bp long RFP gene 
(referred to as fragment II, primer P5 and P6, annealing temperature 53°C) including 
overhangs identical to the sequence shortly before and after the GFP gene. Successful PCR 
amplification was confirmed by the presence of bands at the specific height on an agarose gel 
(Figure 11E). In a next step 5µl of PCR product from II and I were mixed, and a PCR was run 
(for the first 10 cycles without primers, followed by the addition of primer P1 and P6 for further 
30 cycles). The resulting fragment IV was the joint product of fragments II and I with an overall 
length of 1,378bp (Figure 11E). Mixing of 5µl PCR product IV and III, followed by PCR (for the 
first 10 cycles without primers, followed by the addition of primer P1 and P4 for further 30 
cycles), led to the production of the final 2,686bp fragment (Figure 11F). This fragment was 
gel purified and via restriction digestion with XbaI and XhoI cloned into the pGIPZ backbone. 
The correct sequence of the newly produced pRIPZ backbone was confirmed by sequencing. 
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Figure 11: Generation of a pRIPZ plasmid. Scheme of the PCR-based strategy executed to generate 
a plasmid containing the RFP gene under a constant active promoter (A-D). Verification of PCR 
amplified fragments by agarose gel electrophoresis (E, F). Expected fragment size: Fragment I 634bp, 
fragment II 1,308bp, fragment III 695bp, fragment IV 1,378bp, fragment V 2,686bp. M= marker. 
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Further, the generated pRIPZ plasmid was tested for its functionality. For this, HEK293T cells 
were transfected and expression of RFP was checked by fluorescent microscope. As seen in 
Figure 12, RFP expression can be readily detected after 48h post transfection without the 
addition of doxycycline. Thus, the generation of a non-inducible RFP expression plasmid was 
successful.  
 
 
Figure 12: Confirmation of pRIPZ generation. HEK293T cells were transfected with newly generated 
pRIPZ plasmid, presence of RFP was checked microscopically 48h post-transfection. 
 
In a final set of experiments, the different shRNA in the pTRIPZ backbone were cloned via 
restriction digest into the pRIPZ backbone. Successful cloning was confirmed by plasmid 
sequencing.  
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3.3.5 Non-inducible shRNA encoding J-Lat 8.4 cells - establishment of 
experimental system 
In order to test the effect of host factor knockdown in J-Lat 8.4 cells, lentiviral particles for all 
pRIPZ constructs were produced and used to transduce J-Lat 8.4 cells. The transduced cells 
were selected with puromycin for at least a week. The percentage of RFP expressing cells of 
the different stable cell lines was evaluated by flow cytometry and the knockdown efficiency 
was determined by RT-qPCR. As a positive control shCYLD was used instead of shBRD4, as 
the effect of CYLD knockdown was assumed to be greater (as seen in Figure 7A for the 
luciferase results in HIVluc HEK293T) and due to this easier to determine. The results are 
shown in Figure 13 (for CYLD Figure 13A and B, for TRRAP Figure 13C and D, respectively). 
The RFP results (Figure 13A and C) clearly showed that stable cell lines encoding a non-
inducible shRNA produced on average 90% of RFP positive cells. This being around 30% 
more when compared to the RFP results produced from inducible TRIPZ transduced cells (see 
Figure 9B). The knockdown efficiency, as seen in Figure 13B and D, showed a mRNA 
decrease to a varying degree, ranging from around 10-fold reduction, as seen for the best 
shRNA (RIPZ shCYLD 89) to less than 2-fold reduction (RIPZ shTRRAP 543).  
 
Figure 13: Correlation of RFP expression and host factor knockdown. Stable pRIPZ J-Lat 8.4 cells 
were generated and tested for the expression of RFP as determined by flow cytometry and for the level 
C D 
13A B 
3.3 Results approach I: Chromatin targets 
74 
of host factor knockdown as determined by RT-qPCR. Results for CYLD used as positive control (A, B), 
results for TRRAP as factor of interest (C, D). The experiment was performed in technical duplicates 
and standard deviation was indicated. 
 
Further, the RFP expression and host factor knockdown level were determined under 
continued puromycin selection pressure, as seen in Figure 14A for the different stable 
shTRRAP containing cell lines. Even though, an additional week of puromycin treatment could 
increase the number of RFP expressing cells further, the knockdown efficiency for all tested 
cell lines was halved (Figure 14B). In an additional experiment, the knockdown stability over 
one freeze-thaw cycle was tested. As seen in Figure 14C, the cells expressed RFP to high 
levels after thawing but the knockdown (Figure 14D) was completely lost.  
 
 
Figure 14: Prolonged puromycin selection of stable RIPZ cells in correlation to knockdown 
levels. Stable pRIPZ derived knockdown J-Lat 8.4 cells were checked for % RFP expression (A) by 
flow cytometry (single measurements only) and for knockdown (B) on mRNA level by RT-qPCR after 
one week and two weeks under continued puromycin selection. Negative control cell lines were 
averaged, and the other values normalized to the control. C) Generated knockdown cell lines were 
exposed to one freeze-thaw cycle and % RFP expression was checked via flow cytometry and for 
knockdown of host factor (D) by RT-qPCR on mRNA level. 
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In summary, the RIPZ approach led to high numbers of stable RFP expressing cells. The 
knockdown efficiency was initially robust but was gradually lost. The test period of the stable 
cell needed to be kept short. 
 
3.3.6 pRIPZ knockdown of TRRAP 
In a final set of experiments, stable shRNA encoding J-Lat 8.4 cell lines were stimulated or 
medium treated for 24h and analyzed by flow cytometry for double positive cells, expressing 
RFP and GFP for the shRNA mediated knockdown and the reversal of latency, respectively. 
The results are shown in Figure 15. Two stable cells lines encoding for a non-silencing shRNA 
or no shRNA served as negative controls, representing the level of double positive cells which 
can be attributed to the stimulus itself. Further, two stable cell lines were included targeting 
CYLD serving as positive control. For the host factor of interest, TRRAP, three cell lines were 
tested. For this, stable knockdown cell lines were exposed to a stimulus or medium and 
analyzed by flow cytometry for an increase in double positive cells 24h post treatment.  
Treatment of stable knockdown cell lines with medium only (Figure 15A) did not lead to more 
than 3% of double positive cells and was not considered significant. Upon treatment with TNFα     
(Figure 15B) a clear increase in double positive cells was seen only for shCYLD89. Treatment 
with prostratin (Figure 15C) led to a marked increase in double positive cells as seen for both 
positive controls, whereas no effect was seen in cell lines targeting TRRAP. Upon treatment 
with either SAHA (Figure 15D) or sodium butyrate (Figure 15E), an increase in double positive 
cells was only seen for the positive controls, but not for the TRRAP knockdown cell lines. 
Successful knockdown on mRNA level was determined by RT-qPCR as shown before    
(Figure 13B and D).  
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Figure 15: Effect of host factor knockdown in combination with different LRAs. Stable pRIPZ 
derived knockdown J-Lat 8.4 knockdown cells were generated and treated with either medium (A), TNFα 
(B), prostratin (C), SAHA (D) or sodium butyrate (E) for 24h. % Double positive cells (RFP and GFP) 
were assessed by flow cytometry. The experiment was performed twice and in technical duplicates, the 
result of one representative experiment was shown and standard deviation is indicated. 
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In summary, different stable cell lines were generated and exposed to medium or stimuli. The 
stimulation of knockdown cell lines targeting TRRAP did not lead to an increase in number of 
double positive cells beyond the numbers achieved with the negative controls whereas 
targeting of CYLD, used as positive control, did.  
 
3.3.7 Transient knockdown of host factors by siRNA - establishment of 
experimental system 
In order to confirm the results generated with the stable shRNA knockdown approach, a 
transient knockdown approach was chosen utilizing electroporation of siRNAs. This approach 
allowed detection of increased GFP positive cells by flow cytometry. In an initial experiment, 
four individual siRNAs either against CYLD (as positive control) or against TRRAP were tested 
for their potential in decreasing host factor mRNA levels as determined by RT-qPCR. 
Successful electroporation was confirmed by electroporating pMax EGFP (provided by the 
manufacturer) and GFP expression was microscopically checked after 24h (Figure 16A). The 
knockdown results for electroporated J-Lat 8.4 cells are shown in Figure 16B and C for CYLD 
and TRRAP, respectively. Knockdown of host factors by different siRNAs proved successful 
to a varying degree and only the best siRNAs were chosen for all further experiments, i.e. 
siCYLD #3 and siTRRAP #3. Of note, the proof of CYLD and TRRAP knockdown was only 
confirmed on mRNA level but not on protein level. In addition, electroporated cells were 
checked by fluorescence microscope to exclude GFP induction upon electroporation, which 
was not observed.  
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Figure 16: Establishment of siRNA mediated knockdown of host factors by electroporation.          
J-Lat 8.4 cells were electroporated with pMAX EGFP plasmid and microscopically checked for the 
presence of GFP (A) after 24h. Determination of CYLD knockdown levels (B) and TRRAP knockdown 
levels (C) in electroporated cells, as determined on mRNA level by RT-qPCR for four individual siRNAs 
per target. Samples were taken 24h post electroporation, two non-targeting controls were averaged, 
and the other values normalized to it. 
 
3.3.8 Transient knockdown of TRRAP 
In a final set of experiments, the effect of transient TRRAP knockdown plus stimulation on the 
percentage of GFP positive cells was evaluated, to elucidate a potential effect of TRRAP on 
HIV-1 latency. For this, J-Lat 8.4 cells were electroporated with siRNA and incubated for 24h, 
then split into equal portions for stimulation or medium treatment for 24h before being analyzed 
by flow cytometry. Of note, due to cell number limitation for electroporation cuvettes along with 
the need for enough cells to allow for differential analysis afterwards, it was decided to reduce 
the number of LRAs from four to two, i.e. including only prostratin and sodium butyrate next to 
medium for all further experiments.  
Treatment of electroporated cells (Figure 17A) with medium did not lead to an induction of 
GFP (A, first block), whereas prostratin treatment (A, middle block) led to around 6% GFP 
positive cells for the negative controls used (black column) serving as reference for the 
stimulus activation capacity. A clear increase, up to 14% in GFP positive cells, was only seen 
upon knockdown of CYLD (dark grey column) but not for the TRRAP knockdown results (A, 
middle block, light grey column). The increase in GFP positive cells with sodium butyrate 
treatment (A, last block) was less pronounced for all tested targets. Baseline activation was 
found to be around 8%, upon knockdown of CYLD a slight increase of around 12% was seen 
and for TRRAP an increase of around 11% was found.  
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Further, the viability was determined in this experiment (Figure 17B), showing that 
electroporation did not negatively affect cell viability. Addition of prostratin or sodium butyrate 
led to a slight reduction in viability of maximally 10%, an effect already observed earlier. The 
knockdown (Figure 17C) was confirmed for the positive control CYLD and the host factor of 
interest, i.e. TRRAP on mRNA level as determined by RT-qPCR. 
 
Figure 17: Effect of transient host factor knockdown in combination with two different LRAs.                
J-Lat 8.4 cells were electroporated with siRNA followed by stimulation with either medium, prostratin or 
sodium butyrate. % GFP positive cells (A) and % viability (B) were assessed by flow cytometry. In 
addition, knockdown on mRNA level (C) was determined by RT-qPCR. Results for TRRAP were 
indicated in light grey, for CYLD in dark grey and for the averaged negative controls in black. Samples 
were measured in technical duplicates and standard deviation was indicated. 
 
In summary, the siRNA knockdown approach was successfully established and influence of 
host factor knockdown plus stimulation was tested. Electroporation led to a robust knockdown 
of both factors on mRNA level, did not reactivate the cells per se and did not negatively impact 
cell viability. The drastic increase in GFP positive cells upon CYLD knockdown along with 
prostratin treatment confirmed published results (Manganaro et al., 2014), while knockdown of 
TRRAP led to a slight increase over the negative control.  
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3.4 Approach II: Druggability  
3.4.1 Compound selection 
In a second approach, hits from the primary RNAi screen were selected based on their property 
to be druggable and are known targets of available compounds. The idea behind is so-called 
“drug repurposing”, a drug development strategy predicated on the reuse of existing licensed 
drugs for new medical indications. In this thesis, the aim was to identify compounds for known 
targets within the hit list that could reverse latency on its own or would elicit latency reversal in 
combination or in synergy with LRAs. Importantly, the combinational application has been 
proven advantageous over single compound application, as several pathways have to be 
targeted to grant latency reversal of the complete reservoir. First, the compounds were 
identified, then tested for their optimal working concentration and further tested for their effect 
on latency reversal alone or in combination with an LRA.  
To identify potential compounds targeting primary hits two independent databases were 
employed, i.e. the Drug-Gene Interaction database (DGIbd) (Cotto et al., 2018) and the 
proprietary Genego database. The DGIbd combines multiple other databases, which allow 
mining for targets or compounds without restriction to one database only. This database is 
freely available, whereas the Genego database is proprietary. From the initial 706 primary hits 
(see Table S1, Appendix) only the hits with a Z-score ≥ +2, i.e. being potential restrictive host 
factors, were considered. This choice was made due to the published positive controls, being 
restrictive to latency reversal and possessing a +Z-score. The remaining 562 hits were run 
through both databases revealing 73 hits to be targetable according to the DGIbd and 82 hits 
according to the Genego database. The hits from both databases were merged and only hits 
further selected which are targetable according to both databases, leading to 42 hits. The 
remaining hits were checked for their expression levels with the help of ‘The Human Protein 
Atlas’ (Uhlén et al., 2015). Inclusion criteria for follow-up hit selection included their expression 
levels to be ≥ ‘low’ in the category ‘bone marrow and immune system’ and data reliability 
needed to be consistent according to ‘The Human Protein Atlas’. Upon this final selection step 
24 hits remained. Out of the 24 hits 7 hits were randomly chosen, the compounds purchased 
and tested in J-Lat 8.4 cells. A scheme of the selection strategy is shown in Figure 18 including 
the compounds tested and their potential targets.  
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Figure 18: Detailed presentation of compound selection strategy. Selection of compounds was 
based on the overlap of two different databases (DGIbd (Li et al., 2018) and proprietary Genego 
database) and further on expression levels of host factors according to ‘The Human Protein Atlas’ (Uhlén 
et al., 2015) (inclusion criteria: expression level ≥ low; exclusion criteria: inconsistent data). 7 hits were 
finally selected plus JQ1 inhibiting BRD4, which served as positive control in further experiments. 
ANPEP= alanyl aminopeptidase, BIRC5= baculoviral IAP repeat containing 5, MMP= matrix 
metallopeptidase, PRDX4/5= peroxiredoxin 4/5, SCN11A= sodium voltage-gated channel alpha subunit 
11, SHMT1= serine hydroxymethyltransferase 1, BRD4= bromodomain containing protein 4. 
18 
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3.4.2 Compound titration and test in combination with LRAs 
In order to determine the optimal working concentration for the different compounds, a dilution 
series was prepared for each compound. J-Lat 8.4 cells were treated with the respective 
compound dilution or with the appropriate solvent controls for 24h. The results are shown in   
Figure 19 and the working concentration for all following assays was determined to be 0.2µM 
for auranofin (Figure 19A), 12.5µM for docetaxel (Figure 19B), 20µM for HOE140           
(Figure 19C), 10µM for marimastat (Figure 19D), 32µM for mimosine (Figure 19E), 2µM for 
terameprocol (Figure 19F), 20µM for zonisamide (Figure 19G), and 0.25µM for JQ1       
(Figure 19H). JQ1 served as positive control as it inhibits the host factor BRD4 and will be 
used in all further experiments. None of the tested compounds showed induction of GFP 
greater than 0.2%, and thereby none of the tested compounds could induce reversal of latency 
on its own. 
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Figure 19: Optimal concentration determination of selected compounds. J-Lat 8.4 cells were 
treated with different concentrations of auranofin (A), docetaxel (B), HOE140 (C), marimastat (D), 
mimosine (E), terameprocol (F), zonisamide (G) or JQ1 (H) as positive control for 24h. % Viable cells 
(right y-axis) and % GFP induction (left y-axis) were assessed by flow cytometry. Each condition was 
measured in technical duplicates and standard deviation was indicated. 
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Next, the compounds were tested along with LRAs to address whether they would elicit latency 
reversal in combination/synergy (Figure 20). JQ1, an inhibitor of BRD4, on its own could not 
reverse latency in J-Lat 8.4 cells, but with addition of either TNFα or prostratin (both T cell 
activating LRAs), the number of GFP positive cells almost doubled when compared to stimulus 
only treatment (Figure 20H). Interestingly, only auranofin was found to have a positive effect 
on latency reversal (Figure 20A). Auranofin, supposedly targeting the peroxiredoxin 5 
(PRDX5), enhanced reversal of latency in combination with all applied stimuli even though the 
increase in GFP positive cells was not as outstanding as for the positive control JQ1. 
Interestingly, mimosine was found to hinder reversal of latency, leading to a decrease in GFP 
positive cell numbers applied with any LRA (Figure 20E). 
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Figure 20: Effect of compounds in combination with different LRAs. J-Lat 8.4 cells were treated 
with auranofin (A), docetaxel (B), HOE140 (C), marimastat (D), mimosine (E), terameprocol (F), 
zonisamide (G) or JQ1 (H) as positive control in combination with either medium, TNFα, prostratin, 
SAHA or sodium butyrate for 24h. % GFP positive cells were assessed by flow cytometry. Each condition 
was measured in technical duplicates and standard deviation was indicated. 
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3.4.3 Targeting PRDX5 by different compounds 
Auranofin, as stated by the DrugBank database (Law et al., 2014), targets the primary 
screening hit PRDX5 and was found to have a positive effect on the reversal of latency in J-
Lat 8.4 cells when applied in combination with any stimulus tested. To validate the target of 
auranofin, three different databases (proprietary Genego database and freely accessible 
Therapeutic Target Database (Li et al., 2018) and DrugBank database) were researched for 
additional compounds described to target PRDX5, a host factor involved in detoxification of 
reactive oxygen species. A graphical overview is shown in Figure 21. As further candidate 
compounds benzoic acid, diminazene and 4hydroxynonenal were identified and tested for their 
potential to induce the reversal of latency. The Therapeutic Target Database did not list PRDX5 
to be targetable by any compound. 
 
 
Figure 21: Graphical presentation of compounds targeting the host factor PRDX5. Three different 
databases were used (proprietary Genego, DrugBank (Law et al., 2014), and TTD (Li et al., 2018) as 
indicated by colored frames, to identify compounds targeting PRDX5. The TTD database did not list a 
specific compound to target PRDX5. PRDX5= peroxiredoxin 5 
 
In addition, an inverse search was performed on all compounds to identify all further known 
cellular targets. Figure 22 shows all known cellular targets for the different compounds tested 
as derived from three different databases. Interestingly, but not surprisingly, only very few 
compounds had only one specific cellular target, most of the compounds targeted several. Of 
note, 4hydroxynonenal was not listed by the DrugBank database and also not by the 
21 
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Therapeutic Target Database. Further, the different databases revealed hardly any overlap in 
target for the different compounds and PRDX5 was not claimed as target of auranofin by any 
other database. Of importance, auranofin was listed to be inhibiting thioredoxin reductase 
(TXNRD) family members by two independent databases, a factor situated upstream of the 
PRDX family. The potential action of auranofin against TXNRDs was also described in several 
publications (Becker et al., 2000; Hwang-Bo et al., 2017). Due to this, inhibition of TXNRDs by 
fotemustine (Schallreuter et al., 1990), a specific inhibitor, was included in all further 
experiments.  
 
 
Figure 22: Graphical presentation of compounds tested and their potential host factor targets. 
Three different databases were used, as indicated by colored frame, to identify all possible cellular 
targets of auranofin (A), diminazene (B), benzoic acid (C), 4hydroxynonenal and (D) fotemustine.  
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3.4.4 Titration of compounds targeting PRDX5 and upstream pathway 
In order to determine the optimal working concentration for the different compounds described 
to target PRDX5 or upstream pathway, a dilution series was prepared, and J-Lat 8.4 cells were 
treated with respective compound dilutions or solvent controls for 24h and analyzed by flow 
cytometry. The results are shown in Figure 23. The working concentration for all following 
assays was determined to be 2.5mM for benzoic acid (Figure 23A), 100µg/ml for diminazene            
(Figure 23B), 1.5µM for 4hydroxynonenal (Figure 23C) and 15µM for fotemustine           
(Figure 23D). None of the compounds negatively influenced cell viability except for 
4hydroxynonenal. Also, none of the compounds tested could reverse latency. 
 
 
Figure 23: Optimal concentration determination of selected compounds. J-Lat 8.4 cells were 
treated with different concentrations of benzoic acid (A), diminazene (B), 4hydroxynonenal (C) or 
fotemustine (D) for 24h. % Viability (right y-axis) and %GFP positive cells (left y-axis) were assessed by 
flow cytometry. Each condition was measured in technical duplicates and standard deviation was 
indicated. Compound solvent controls were included. 
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Next, the compounds were tested along with an LRA to check for increased reversal of latency 
and JQ1 was used as positive control. The results are shown in Figure 24 for each LRA 
separately. As seen in Figure 24A again, none of the compounds could reverse latency on its 
own. Upon addition of TNFα (Figure 24B) to the compounds, only auranofin and diminazene 
along with the positive control JQ1 showed significant increase in GFP positive cell numbers 
above the level of TNFα only treatment (last column). Upon prostratin treatment (Figure 24C), 
only diminazene along with the positive control significantly enhanced the number of GFP 
positive cells beyond the levels of prostratin only treatment, whereas for auranofin only a slight, 
non-significant increase was determined. SAHA addition (Figure 24D) to auranofin, 
diminazene, fotemustine or JQ1 led to a statistically significant increase in GFP positive cell 
numbers. The same compounds showed increased numbers in GFP positive when applied in 
combination with sodium butyrate (Figure 24E). In addition, neither benzoic acid nor 
4hydroxynonenal could increase the number of GFP positive cells with any LRA applied. 
Moreover, along with the flow cytometry results on GFP expression, provirus induction on 
mRNA level was determined by RT-qPCR. For this, samples were tested for elevated levels 
of gag and gfp mRNA. The results are shown in Figure 25 (gag levels left column, gfp levels 
right column, respectively). The results for compound only treatment without any additional 
stimuli are not shown, since none of the compounds on its own induced gfp mRNA levels that 
could be reliably detected by RT-qPCR, i.e. ct values ≤ 35. In general, the results for gag 
induction (left) showed the same trend as seen for gfp induction (right). The slight fold change 
increase for auranofin along with TNFα (Figure 25A) and the more pronounced fold change 
increase for diminazene along with TNFα (Figure 25A) and diminazene along with prostratin 
(Figure 25B) verified the flow cytometry results. Nevertheless, the RT-qPCR results for the 
different compounds treated with either of the two HDACi (Figure 25C and D, respectively) did 
not confirm the observed enhancement of GFP signal as measured in Figure 24.  
In summary, certain combinations of LRA with auranofin or diminazene led to latency reversal 
suggesting that the PRDX5 pathway might be the common target of these compounds.  
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Figure 24: J-Lat 8.4 cells were treated with candidate compounds and different LRAs. J-Lat 8.4 
cells were treated for 24h with different compounds alone (A), or in combination with TNFα (B), prostratin 
(C), SAHA (D) or Sodium butyrate (E). % GFP positive cells were assessed by flow cytometry. A 
minimum of four independent experiments is shown. Standard deviation was indicated, and statistical 
significance was tested with non-parametric Kruskal-Wallis test in comparison to the control group, i.e. 
LRA treatment only. 
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Figure 25: Provirus induction by compound treatment along with different LRAs as determined 
on mRNA level by RT-qPCR. J-Lat 8.4 cells were treated with candidate compounds and TNFα (A), 
prostratin (B), SAHA (C) or sodium butyrate (D) for 24h. Gag (left) and gfp (right) mRNA levels were 
determined by RT-qPCR. Each data point represents an independent experiment and standard 
deviation was indicated. 
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In a final experiment, the best compound candidates i.e. auranofin and diminazene, along with 
the positive control JQ1, were tested for their induction of intracellular Gag levels (unspliced 
Gag around 56kDa) by Western blot. As loading control GAPDH was used (around 37kDa). 
The results are shown in Figure 26. J-Lat 8.4 cells did not express Gag protein without 
stimulation and also not upon treatment of either auranofin or diminazene, verifying the 
previous flow cytometry and RT-qPCR results. Auranofin induced Gag expression in J-Lat 8.4 
cells with all tested stimuli above the level of stimulus only. Diminazene in comparison showed 
a much stronger Gag induction with TNFα or prostratin but showed no additive effect when 
used in combination with either SAHA or sodium butyrate confirming the RT-qPCR results. 
The Gag protein levels resulting from diminazene treatment were comparable to the results of 
the positive control JQ1.  
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Figure 26: Verification of candidate compounds on protein level by Western blot. J-Lat 8.4 cells 
were treated with medium, candidate compounds (auranofin or diminazene) or JQ1 as positive control, 
alone or in combination with TNFα, prostratin (upper blot), SAHA or sodium butyrate (lower blot) for 24h. 
Gag levels were visualized by Western blot; GAPDH was used as loading control. Two different 
exposure times for Gag are shown. 
 
Altogether the results obtained by various methods in J-Lat 8.4 cells showed that auranofin 
enhanced the level of latency reversal with any applied stimulus. Further, diminazene was 
identified to have a positive influence on latency reversal when applied along with T cell 
activating LRAs, i.e. TNFα or prostratin. 
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3.4.5 Verification of compound effects in different J-Lat clones 
In a next step, the compounds of interest, i.e. auranofin as well as diminazene, were tested in 
the same experimental settings using J-Lat 6.3 cells instead (another J-Lat clone) to confirm 
the results derived from the J-Lat 8.4 cells. The reactivation pattern as measured by 
percentage of GFP positive cells (Figure 27) was highly comparable (see Figure 24). But the 
overall reactivation potential of this J-Lat 6.3 clone was slightly lower when compared to             
J-Lat 8.4. Auranofin could enhance reversal of latency when applied in combination with all 
tested LRAs, whereas diminazene only in combination with TNFα or prostratin led to a marked 
increase in GFP positive cells. The results for compound treatment with either SAHA       
(Figure 27D) or sodium butyrate (Figure 27E) showed some variance, which was attributed 
to the loss of activity of the LRA. 
In addition, the gfp and gag mRNA levels were determined (Figure 28, left or right column, 
respectively) by RT-qPCR to verify the flow cytometry results. The results for compound only 
treatment without any additional stimuli are not shown, since none of the compounds on its 
own induced GFP mRNA levels that could be reliably detected by RT-qPCR, i.e. ct values ≤ 
35. The results for compounds used in combination with either TNFα (Figure 28A) or prostratin         
(Figure 28B) were comparable to the results obtained from flow cytometry. Auranofin, 
diminazene and JQ1 induced robust mRNA transcription. The results achieved in combination 
with either SAHA (Figure 28C) or sodium butyrate (Figure 28D) showed greater deviation and 
were not in line with the flow cytometry results, this was especially seen for JQ1.  
In summary, the results obtained from J-Lat 6.3 cells are highly comparable to the results from 
the J-Lat 8.4 cells, thus confirming the latency reversing capacity of auranofin and diminazene 
in combination with certain LRAs. 
3.4 Results approach II: Druggability 
95 
Figure 27: Verification of candidate compounds in in J-Lat 6.3 cells. J-Lat 6.3 cells were treated 
with candidate compounds along with medium (A), TNFα (B), prostratin (C), SAHA (D) or sodium 
butyrate (E) for 24h. % GFP positive cells were assessed by flow cytometry. The results of three 
independent experiments are shown and standard deviation was indicated. Standard deviation was 
indicated, and statistical significance was tested with non-parametric Kruskal-Wallis test in comparison 
to the control group, i.e. LRA treatment only. 
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Figure 28: Provirus induction by compound treatment along with different LRAs as determined 
on mRNA level by RT-qPCR. J-Lat 6.3 cells were treated with candidate compounds and TNFα (A), 
prostratin (B), SAHA (C) or sodium butyrate (D) for 24h. Gag (left) and gfp (right) mRNA levels were 
determined by RT-qPCR. Each data point represents an independent experiment and standard 
deviation was indicated. 
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3.4.6 Verification of compound effects in a different latency cell line 
To verify the reactivation pattern of the different compounds in a latency cell model with a 
different cellular origin, U1 cells derived from monocytic U937 cells were tested. This latency 
cell model possesses two integrated copies of HIV-1 with no reporter gene, therefore a p24 
ELISA was chosen as read-out. The stimulation was performed as described for J-Lat 8.4 cells 
and the p24 ELISA was performed on the undiluted supernatant. As seen in Figure 29A, U1 
cells treated with compounds or medium only showed p24 levels close to the detection limit of 
100pg/ml. Treatment of compounds along with TNFα (Figure 29B) showed no increase in p24 
levels except for JQ1. Treatment with prostratin (Figure 29C) without additional compound led 
to a tremendous production of p24, a further increase was only seen upon addition of JQ1 but 
neither with auranofin nor with diminazene. The addition of SAHA (Figure 29D) on its own did 
not lead to a significant increase in p24 levels, but in combination of either auranofin or JQ1 
showed increased p24 levels. The same tendency was seen upon stimulation with sodium 
butyrate (Figure 29E).  
In summary, auranofin could support reactivation when applied in combination with either 
SAHA or sodium butyrate (i.e. HDACi, non-T cell activating LRA) but did not lead to an effect 
when used in combination with either TNFα or prostratin (i.e. T cell activating LRAs via NFκB 
pathway). Diminazene in combination with any stimulus tested did not lead to an effect. Of 
note, the reactivation pattern in U1 cells differed from J-Lat cells. Neither TNFα, SAHA or 
sodium butyrate alone did induce reactivation to a robust level beyond the minimum detection 
limit of the used p24 ELISA. 
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Figure 29: Verification of candidate compounds in U1 cells. U1 cells were treated with candidate 
compounds and medium (A), TNFα (B), prostratin (C), SAHA (D) or sodium butyrate (E) for 24h. 
Provirus induction was measured by p24 production in the supernatant. A minimum of two individual 
experiments is shown, for each experiment measurements were done technical duplicates and standard 
deviation was indicated. Dotted lines represent the lower level of detection as denoted by the 
manufacturer. 
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RT-qPCR was performed on HIV-1 gag mRNA levels on compound and LRA treated U1 cells 
to verify the results obtained by p24 ELISA. The results are shown in Figure 30. Treatment 
with compound only (Figure 30A) led to an induction of gag mRNA for JQ1 and for diminazene. 
Upon additional stimulation with either TNFα (Figure 30B) or prostratin (Figure 30C), only 
JQ1 showed increased levels of gag mRNA, which was not seen for either auranofin or 
diminazene. Treatment in combination with either SAHA (Figure 30D) did lead to increased 
induction when applied along with auranofin, while diminazene did not show an effect. The 
results for JQ1 showed a high variation between the samples tested and were therefore 
inconclusive. Treatment of compounds along with sodium butyrate (Figure 30E) showed no 
effect with diminazene or JQ1. The results for auranofin were inconclusive due to high 
variability between samples tested.  
Overall, the results of gag mRNA levels followed the results determined by p24 ELISA even 
though a direct correlation was not possible due to a high variability. Furthermore, the fold 
change increases seen did not correlate with the p24 levels obtained. 
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Figure 30: Verification of candidate compounds on mRNA level in U1 cells.  U1 cells were treated 
with candidate compounds alone (A), or with TNFα (B), prostratin (C), SAHA (D), or sodium butyrate 
(E) for 24h. Gag mRNA levels were determined by RT-qPCR. Each data point presents an independent 
experiment and standard deviation was indicated. 
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In a final experiment, the effect of auranofin and diminazene on intracellular Gag levels was 
tested by Western blot. The results are shown in Figure 31. Unequal loading of samples was 
observed, as seen by the tubulin bands (around 50kDa). Due to this, only a tendency of p24 
(around 24kDa) induction could be deduced. Treatment with compounds alone led to an 
induction of p24 only in the case of JQ1. Treatment with compounds along with TNFα or 
prostratin led to a reliable p24 induction only in combination with JQ1. An additional effect was 
neither seen for auranofin, nor for diminazene. Further, upon treatment along with SAHA or 
sodium butyrate only Auranofin showed a clear increase, whereas diminazene did not show 
an additional effect.  
Taking together the results obtained for U1 cells with different methods, increased reactivation 
was found for auranofin only in combination with SAHA and sodium butyrate. Diminazene was 
not found to have a potential effect on latency reversal in this latency cell model.  
 
 
Figure 31: Verification of candidate compounds on protein level by Western blot. U1 cells were 
treated with medium or candidate compounds (Auranofin, Diminazene or JQ1) and TNFα, prostratin 
(upper blot), SAHA or sodium butyrate (lower blot) for 24h. p24 levels were visualized by Western blot, 
tubulin was used as loading control. 
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3.4.7 Summary compounds  
In summary, auranofin was validated as compound with the potential to drive reversal of 
latency when applied in combination with an LRA (see Table 14, upper part). The effect was 
robust when tested in combination with one of the used HDACi in all applied latency cell models 
and with various methods. An effect of auranofin with either TNFα or prostratin was only seen 
for the J-Lat latency cell model.  
Diminazene application, on the other hand, led to a sound induction of GFP on protein and 
mRNA level when applied along with either TNFα or prostratin, a potential which outranged 
the one of auranofin (see Table 14, lower part). The reactivation pattern of diminazene was 
comparable to the one seen for JQ1. This effect was seen for both J-Lat clones tested but was 
not found in U1 cells.  
None of the tested compounds, chosen on basis to target either PRDX5 or TXNRD family 
members, recapitulated the exact reactivation pattern than the one seen for auranofin. 
4hydroxynonenal and benzoic acid showed no effect in the tested J-Lat 8.4 cell model. 
Fotemustine showed a slight additive effect when applied in combination with either of the 
HDACi. Those compounds were not further tested.  
Taken together, auranofin and diminazene proved to have an additive effect on the reversal of 
latency (under selected conditions); but the potential host target(s) still need to be identified by 
further experiments. 
 
Table 14: Overview over effect of either auranofin or diminazene alone or in combination with 
different LRAs in all latency cell models. 
  
medium + 
auranofin 
TNFα + 
auranofin 
prostratin + 
auranofin 
SAHA + 
auranofin 
sod. but. + 
auranofin 
  RT-qPCR gag & gfp b.d. ↑  -  -  - 
J-Lat 8.4 FACS GFP  - ↑ ↑ ↑↑ ↑ 
  WB Gag  - ↑  - ↑ ↑ 
  RT-qPCR gag & gfp b.d. ↑ ↑ ↑ ↑ 
J-Lat 6.3 FACS GFP  - ↑ - ↑ ↑ 
  WB Gag n.t. n.t. n.t. n.t. n.t. 
  RT-qPCR gag  -  -  - ↑ ↑ 
U1 ELISA p24  -  -   - ↑ ↑ 
  WB Gag  - ↑ ↑ ↑↑ ↑↑ 
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medium + 
diminazene 
TNFα + 
diminazene 
prostratin + 
diminazene 
SAHA + 
diminazene 
sod. but. + 
diminazene 
  RT-qPCR gag & gfp b.d. ↑↑ ↑  -  - 
J-Lat 8.4 FACS GFP  - ↑↑ ↑↑ ↑ ↑ 
  WB Gag  - ↑↑ ↑↑  -  - 
  RT-qPCR gag & gfp b.d. ↑ ↑  - ↑ 
J-Lat 6.3 FACS GFP  - ↑↑ ↑ ↑ ↑ 
  WB Gag n.t. n.t. n.t. n.t. n.t. 
  RT-qPCR gag ↑  -  -  -  - 
U1 ELISA p24  -  -  -  -  - 
  WB P24  -  -  -  -  - 
b.d.= below detection, n.t.= not tested; for qRT-PCR results : ↑ ≤ 10 fold increase to LRA only, ↑↑ ≤ 100 
fold increase to LRA only ; for GFP results : ↑ ≤ 5% increase to LRA only, ↑↑ ≥ doubling of GFP % to 
LRA only ; for p24 ELISA results : ↑ ≤ 5 times increase to LRA only ; for WB results : ↑ ≥ visbile increase 
on protein level above LRA only, ↑↑ ≥ increase on protein level comparable to/or greater than positive 
control JQ1. Grey shaded cells: increase in reactivation seen, non-robust results linked to reduced 
activity of SAHA and sodium butyrate. 
 
3.4.8 Validation of host factors by genetic manipulation 
3.4.8.1 Choosing optimal siRNAs and knockdown time points 
In order to attribute the compound effects to specific host factors, i.e. PRDX5, TXNRD1 and 
TXNRD2, a direct knockdown of host factor by siRNA electroporation was performed. For this, 
four individual siRNAs per host factor were tested for their knockdown potential in either J-Lat 
8.4 cells (Figure 32A-C) or U1 cells (Figure 32D-F) as determined by RT-qPCR. The 
knockdown of prdx5 was most efficient when targeted by siPRDX5#5 for both J-Lat and U1 
cells, as seen Figure 32A and D, respectively. Further, the knockdown of txnrd1 was most 
efficient when targeted by siTXNRD1#3 for both cell lines as seen in Figure 32B and E. The 
knockdown of txndr2 was most efficient when targeted by siTXNRD2#6 in J-Lat 8.4 cells 
(Figure 32C) and in U1 cells (Figure 32F). These siRNAs were used for all further 
experiments. 
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Figure 32: Determination of best siRNAs for J-Lat and U1 cells. Four individual siRNAs against a 
host factor of interest were individually tested. For this, either J-Lat 8.4 cells (A, B, C) or U1 cells (D, E, 
F) cells were checked for reduction on mRNA level by RT-qPCR 24h post electroporation of the indicated 
siRNAs. Knockdown results are shown for PRDX5 (A and D), TXNRD1 (B and E) and for TXNRD2 (C 
and F). 
 
In a next set of experiments, the time course of knockdown for each host factor was determined 
on mRNA level by RT-qPCR as well as on protein level by Western blot. The results are shown 
for J-Lat 8.4 cells Figure 33A-C and for U1 cells Figure 33E-F. The knockdown of PRDX5   
(Figure 33A) showed a drastic decrease on mRNA level after 24h, which was gradually lost 
over 72h. The knockdown on protein level was readily detected after 48h and lost upon 72h. 
PRDX5 knockdown in U1 cells (Figure 33D) showed a reduction on the mRNA level after 24h, 
which lasted up to 72h. The RT-qPCR results were confirmed by Western blot, which showed 
a pronounced decrease in PRDX5 protein levels for up to 48h and a slight increase upon 72h       
post-knockdown.  
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The knockdown results for TXNRD1 in J-Lat 8.4 cells on mRNA level showed a distinct 
reduction for up to 72h (Figure 33B), whereas an effect on protein level gradually increased 
upon time. Comparable results were also found in U1 cells (Figure 33E).  
The knockdown of TXNRD2 in J-Lat 8.4 cells (Figure 33C) showed a gradual decrease on 
mRNA level for all time points determined. The knockdown on mRNA level was found to be 
low already upon 24h post-siRNA electroporation. This effect seemed to last up to 72h even 
though the loading control for the 72h value showed reduced loading. The knockdown of 
TXNRD2 in U1 cells (Figure 33F) showed reduction on mRNA level already upon 24h, which 
persisted until 48h and was lost after 72h. Those results were in line with the Western blot 
results even though a slightly decreased loading was observed for 24h.  
In summary, the knockdown of different host factors could be reliably detected on protein level 
48h post-electroporation in J-Lat 8.4 and U1 cells. Nevertheless, it has to be taken into account 
that knockdown efficiency as well as duration varied for the different host factors and between 
the cell lines. 
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Figure 33: Determination of optimal time point for host factor knockdown on mRNA and protein 
level. siRNAs were electroporated and samples harvested at 24h, 48h and 72h to determine knockdown 
efficiency on mRNA level (upper graphs) and on protein level (lower Western blot images) for J-Lat 8.4 
cells (A, B, C) and U1 cells (D, E, F). Knockdown results are shown for PRDX5 (A and D), TXNRD1 (B 
and E) and for TXNRD2 (C and F).  
 
3.4.9 siRNA knockdown followed by LRA treatment 
In a final step, the potential role of direct host factor knockdown on reversal of latency was 
determined. For this, J-Lat 8.4 and U1 cells were electroporated with siRNA, after 36h the cells 
were split into four equal portions. One portion was taken to prepare Western blot samples to 
confirm successful knockdown. The remaining three portions were either treated with medium 
or stimulated with prostratin or sodium butyrate for another 24h.  
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J-Lat 8.4 cells were analyzed for increased numbers of GFP positive cells by flow cytometry 
(Figure 34), and U1 cells were analyzed for increased p24 levels determined by ELISA         
(Figure 35). As positive control, CYLD knockdown was included and as negative controls non-
target siRNAs (referred to as ‘si control’) were used. Of note, CYLD knockdown was not 
confirmed on protein level. The results for the knockdown of PRDX5, TXNRD1 alone or in 
combination for J-Lat 8.4 cells are shown in Figure 34. siRNA knockdown followed by medium 
treatment did not lead to any GFP induction for any tested target (Figure 34A, first block), 
which was in line with former results. Knockdown followed by stimulation with prostratin 
(Figure 34A, middle block) led to an induction of GFP up to 6% for the negative control. The 
knockdown of either PRDX5, TXNRD1 or in combination did not lead to an additional increase 
in GFP positive cells above the level of the negative control. Only the knockdown of the positive 
control CYLD followed by prostratin stimulation led to an enhanced number of GFP positive 
cells of around 13%. The effect of knockdown in addition with sodium butyrate stimulation led 
to around 9% of GFP positive cells for the negative control. A slight increase in GFP positive 
cells, upon TXNRD1 knockdown compared to the negative control was seen in combination 
with sodium butyrate same as with the positive control CYLD, hinting towards the involvement 
of the pathway for latency reversal in this particular cell system (Figure 34A, last block).  
The knockdown on protein level as determined by Western blot (Figure 34B) was successful 
for PRDX5, TXNRD1 and the double knockdown of both host factors, even though the joint 
knockdown of PRDX5 and TXNRD1 was less efficient than the single ones. It needs to be kept 
in mind that the decreased knockdown efficiency for both host factors together might have 
masked an effect on latency reversal. In addition, the viability after treatment was determined, 
as shown in Figure 34C. None of the siRNAs tested led to a significant decrease in viability, 
additional stimulation led to a slight decrease in viability. 
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Figure 34: siRNA knockdown of host factors in combination with LRA stimulation in J-Lat 8.4 
cells. PRDX5, TXNRD1 alone or in combination were knocked down in J-Lat 8.4 cells followed by 
stimulation with either prostratin or sodium butyrate for 24h. A) % GFP positive cells as determined by 
flow cytometry. B) Verification of knockdown on protein level by Western blot. C) Influence of knockdown 
and stimulation on cell viability. 
 
The results for the single and double knockdown in U1 cells are shown in Figure 35. 
Knockdown on its own, without additional stimulation, did not lead to a statistically significant 
p24 induction, still slight induction above the negative control (Figure 35A, first graph) was 
detected. Interestingly, prostratin and sodium butyrate treatment did increase p24 levels 
compared to the negative control for the double knockdown of PRDX5 and TXNRD1, whereas 
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the respective single knockdowns did not show an effect. Of interest, knockdown of CYLD did 
not lead to significantly increased p24 levels in U1 cells (Figure 35A, second and third graph).  
The knockdown on protein level for the single and double knockdown was successful as seen 
in Figure 35B. And viability was not negatively affected by electroporation and LRA treatment 
(Figure 35C). 
 
 
Figure 35: siRNA knockdown of host factors in combination with LRA stimulation in U1 cells. 
PRDX5, TXNRD1 alone or in combination were knocked down in U1 cells followed by stimulation with 
either prostratin or sodium butyrate for 24h. A) Level of reactivation determined by p24 ELISA on culture 
supernatant. B) Verification of knockdown on protein level by Western blot. C) Influence of knockdown 
and stimulation on cell viability. 
 
In summary, silencing of PRDX5 and TXNRD1 was successful in J-Lat 8.4 and U1 cells as 
indicated by Western blot results on the expression levels of the respective genes. In the           
J-Lat 8.4 cell system, in TXNRD1 silenced cells upon sodium butyrate treatment, a marginal 
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increase in latency reversal measured by percentage of GFP positive cells compared to control 
cells was detected, similar to the positive control CYLD silenced cells. However, in the U1 cell 
system, in double knockdown PRDX5 and TXNRD1 cells, upon LRA treatment, i.e. prostratin 
or sodium butyrate, a successful latency reversal was detected compared to negative control 
cells suggesting an involvement of this pathway in latency reversal.  
 
3.4.10 Results on HIV-1 positive primary cells  
3.4.10.1 Setup of methods 
3.4.10.1.1 Experimental design 
As described in the present study, both identified compounds (auranofin and diminazene) 
showed (differential) increases in latency reversal in the tested latency models, i.e. J-Lat clones 
and U1 cells. To test whether those compounds would also show this effect in long term        
HIV-1 infected primary cells, resting CD4+ T cells were isolated from HIV-1 positive patient 
blood and reactivation of the latent reservoir was tested.  
An overview of the initial procedure is shown in Figure 36, which was adapted from 
experimental procedures previously published (Darcis et al., 2015). PBMCs were isolated from 
HIV-1 positive full blood and one million cells were used for DNA extraction followed by 
analysis for proviral integrates by qPCR. The remaining PBMCs were further used to isolate 
CD4+ T cells followed by final isolation of non-activated CD4+ T cells, i.e. cells not expressing 
activation markers and therefore considered resting. Those cells were treated with compound, 
stimuli, a combination of those, medium (negative control) or antiCD3/antiCD28 antibodies 
(positive control). After three days, the supernatant was collected for p24 ELISA and the 
treatment conditions refreshed. At day six, the cells were collected for the potential analysis of 
viral RNA and the supernatant for p24 ELISA. 
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Figure 36: Overview on the experimental workflow on primary HIV-1 positive cell isolation and 
their reactivation. Stepwise isolation of non-activated CD4+ T cells from PBMCs, followed by 
stimulation with candidate compounds: LRAs and positive control or medium to reactivate the latent 
reservoir. Treatment refreshment after three days, cell collection for viral RNA (vRNA) isolation and 
supernatant collection for p24 ELISA testing on day six. 
 
 
3.4.10.1.2 Establishment and verification of target cell isolation 
In an initial setup experiment, the purity of the isolated cells was checked by flow cytometry. 
The results are shown in Figure 37A. Isolated resting CD4+ T cells from one representative 
donor were analyzed for viability, purity (presence of CD4) and for activation status (absence 
of activation markers HLA-DR, CD25 and CD69). Isolated cells were highly viable; around 94% 
of isolated cells were CD4+ and resting, due to the absence of activation marker expression      
(Figure 37A). The isolation of resting CD4+ T cells was successfully established.  
36 
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Figure 37B shows the decrease in cell numbers during the isolation process for 8 donors. 
Between 22 - 37 million PBMCs were isolated from the obtained patient full blood. In a next 
isolation step, untouched CD4+ T cells were purified from PBMCs, on average six million cells 
were obtained in this isolation step. In a final isolation, the untouched CD4+ T cells were further 
purified for non-activated CD4+ T cells. The removal of activated cells resulted in averaged 0.9 
million non-activated CD4+ T cells. This cell number drastically limited the experimental 
conditions, which could be tested. In case the overall CD4+ T cell number was ≤ 3 million, the 
cells were not further isolated but used directly for reactivation testing. 
 
Figure 37: Determination of purity of isolated cells and reduction of cell counts during the 
isolation process. A) Isolated non-activated CD4+ T cells from one respective donor were stained for 
viability, CD4 and activation marker (HLA-DR, CD69, and CD25) expression after isolation. B) Reduction 
in cell numbers over stepwise isolation of target cells for eight donors. 
 
3.4.10.1.3 Confirmation of viability after treatment 
To determine the optimal compound and LRA concentration, primary CD4+ T cells from two 
healthy donors were treated for 24h and viability was analyzed by flow cytometry (Figure 38). 
Auranofin (Figure 38A) and prostratin (Figure 38D) treatment led to a massive decrease in 
viability when applied at high concentration. Sodium butyrate treatment (Figure 38B) was less 
toxic even at high concentrations. Diminazene treatment (Figure 38C) did not negatively 
influence viability even at high concentrations.  
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Figure 38: Effect on viability of candidate compounds or LRAs on primary CD4+ T cells. Primary 
CD4+ T cells were isolated from PBMCs (from two healthy donors) and treated with auranofin (A), 
sodium butyrate (B), diminazene (C), or prostratin (D) dilution series and viability was assessed by flow 
cytometry after 24h of treatment. 
 
In a next step, the effect of LRAs in combination with the respective compound on cell viability 
was determined after three and six days for CD4+ T cells from two healthy donors (Figure 39). 
It was decided to test auranofin in combination with sodium butyrate, as auranofin treatment 
led to an enhanced reversal when applied in combination with non-T cell activating LRAs. 
Further, diminazene was tested in combination with prostratin. Two different concentrations of 
LRAs were tested along with a constant concentration of the respective compound. The stimuli 
and compounds were replenished at day three. Here, prolonged combined treatment with 
auranofin and sodium butyrate led to a significant decrease in viability (Figure 39A). Sodium 
butyrate, however, showed high toxicity over six days of treatment on its own. It was decided 
to use 1mM sodium butyrate in combination with 0.2µM auranofin. The results for combined 
prostratin treatment along with diminazene (Figure 39B) showed a less toxic effect even over 
a prolonged period of treatment. It was decided to use 0.5µM prostratin with 100µg/ml 
diminazene for further experiments. 
38A B 
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Figure 39: Effect on viability of candidate compounds in combination with LRAs on primary CD4+ 
T cells. Primary CD4+ T cells were isolated from PBMCs (from two healthy donors) and treated with two 
different concentrations of sodium butyrate alone or in combination with auranofin (A), or with two 
different concentrations of prostratin with diminazene (B). % Cell viability was determined by flow 
cytometry after three and six days. 
 
In a final set of experiments, cell viability of non-activated CD4+ T (HIV-1 positive) cells was 
determined after treatment (Figure 40). In general, non-activated CD4+ T cells showed an 
overall decrease in viability over six days of culture (Figure 40A). The presence of prostratin 
in the medium led to a decrease in viability, whereas sodium butyrate treatment led to an even 
stronger decrease in viability. For the compounds tested, diminazene did not affect cell viability, 
whereas auranofin treatment led to over 90% of dead cells. Next, the viability after three days 
of compound treatment was determined (Figure 40B). The non-activated CD4+ T cells 
survived the treatment for a shortened period with a decrease in viability that was acceptable. 
Due to time limitations, it was decided to shorten the experimental procedure to three days. 
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Figure 40: Effect on viability of candidate compounds in combination with LRAs on non-
activated CD4+ T cells from HIV-1 positive donors. Determination of cell viability after six days (A) 
and three days (B) of treatment with the indicated compounds, LRAs, combinations of those, positive 
control (antiCD3/antiCD28) or medium. Data is derived from 8 different donors; due to low cell numbers 
not all experimental conditions could be tested. 
 
3.4.11 Increasing chances - Copy number PCR 
In addition, a qPCR was performed on genomic DNA from HIV-1 positive PBMCs, which 
allowed determining the HIV-1 copies per genome equivalents of PBMCs (Malnati et al., 2008). 
For this, the CCR5 gene and a conserved region of the HIV-1 LTR-gag were PCR amplified. 
The number of HIV-1 copies was determined by amplification of a plasmid standard with known 
numbers of copies and corrected for the CCR5 copy number input. An example of PCR 
amplified HIV-1 and CCR5 fragments run on agarose gel is shown in Figure 41. For donor 8 
a faint band (285bp) was seen above CCR5 fragment (81bp), indicating the presence of       
HIV-1 integrates in this donor, whereas in donor 12 only the CCR5 fragment amplification was 
seen after PCR. One standard dilution was run on gel serving as positive control.  
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Figure 41: Representative result from two donors tested for the presence of HIV-1 provirus. 
Duplex qPCR was run to amplify a fragment specific for the CCR5 gene (81bp) and a fragment specific 
for HIV-1 LTR-gag (285bp). The qPCR was run on a 1% agarose gel for size separation followed by 
visualization. As control one standard dilution (containing known numbers of CCR5 and HIV-1 copies) 
was taken along. M= marker. 
 
Table 15 shows the extrapolated numbers of extracted HIV-1 genomes from all isolated 
donors. Out of 19 donors, 13 were found positive for HIV-1 integrates. PBMCs, which were 
tested positive for HIV-1 integrates, varied greatly in numbers, ranging from 1 to around 
360,000 HIV-1 genome equivalents found in one million PBMCs. Whereas in PBMCs from 
donors 5, 9, 10 and 12, no HIV-1 integrates could be determined. Furthermore, in donor 15 
and 17 only two integrates per 100 million cells could be determined, which was considered 
below detection limit of the PCR. Only if proviruses were detected in donor PBMCs, cells were 
further isolated and tested. In total, 13 donors were isolated of which 7 donors were isolated 
for non-activated CD4+ T cells and 6 donors were only isolated for CD4+ T cells. Those cells 
were tested for reactivation of latent provirus after three days of treatment. It is important to 
highlight that a positive qPCR on genomic DNA does not specify whether the provirus is intact. 
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Table 15: Overview over primary donors isolated and HIV-1 genome equivalents determined by 
qPCR on genomic DNA. Indicated in light grey (donors 1-8, respectively) are donors isolated for non-
activated CD4+ T cells, whereas non-highlighted (donors 9-19, respectively) donors were isolated for 
(overall) CD4+ T cells only, due to low cell cumbers. Marked in red are donors with HIV-1 integrates 
below detection limit of the assay. Those donors were excluded from further testing. 
 
Donor 
number 
HIV-1 copies/million genome 
equivalents in PBMCs 
1 63.10 
2 173632.17 
3 2.64 
4 3036.78 
5 0.00 
6 288.90 
7 31.35 
8 518.25 
9 0.00 
10 0.00 
11 1.28 
12 0.00 
13 6.87 
14 4.96 
15 0.02 
16 1.52 
17 0.02 
18 40.64 
19 360268.23 
 
3.4.12 p24 ELISA results from primary CD4+ T cells after reactivation 
To measure reactivation of latent provirus, the supernatant was collected at day 3 post-
stimulation and tested for the presence of p24 capsid protein by a high sensitivity and 
commercially available ELISA (tested in singlets). Out of 13 donors tested under various 
conditions, only donor 19 was positive for p24 as shown in Figure 42. Prostratin treatment led 
to around 20pg/ml of p24 in the supernatant, whereas diminazene treatment alone led to 
around 11pg/ml. The combinational treatment led to around 20pg/ml. There was no synergistic 
or additive effect on reactivation when compound and LRA were applied together. The medium 
treatment led to a 7pg/ml of p24, an amount slightly smaller than the one seen for diminazene 
treatment. The highest amount of p24 was seen for the positive control using 
antiCD3/antiCD28 for overall T cell activation. Of note, the results were obtained from overall 
isolated CD4+ T cells. This donor also showed highest number of HIV-1 copies per genome 
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equivalent. Since only one donor was positive tested for p24, the sample number was too small 
to draw adequate conclusions from this experiment. 
 
Figure 42: p24 ELISA results of donor 19. p24 ELISA was performed on culture supernatant of all 
isolated donors; 13 donors in total. Here the results of donor 19 are shown, the only donor in which 
reactivation of latent HIV-1 could be detected. Results are derived from treatment with prostratin, 
diminazene, a combination of both, medium or antiCD3/antiCD28 as positive control for three days. 
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4 Discussion  
In this scientific work, two differential approaches were followed to validate candidates involved 
in HIV-1 latency. The candidate factors were derived from a genome-wide siRNA screen 
performed in HIVluc HEK293T cells, which were transduced with a HIVluc reporter construct, 
cultivated over several weeks before effect of host factor knockdown on HIV driven luciferase 
expression was determined (graphical presentation Figure 5, details on the screening setup 
described in section 3.1). A graphical scheme of the two approaches taken is shown in     
Figure 6. The results of the two approaches will be separately discussed in the following 
sections. 
 
4.1 Approach I: Chromatin targets 
4.1.1 Summary of TRRAP results 
A graphical scheme is shown in Figure 43 and represents the consecutive steps taken in this 
work to choose follow-up hits and the validation approach to identify a potential influence on 
HIV-1 latency.  
The initial hits from a genome-wide siRNA screen were searched for host factors involved in 
chromatin binding and/or modification, as the chromatin environment along with the presence 
or availability of transcription and co-factors plays a crucial role in overall gene expression and 
also impacts HIV-1 transcriptional processes. It is assumed that a subset of factors involved in 
HIV-1 transcription might also impact HIV-1 latency. This assumption is supported by the two 
positive controls BRD4 and CYLD, which increased luciferase signal upon their knockdown in 
HIVluc HEK293 cells (Figure 7A), i.e. model for HIV-1 transcriptional influences (overview 
scheme Figure 5B), but were also found to support reversal of latency upon their knockdown 
(Manganaro et al., 2014; Zhu et al., 2012). The chosen set of host factors was tested under 
the same experimental conditions and transient knockdown of TRRAP by four individual 
siRNAs led to a robust increase in luciferase signal in HIVluc-infected HEK293T cells      
(Figure 7A), verifying TRRAP as a hit in this model system on HIV-1 transcriptional processes. 
The increase in luciferase signal in this system points towards a restrictive action of TRRAP 
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on HIV-1 transcription. In a consecutive step, stable TRRAP knockdown J-Lat cells were 
generated and tested with medium or in combination with different LRAs for a potential 
increase in latency reactivation (Figure 15). The results in J-Lat cells did not support an 
influence of TRRAP in this latency test system. In a final step, the stable knockdown results 
were confirmed by transient TRRAP knockdown via siRNA (Figure 17A) and again no effect 
of TRRAP knockdown on latency reversal was observed. In summary, the results of the 
conducted experiments point towards a restrictive involvement of TRRAP on HIV-1 
transcriptional processes, whereas an involvement of TRRAP in HIV-1 latency could not be 
definitely determined. Potential experimental effects will be discussed separately (see section 
4.1.4). 
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Figure 43: Graphical overview of approach I: Chromatin targets – Identification of potential 
latency reversing factors with chromatin binding and/or modification properties. Initial target 
selection was followed by validation in HIVluc HEK293T cells. TRRAP was confirmed as hit in HIV-1 
transcriptional processes. Several methodologies were established to generate stable and transient 
knockdown J-Lat 8.4 cells. Stable knockdown of TRRAP in combination with various LRAs did not result 
in reversal of latency. Also, transient knockdown of TRRAP did not lead to a reversal of latency.  
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4.1.2 TRRAP involvement in HIV-1 transcriptional processes 
TRRAP is conserved among many species (McMahon et al., 1998) and possesses an essential 
function during embryonic development, as mutations or gene disruptions lead to embryonic 
lethality (Herceg et al., 2001; Saleh et al., 1998). TRRAP itself is a huge protein with a 
molecular mass of >400kDa, therefore offers many binding sites for e.g. Skp1, c-Myc, p53 as 
well as E2F among others, and it is found in large complexes localized in the nucleus. Those 
TRRAP containing multi-protein complexes possess HAT activity, i.e. catalyzing the addition 
of acetyl groups to histone tails and thereby allowing spatial accessibility of DNA to 
transcription factors. It is noteworthy, that TRRAP itself does not possess HAT activity on its 
own. The composition of HAT complexes greatly varies by its subunit composition, while 
TRRAP remains the shared element between different complexes (Murr et al., 2007). It is 
assumed that HAT composition is dictating its substrate specificity. Therefore, TRRAP 
knockdown can have different effects on various pathways. The fact that TRRAP is of 
importance for the cell is underlined by its expression in all tissues (acc.to ‘The Human Protein 
Atlas for TRRAP (Uhlén et al., 2015)).  
There is also a report on TRRAP being an interaction partner of HIV-1 Tat, as TRRAP was 
identified in an affinity chromatography coupled to mass spectrometry approach from cellular 
extracts of Jurkat cells (Gautier et al., 2009). In this experimental setting, Tat binding of TRRAP 
could also be mediated by an intermediary protein and not by direct interaction. Moreover, in 
this study, the potential effect of Tat’s interaction with TRRAP was assumed on TRRAP’s role 
as being a transcriptional activator (by literature) but not further tested.  
Another study proposed c-Myc along with TRRAP to be of importance for Tat transactivation 
downstream of P-TEFb engagement (Brès et al., 2009). The authors proposed that Tat recruits 
P-TEFb followed by c-Ski-interacting protein (SKIP) to the viral promoter (Brès et al., 2005), 
which consecutively leads to the recruitment of c-Myc and TRRAP and to the specific 
methylation of histones by HMT and viral gene transcription. The requirement of those factors 
was changed upon stress (as seen by UV induction) (Brès et al., 2009). This as well supports 
TRRAP as a candidate involved in HIV-1 transcriptional processes, but rather as a supportive 
factor, which would be in direct contrast to what was observed in the initial genome-wide siRNA 
screen and in the confirmation experiments performed in this study (Figure 7A) where TRRAP 
was found to be a restrictive factor. The difference might arise from divergent test systems 
used in both studies: On the one hand, Brès et al. transfected Hela LTR-luciferase cells with 
(varying) concentrations of Tat protein or with plasmid, from which Tat was expressed, 
whereas in the genome-wide siRNA screen HEK293T cells were transduced with an HIV-1 
derived reporter virus (pNL4.3 expressing luciferase instead of nef, env deleted by frameshift 
4.1 Discussion approach I: Chromatin targets 
123 
mutation and VSV-G pseudotyped, see Figure 5A). This already encompasses a big 
difference, as on one hand in the first approach Tat was additionally supplemented by 
transfection (Brès et al., 2009) whereas in the other case Tat needed to be produced from the 
integrate before it could push viral transcription. In addition to this, the pNL4.3-derived vector 
transcribed for additional viral proteins, which can also influence the results. Further, the usage 
of lentiviral particles leads to an integration of transgene/provirus into the host genome, 
whereas plasmid transfection will have only a transient but strong effect, as the cell will produce 
huge amounts of gene product from transfected plasmid, whereas the production from the 
integrated transgene might be lower, due to the usage of the viral LTR as promoter. The 
difference in test systems might account for the different results concerning the involvement of 
TRRAP in HIV-1 transcription.  
Further, one could also argue that TRRAP-containing HAT complexes are supportive to 
transcription by acetylating histone tails and releasing the DNA from tightly bond nucleosomes. 
This would point towards a supportive role of TRRAP for HIV-1 transcription and that the results 
from the genome-wide siRNA screen are derived from an accumulation of aberrant processes 
which also affect, on the second line and not by a direct effect, the HIV-1 promoter. More 
experiments will be needed to determine under which conditions TRRAP functions as a 
supportive or a restrictive factor in HIV-1 transcription. 
 
4.1.3 TRRAP involvement in HIV-1 latency reversal 
Further, there was no significant effect after TRRAP knockdown on HIV-1 latency reversal 
neither on its own nor in combination with an LRA as determined in J-Lat 8.4 cells (Figure 15,              
Figure 17A). Therefore, one might argue against a role of TRRAP in HIV latency and 
reactivation from it. It is possible that TRRAP containing complexes might be differentially 
presented in a latency setting and by this evoke a different effect on latency than under ‘normal’ 
transcription, i.e. transcriptional processes in resting versus activated CD4+ T cells. However, 
this potential difference cannot be elucidated by the usage of immortal cell lines.  
Nevertheless, it could be possible that TRRAP elicits differential effects on HIV-1 transcription 
and latency as, for example, described for c-Myc: On the one hand, c-Myc supports Tat 
transactivation needed for HIV-1 transcription processes, but on the other hand acts restrictive 
in HIV-1 latency reactivation (Jiang et al., 2007). As TRRAP associates with c-Myc (McMahon 
et al., 1998), it is daring to argue for a differential role of TRRAP as well. But it is likely that the 
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restrictive effect of c-Myc in latency cell lines is due to its higher expression (de la Fuente et 
al., 2002; Stojanova et al., 2004), forming a repressive complex at the viral promoter and the 
recruitment of HDAC1 (Satou et al., 2001). This repressive mark would likely outrange the 
capacity of co-activators and chromatin remodelers without additional stimulation. Whether 
TRRAP plays a role in HIV-1 latency could not be definitely determined (also due to some 
technical considerations, discussed below). Further, TRRAP expression as well as its half-life 
might differ in J-Lat cells, i.e. actively dividing cells, from resting CD4+ T cells, masking a direct 
or second line effect of TRRAP on latency due to its abundance or stability. Unfortunately, 
there are no reports on TRRAP half-life and stability in non-dividing cells and further no reports 
exist on TRRAP and HIV latency.  
 
4.1.4 Experimental aspects 
There are several technical considerations regarding the experimental settings and the 
techniques used. As first point, TRRAP knockdown was only confirmed on mRNA level in all 
experiments since the confirmation on protein level failed twice by Western blot. Adaption of 
the Western blot test system should have included low percentage polyacrylamide gels plus a 
size-suitable protein marker, which would confirm successful migration into the gel and 
successful transfer to the membrane after blotting. Further, as also a dot blot with protein 
extracts failed, an extraction of nuclear extracts followed by DNase digest could support 
detection of ‘freed’ TRRAP in the supernatant. Since knockdown with siRNA/shRNA only 
affects newly produced mRNA but does not affect the level of produced protein, it is impossible 
to conclude that knockdown was achieved and/or maintained. In addition, TRRAP protein 
abundance peaks in S phase while is lowest in G0/G1 phase, demonstrating its involvement 
in cell cycle-progression (Ichim et al., 2014). Its mRNA levels, however, stay constant during 
different cell cycle-phases, pointing towards a post-transcriptional regulation of TRRAP in 
which e.g. binding partners will impact its protein half-life (Ichim et al., 2014). Therefore, to 
elucidate an effect of TRRAP in resting (HIV-1 positive) CD4+ T cells, the usage of cycling cells 
might not result in a reliable result.  
Further, the production of stable inducible knockdown cells was complicated as seen for the 
results of inducible shBRD4 knockdown J-Lat 8.4 cells (serving as positive control). The 
inducible knockdown did result in averaged 60% knockdown degree on mRNA level        
(Figure 9C) with correlatable RFP expression levels (Figure 9B) but no effect on increased 
reversal of latency was observed when tested along with an LRA (Figure 10) which is in 
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contrast to the results in HIVluc HEK293T (Figure 7A) and published data (as mentioned 
above), suggesting the inducible shRNA test system not being sensitive enough to detect small 
changes. And this low sensitivity probably stems from the low induction capacity of shRNA. 
Neither selection with puromycin to allow only transduced cells to survive or higher 
concentrations of doxycycline or prolonged exposure did result in a better knockdown result. 
The consequent change towards a non-inducible system (RIPZ derived shTRRAP and 
shCYLD) led to slightly better knockdown results along with increased RFP expression  
(Figure 13), even though a correlation of mRNA knockdown and RFP expression was less 
robust. An explanation for this could be the high multiplicity of infection used for the 
transduction process leading to multiple transductions and a potential loss of transgene over 
time. Further, it is also possible that TRRAP, since it participates in cell cycle progression, is 
of importance for cellular integrity and survival with a different turnover time than the positive 
control CYLD. In this case, the puromycin selection process could select on cells, which can 
outgrow the knockdown effect of TRRAP, and this could explain why RFP expression stayed 
high while mRNA knockdown was gradually lost over time and after freezing (Figure 14).  
 
4.1.5 TRRAP outlook 
For the elucidation of a potential role of TRRAP in HIV-1 latency, the protein expression levels 
need to be determined in target, i.e. resting, cells. It is likely that TRRAP levels are reduced in 
resting cells as compared to cycling cells, since the lack of proliferation. In a consecutive step, 
TRRAP knockdown (by shRNA/siRNA, CRISPR or other means) would need to be achieved 
and proven on protein level in a time dependent manner, to allow a predication on protein half-
life and the elucidation of a potential direct effect on the cellular viability. In addition, the status 
of transcription factors known to also initiate HIV transcription could be quantitated after 
TRRAP knockdown, which could support TRRAP’s potential role in affecting gene expression. 
The next step would aim at identifying TRRAP’s involvement in HIV-1 latency alone or in 
combination with an LRA, while this will be experimentally challenging, due to the low number 
of circulating resting CD4+ T cells, which carry an intact provirus. Leukapheresis could be an 
option to obtain high numbers of resting cells from patients, while a potential influence of 
TRRAP knockdown on HIV-1 latency could be easily masked by the bulk of non-infected ones 
and would need highly sensitive techniques or propagation of reactivated virus as by a 
quantitative viral outgrow assay. As a possible alternative direct infection of non-activated 
CD4+ T cells would allow the isolation cells from HIV-1 negative donors and infection with a 
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characterized virus without considering the presence of quasi species. Even though direct 
infection of resting cells is possible, it only leads to low number of infected cells (Lassen et al., 
2012; Swiggard et al., 2005). Of course, also the usage of other primary models (using 
activated T cells for infection and allowing the cells to return to a resting state) could be used 
to test for a potential effect of TRRAP on latency.  
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4.2 Approach II: Druggability 
4.2.1 Auranofin, diminazene summary 
In the second approach, the follow-up hits were chosen based on the availability of 
compounds, which are documented to inhibit the respective host factors. Figure 44 
summarizes the steps taken to identify and validate compounds, which possibly influence HIV-
1 latency: The chosen compounds were titrated on J-Lat 8.4 cells to determine the optimal 
concentration and tested along with different LRAs to determine potential effects on latency 
reversal. Auranofin was found to have a positive effect on latency reversal tested in 
combination with any LRA in J-Lat clones tested but not its own (Figure 20), whereas in U1 
cells auranofin robustly reversed latency only in combination with the tested HDACi         
(Figure 29). In a consecutive step, the effect of auranofin on latency reversal was mimicked 
by other compounds, which were proposed to inhibit auranofin’s target PRDX5 and its 
upstream pathway. None of the mimicking compounds showed the exact effect than auranofin 
(Figure 24). 
However, diminazene was identified to impact latency reversal in J-Lat cells when applied in 
combination with either TNFα or prostratin, to a level, which was even greater than what was 
seen for auranofin. This could point towards a certain overlap in target(s) of auranofin and 
diminazene. However, diminazene’s effect was cell line specific and was only detected in          
J-Lat clones but not in U1 cells. Target validation by siRNA knockdown followed by stimulation 
in specific combinations and cell systems showed slight induction in HIV-1 latency reversal 
(Figure 34A, Figure 35A), supporting this pathway to be the target of auranofin and potentially 
also of diminazene (see following sections). In a final step, the methodology of testing 
auranofin or diminazene in combination with an LRA was established in primary HIV-1+ CD4+ 
T cells. In the following sections, auranofin, diminazene and primary HIV-1+ CD4+ T cell results 
will be discussed separately.  
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Figure 44: Graphical overview of approach II - Druggability. The initial selection of compounds was 
chosen and tested in J-Lat 8.4 cells. Auranofin was identified to enhance the reactivation of latency 
when applied in combination with any of the tested LRAs, i.e. TNFα, prostratin, SAHA or sodium 
butyrate. As consecutive step, compounds were identified which were stated to target the same host 
factor, i.e. PRDX5 and its upstream pathway member TXNRD. The subsequent testing of the additional 
compounds identified diminazene to enhance reactivation, an effect which differed from auranofin and 
which was cell line specific. Target validation was performed by siRNA, which could slightly recapitulate 
the effect of auranofin (and diminazene). As a final step the methodology of testing the identified 
compounds in primary HIV-1+ CD4+ T cells was established. 
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4.2.2 Auranofin and its mechanisms of action 
4.2.2.1 Auranofin and the thioredoxin system 
Auranofin is an organo-gold compound, which is approved for the treatment of rheumatoid 
arthritis, although its exact mechanisms of action is not yet fully elucidated (Tejman-Yarden et 
al., 2013). Auranofin gained interest as it might also be useful in treatment of cancer (Chen et 
al., 2014; Fiskus et al., 2014; Marzano et al., 2007), bacterial (Hokai et al., 2014; Jackson-
Rosario and Self, 2009; Jackson-Rosario et al., 2009) as well as parasite infections (Ilari et al., 
2012; Lobanov et al., 2006; Sharlow et al., 2014) and potentially even in neurodegenerative 
diseases (Madeira et al., 2013, 2014). There is cumulating evidence that auranofin evokes its 
effect by the thioredoxin system. This system, with its contributing partners thioredoxin 
reductase (TXNRD), thioredoxin (TRX) and the reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH), supports the cellular redox homeostasis by scavenging 
reactive oxygen species (ROS) species and oxidized proteins (Arnér and Holmgren, 2011; 
Holmgren and Björnstedt, 1995). ROS species, as H2O2 and OH, are instable, highly reactive 
and continuously produced as by-product from essential metabolic processes, like oxidative 
phosphorylation in the mitochondria, but can also be derived from pollutants, chemicals, and 
radiation, among others (Lobo et al., 2010). An imbalance in the redox regulation, by an excess 
of ROS or an inadequacy of redox proteins, leads to oxidative stress, which compromises the 
integrity of DNA, lipids and proteins and can ultimately lead to apoptosis (Du et al., 2012). An 
imbalanced redox homeostasis is also associated with aging and cancer (Kruk and Aboul-
Enein, 2017; Liochev, 2013). However, it is important to mention that ROS not only has 
detrimental effects but also serves as a crucial second messenger in various signaling 
cascades. Further, ROS are also implemented in NFκB signaling, whereas it can have both 
activating and inhibiting effects, which is dependent on the kind of ROS, its exposure 
time/intensity and the cell type (Hirota et al., 1999; Morgan and Liu, 2011).  
TXNRD (cytosolic TXNRD1 and mitochondrial TXNRD2) uses NADPH to reduce oxidized TRX 
(cytosolic TRX1 and mitochondrial TXR2) and also other targets. Reduced TRX is a powerful 
protein disulfide reductase, which serves as electron donor for ribonucleotide reductase 
(Holmgren and Björnstedt, 1995), influences the DNA-binding of transcription factors such as 
NFκB and activator protein 1 (AP-1), and reduces PRDX, which in turn reduces H2O2 (Du et 
al., 2012; Halliwell and Gutteridge, 2015; Matthews et al., 1992; Zhang et al., 2014). The 
oxidized forms of PRDX and TRX are recycled to its reduced form by electron donation from 
TRX and TXNRD, respectively. A graphical presentation of the thioredoxin system is shown in 
Figure 45. 
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Figure 45: Schematic representation of the thioredoxin system. Reduced TXNRD serves as 
electron donor for oxidized TXR and other substrates. Reduced TRX serves as electron donor for PRDX, 
ROS directly and other substrates. Further, TRX can influence binding of transcription factors, suppress 
apoptosis, stimulate cell growth among many other functions. AP-1= activator protein 1, ASK-1= 
apoptosis signal-regulating kinase 1, NADP+= nicotinamide adenine dinucleotide phosphate, NADPH= 
reduced form of nicotinamide adenine dinucleotide phosphate, GPX= glutathione peroxidase, ox= 
oxidized, PRDX= peroxiredoxin, PKC= protein kinase family C, red= reduced, TRX= thioredoxin, 
TXNRD= thioredoxin reductase. 
 
Auranofin’s proposed mode of action is by inhibiting TXNRD (TXNRD2 more potently than 
TXNRD1 (Rigobello et al., 2005)) and by this, it induces apoptosis via the mitochondrial 
pathway (Cox et al., 2008; Rigobello et al., 2005, 2008). It does not increase H2O2 levels 
directly but indirectly by its irreversible binding to TXNRD (Fan et al., 2014), leading to an 
oxidized status and a decreased mitochondrial membrane potential. Of note, the cellular redox 
homeostasis involves several pathways with various antioxidant enzymes, which can partially 
account for each other (Du et al., 2012; Zhang et al., 2014).  
It is a possible explanation that auranofin-induced apoptosis leads to a reversal of latency in 
the tested latency cell models. This was shown to be the case for several cytotoxic drugs, 
which induced apoptosis-derived latency reversal in a dose-dependent manner in ACH-2 and 
U1 cells (Khan et al., 2015). On the other hand, the auranofin concentration applied was tested 
for its effect on cell viability and no negative influence was determined for the duration tested. 
Therefore, reversal of latency in our experiments cannot be satisfiably explained by a sole 
apoptosis induction capacity of auranofin. This is also further supported by other publications, 
which tested auranofin as cytotoxic drug on various cell lines without observing cell death at 
comparable low concentration (≤0.5µM) but at doses 2µM and higher, which also resulted of 
inhibition of other redox enzymes (Du et al., 2012; Fan et al., 2014; Park and Kim, 2005; 
45 
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Varghese and Büsselberg, 2014). Of note, in various cancers and cancer cell lines the 
thioredoxin system is expressed at higher levels, which allows better response to ROS and 
contributes to cell survival and proliferation (Arnér and Holmgren, 2006; Gopalakrishna et al., 
2018; Lincoln et al.; Yoo et al., 2007). This might also bias the usage of those cell lines. The 
proposed effect of auranofin on the thioredoxin system is shown in Figure 46 on the left side. 
 
4.2.2.2 Auranofin and PKC 
Despite TXNRD, also the protein kinase (PKC) family is described by some publications 
(published around 1990) to be targeted by auranofin (Froscio et al., 1989; Parente et al., 1989; 
Wong et al., 1990). Even though other publications clearly claim PKC not being a target of 
auranofin (Hashimoto et al., 1992), the discrepancy might be derived from the different types 
of cell used, as PKC inhibition was seen in neutrophils, but not in Jurkat cells or by the different 
test systems applied. This kinase family comprises 15 enzymes, which are further grouped 
according to their cofactor dependency (Mellor and Parker, 1998) into conventional, novel and 
atypical isoenzymes. The PKC family is of importance in signal transduction and in cellular 
survival, proliferation, migration, as well as apoptosis (Dempsey et al., 2000). PKC activation 
has been linked to latency reversal, as seen for prostratin, a PKC agonist (Jiang and Dandekar, 
2015) which leads to NFΚB activation (Jeon et al., 2000). The potential inhibition of PKC by 
auranofin is in clear contrast to our results, as treatment of J-Lat cells with both T cell activating 
LRAs led to increased reversal of latency (Figure 20A), whereas the opposite would be 
expected due to their opposed action, i.e. PKC agonist versus inhibition. The difference might 
be explained by the auranofin concentration applied, as PKC inhibition was observed upon 
5µM, whereas our experiments were conducted at 0.2µM- a concentration 25 times lower. It is 
likely that the concentration applied is too low to efficiently block PKC, which would need to be 
experimentally determined. Nevertheless, the synergistic effect of auranofin and prostratin on 
latency reversal is unlikely derived from auranofin’s sole action on PKC.  
Interestingly, there is a link of PKCs, the thioredoxin system and ROS. On the one hand, PKC 
proteins possess a catalytic and a regulatory domain, both domains being cysteine-rich and 
are therefore also prone to oxidation by ROS (Gopalakrishna et al., 2018). It has been shown 
that low levels of ROS can activate PKC, independent of its cofactor, while high levels of ROS 
inactivate PKC (Gopalakrishna and Jaken, 2000). On the other hand, the thiol redoxin system 
is responsible for the reduction of oxidized PKC and further TRX is binding PKC with high 
affinity at its catalytic domain, preventing its autophosphorylation and by this keeping PKC 
inactive (Watson et al., 1999). If auranofin does not directly target PKC, it would still indirectly 
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affect it. So would the inhibition of TXNRD lead to a decrease of reducing capacity of the cell 
and the resulting increase in ROS could activate PKC signaling while oxidized TRX could also 
not occupy its catalytic domain and therefore also not inhibit its (auto-) phosphorylation. PKC 
as potential target of auranofin is shown in Figure 46 middle part. 
 
4.2.2.3 Auranofin and IKK 
One further host factor described in literature to be targeted by auranofin is IKKβ – a member 
of the IKK complex, which is a major player in NFκB activation (Jeon et al., 2003, 2000). The 
inhibition of IKK is used to explain the beneficial effect of auranofin in rheumatoid arthritis 
patients, as it leads to reduction of inflammatory NFκB-signaling. The IKK complex consists of 
IKKα, IKKβ and two molecules of IKKγ (also known as NEMO) for the canonical NFκB 
activation or of two molecules IKKα without IKKγ for the non-canonical pathway. Activation of 
the IKK complex by e.g. proinflammatory cytokines as TNFα or receptor stimulation (canonical 
pathway) will lead to phosphorylation of IKK complex and this will in turn lead to 
phosphorylation of IκBα, which is associated with NFκB (p50/p65) heterodimers, masking the 
nuclear localization signal (NLS). Upon phosphorylation at specific residues, IκBα is marked 
for proteasomal degradation, unmasking the NLS allowing NFκB to translocate to the nucleus 
and induce target gene transcription (Luo et al., 2005; Moynagh, 2005; Scheidereit, 2006). If 
auranofin would block IKK, then NFκB activation followed by nuclear translocation and 
transcription would be inhibited and no reversal of latency would be expected. This contrasts 
with our results, as auranofin together with TNFα (an inflammatory cytokine) or prostratin leads 
to increased reversal as compared to LRA treatment alone (Figure 20A) and not to a decrease. 
The inhibition of IKK by auranofin (as reported by the above-mentioned references) was tested 
in several cell lines at higher concentrations for shorter time points than our presented 
experiments. It is possible that IKK inhibition of auranofin is concentration dependent, whereas 
at low doses no inhibition occurs. It is also possible that IKK inhibition is time dependent and 
is overcome by the cell. Those possibilities have to be experimentally confirmed. Further, there 
is also evidence that NFκB can be activated by ROS independent of IKK phosphorylation, even 
though this is highly dependent on the ROS species, concentration, exposure time and cell 
type (Gloire et al., 2006; Lingappan, 2018). An integrated scheme of IKK as potential target for 
auranofin and the overlap in pathways is shown in Figure 46 on the right side. 
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Figure 46: Graphical presentation of auranofin’s (potential) targets and its effect. Left side) 
TXNRD as potential target of auranofin: TNNRD is blocked by auranofin and cannot reduce its targets 
as TRX. Partly, this will lead to increases in oxidized substrates and susceptibility towards ROS. 
Reduced glutaredoxin as well as glutathione are indicated as backup system and can reduce oxidized 
thioredoxin. Increased levels of ROS will lead to increased redox enzyme transcription, whereas 
prolonged exposure to ROS will lead to the induction of apoptosis. Middle part) PKC as potential target 
of auranofin: PKC can activate various signaling pathways involved in survival, proliferation and 
apoptosis. It can also activate the NFκB pathway. Further, thioredoxin can inhibit PKC activation and 
also ROS can activate and inhibit PKC, dependent on the kind of ROS, exposure time and target cell. 
Right side) IKK as potential target of auranofin: IKK inhibition can inhibit canonical NFκB signaling, 
even though the non-canonical pathway might be unaffected. Further, ROS can induce but also block 
NFκB activation dependent on the kind of ROS, exposure time and target cell. GSH= glutathione (an 
antioxidant), GRX= glutaredoxin, IKK= IκB kinase complex, IκB= inhibitor of kappa B, ox= oxidized, 
p50/p65= NFκB heterodimer, PKC= protein kinase C family, red= reduced, ROS= reactive oxygen 
species, TRX= thioredoxin, TXNRD= thioredoxin reductase. 
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4.2.3 Auranofin and its involvement in latency reversal 
Auranofin‘s effect on the latent reservoir has been reported before as tested on a non-human 
primate model (SIVmac251-infected rhesus macaques) and on ex vivo tested HIV-1+ CD4+ T 
cell populations (Chirullo et al., 2013; Lewis et al., 2011). The mode of action was not 
determined in both studies, but an increase of annexin V positive cells, i.e. marker for 
apoptosis, which went along with a downregulation of CD27 and CD28 surface markers, i.e. 
markers recognized for memory or survival (Hendriks et al., 2000; Mir and Mir, 2015), was 
observed. The authors claim that a lower oxidative status of the memory T cell compartment 
renders those cells more susceptible to auranofin treatment, which subsequently leads to the 
induction of apoptosis, while auranofin treatment did not induce proviral transcription.  
Our primary cell results point towards a higher susceptibility of resting CD4+ T cells to auranofin 
than overall CD4+ T cells (compare Figure 39A and Figure 40). This clearly indicates the 
higher sensitivity of this cell population to auranofin (and sodium butyrate). But whether this 
effect on cell viability is due to lower levels of antioxidant enzymes in non-activated CD4+ T 
cells could not be determined by the experimental setup and read-out. Sorting of different CD4+ 
T cell populations could elucidate the differential susceptibility of these populations to 
auranofin.  
 
4.2.4 Auranofin conclusion and outlook 
Auranofin robustly increases latency reversal in J-Lat cells when tested with various LRAs, 
whereas its mechanism of action remains to be determined. Auranofin also induced reversal 
of latency in U1 cells when treated with HDACi. Supported by literature, auranofin might 
primarily evoke its effect via the redox system and an imbalance leading to an overall effect on 
the cell, due to a change in the redox homeostasis towards more oxidized products, a change 
in binding affinity of transcription factors to DNA and also to a change in NFκB signaling, among 
others. Since redox enzymes can partially account for each other, it is not surprising that 
conducted siRNA knockdown experiments did not fully recapitulate the effect of auranofin. 
Also, other (additional) targets of auranofin cannot be excluded. In addition, the experimental 
possibilities of measuring specific redox processes within a cell are limited and reflect in many 
cases only the overall redox state, complicating the elucidation of auranofin’s specific effect on 
the thioredoxin system. Further, special attention needs to be given to the cells tested, as 
cancer cell lines generally possess higher levels of redox enzymes and might cope differential 
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with redox stress than primary cells. Despite all those considerations and hurdles, auranofin is 
an interesting compound, which is worth to be further tested. A major benefit is that auranofin 
is approved for use in humans and due to this good data on safety, dosing, and side effect 
among others already exist. The results of a currently ongoing clinical trial, testing for an effect 
on the reservoir size under intensified HAART applied in combination with auranofin, are 
eagerly awaited (clinical trial number: NCT02961829). 
 
4.2.5 Diminazene and its mechanisms of action 
4.2.5.1 Diminazene and its trypanocidal action 
Diminazene is a synthetic diamidine used since the 1950s as trypanocidal agent, protecting 
cattle and also other ruminants against protozoal species of the genus Trypsanosoma, 
Babesia and Leishmania, among others (Jean-Moreno et al., 2006; Nehrbass-Stuedli et al., 
2011; Nnadi et al., 2019). Even though diminazene usage is limited to the treatment of 
domestic life stocks, there are also some reports on treatment of African Trypanosomiasis in 
humans, which led to side effects as vomiting, diarrhea and rash among others, but without 
long-term effects once treatment was stopped (Abaru et al., 1984). Its mechanism of action is 
not well understood but there is evidence that it exhibits its effect by binding to AT rich regions 
and due to this inhibiting replication of kinetoplast DNA (kDNA) of Trypsanosoma species and 
potentially also host DNA (Mikek et al., 2018; Tuvshintulga et al., 2017; Valenzuela et al., 
2017), including the blocking of protozoal DNA topoisomerase (Shapiro, 1993) and potentially 
mammalian DNA topoisomerase I (Chen et al., 1993; Portugal, 1994). Since diminazene 
research focused (for a long time) mainly on protozoal research, there is a lack of cumulative 
evidence on diminazene’s effect on host DNA and topoisomerases.  
 
4.2.5.2 Diminazene and angiotensin converting enzyme 2 (ACE2) 
Further, diminazene gained interest in the last two decades, as it might be also beneficial in 
treatment of neurological disorders like Alzheimer’s disease (Kamel et al., 2018) and might 
also protect from myocardial infarcts (Castardeli et al., 2018; Chen et al., 2017) as well as 
ischemic strokes (Bennion et al., 2015). The protective effect of diminazene can be explained 
by diminazene-mediated increase in angiotensin converting enzyme 2 (ACE2) activity, which 
is involved in the regulation of cardiovascular, renal, pulmonary and central nervous systems 
(Guang et al., 2012). Whether diminazene is a direct activator of ACE2 (Bruce et al., 2018; De 
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Maria et al., 2016; Tao et al., 2016) or an indirect one is still a matter of debate (Haber et al., 
2014; Rajapaksha et al., 2018). Nevertheless, the direct or indirect effect of diminazene on the 
ACE2 cannot explain the reversal of latency as seen in the J-Lat cell model as the expression 
of ACE2 is highly organ/tissue specific and not expressed in lymphocytes (acc. to ‘The Human 
Protein Atlas’ for ACE2 (Uhlén et al., 2015)).  
 
4.2.5.3 Diminazene reduces proinflammatory response 
Diminazene’s action has been also linked to reduced phosphorylation of the mitogen-activated 
protein kinases (MAPK) pathway, signal transducer and activator of transcription (STAT) and 
NFκB subunit p65 in protozoa challenged- or lipopolysaccharide (LPS)-treated macrophages, 
leading to reduced proinflammatory cytokine production (Kuriakose and Uzonna, 2014; 
Kuriakose et al., 2012, 2014). Considering a reduction in cytokine production and signaling, 
this might explain why there was no effect seen in U1 cells when treated with diminazene in 
combination with the tested T cell activating LRAs. However, it would not explain the reversing 
effect seen in J-Lat cells (compare Figure 24 and Figure 29). 
 
4.2.5.4 Diminazene and its influence on polyamines 
Other described targets of diminazene include, for instance, the human diamine oxidase (DAO) 
(also known as amine oxidase copper containing 1 (AOC1)), which is an enzyme serving in 
the oxidation of histamines and other polyamines as putrescine or spermidine (Finney et al., 
2014; Jänne et al., 1985; McGrath et al., 2009). Further, adenosylmethionine decarboxylase 
(AMD1) (also known as AdoMedDC) has been stated to be irreversibly blocked by diminazene 
(Karvonen et al., 1985). Interestingly, both enzymes are linked to polyamines, with AMD1 being 
a key enzyme in the polyamine biosynthesis.  
Polyamines are small carbon chains containing at least two amino-groups, are positively 
charged (at neutral pH) and abundantly present in all living cells. In mammalian cells, three 
endogenous polyamines are produced, namely putrescine (diamine), spermidine (triamine) 
and spermine (tetraamine), which are consecutively synthesized (Michael, 2016). In a first 
step, putrescine is formed by ornithine decarboxylation. This enzymatic reaction is performed 
by ornithine decarboxylase (ODC), an enzyme with a short half-life, tightly regulated on various 
levels and transcriptionally initiated by c-Myc (Peña et al., 1993). Another enzyme of major 
importance is the above-mentioned AMD1, which catalyzes the reaction of decarboxylated                                                  
S-adenosylmethioninamine (dcSAM) from S-adenosyl methionine (SAM). The availability of 
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dcSAM is the rate-limiting step in the synthesis of spermidine and spermine, as dcSAM 
provides the aminopropyl group for the spermidine and spermine conversion by their 
respective synthases (Pegg, 2016). The catabolism of those two polyamines is executed by 
the spermidine/spermine-N1-acetyltransferase (SSAT). The acetylated product is then further 
oxidized by the acetylpolyamine oxidase (APAO) to form spermidine (from spermine) or 
putrescine (from spermidine) (Pegg, 2008). Of note, also spermidine/spermine-N1-
acetyltransferase was mentioned to be a target of diminazene (Neidhart et al., 2014). An 
overview scheme on polyamine synthesis and catabolism is shown in Figure 47. 
Figure 47: Scheme of polyamine synthesis and catabolism. Putrescine is formed from ornithine by 
ODC and further processed to spermidine and spermine by spermidine and spermine synthase, 
respectively under the consumption of dcSAM, which is produced from SAM by AMD1. Spermine and 
spermidine are catabolized into spermidine and putrescine respectively by SSAT and APOA. AMD1= 
adenosylmethionine decarboxylase, APAO= acetylpolyamine oxidase, dcSAM= decarboxylated S-
adenosylmethioninamine, ODC= ornithine decarboxylase, SAM= S-adenosyl methionine, SSAT= 
spermidine/spermine-N1-acetyltransferase. Adapted from Huang et al., 2009.  
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The importance of polyamines is reflected in the plethora of cellular functions they support 
(schematically summarized in Figure 48): It was shown that polyamines stabilize DNA by direct 
binding, support DNA bending and protect DNA from oxidation by ROS. Further, polyamines 
also bind RNA (as mRNA, tRNA) and can thereby directly (but also indirectly) influence 
translation (Igarashi and Kashiwagi, 2010). A   well-documented example for an indirect effect 
of polyamines on protein synthesis was described for spermidine, as it provides an aminobutyl 
group to modify the eukaryotic translation initiation factor 5A (eIF5A) (Igarashi and Kashiwagi, 
2010; Park et al., 1981). This post-translational modification of eIF5A is needed to assist 
paused ribosomes at mRNA encoding proline-rich sequences to complete translation and also 
to successfully terminate translation. In addition, polyamines also modulate ion channels and 
receptor-ligand interactions, serve directly as ROS scavengers (even though their catabolism 
also leads to ROS formation (Murray Stewart et al., 2018)) and are involved in growth, 
proliferation and apoptosis. In line with the mentioned examples, it is unsurprising that 
polyamine synthesis and homeostasis are tightly regulated on various levels and by different 
mechanisms: For instance, specific inhibitors of ODC, i.e. antizymes, regulate ODC activity. 
Whereas the antizymes itself are regulated by their own inhibitors, i.e. inhibitor of antizymes 
(Mangold and Leberer, 2005). Further, transcription of e.g. AMD1 and SSAT can be induced 
in response to the cellular polyamine content or by other (upstream) enzymes (Gamble et al., 
2012). In addition, polyamines can be also imported and exported by the cell (Huang et al., 
2009).  
Worthwhile to mention is that polyamines also play a role in the viral life cycle. So has been 
has been found that polyamine synthesis can be differently affected by different viruses (Li and 
MacDonald, 2016; Mounce et al., 2017). Furthermore, it is also known that polyamines 
condense viral genomes which supports the packaging of these into newly produced viruses 
(Sun et al., 2010). A schematic overview on polyamine functions and interactions is shown in 
Figure 48. Regarding HIV-1, evidence exists that inhibition of AMD1 by different compounds 
will negatively impact the viral life cycle (Jin et al., 2015, Schäfer et al., 2006). This also clearly 
shows the importance of polyamines for HIV-1.  
Further, early reports stated that diminazene inhibited AMD1 in vivo and ex vivo and replaced 
DNA-bound spermidine (Da’dara et al., 1998; Karvonen et al., 1985). Inhibition of AMD1 by 
methylglyoxal-bis-guanylhydrazone (MGBG), a polyamine analogue as well as a structural 
analogue of diminazene (Marques et al., 2008; Pegg and McCann, 1992), led to a depletion of 
spermidine and spermine pools, while elevating the levels of ODC (in line with the increased 
putrescine levels observed) (Regenass et al., 1992). The usage of another AMD1 inhibitor, i.e. 
5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (AbeAdo), led also to a decrease 
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in spermidine and spermine levels associated with a decrease in certain transcription factors 
as    c-Fos and c-Jun (Desiderio et al., 1996), an increase in putrescine levels (Byers et al., 
1994a) and to unmodified eIF5A as secondary effect of spermidine depletion (Byers et al., 
1994b). Further, AMD1 inhibition influences the cellular SAM to dcSAM ratio, with higher rates 
of SAM being present. SAM also serves as methyl-group donor for DNA methyltransferases 
(DNMT) as well as HMTs, as a consequence it can affect the DNA and histone methylation 
status, thereby influencing gene transcription in an either supporting or silencing fashion 
(Hashimoto et al., 2010; Poomipark et al., 2016). This is supported by the finding that dcSAM 
blocks the activity of DNMTs (Yamamoto et al., 2010). Further, an (age related) decline of 
spermidine was found to increase HAT activity (Eisenberg et al., 2009). The mentioned 
examples will affect transcription and translation, alter cell proliferation and can induce 
apoptosis. Further, it is also likely that depleted polyamines are lacking as ROS scavengers 
and stabilizers for DNA and RNA, which further influence the cell and its fate. The wide-ranging 
consequences of a disturbed polyamine homeostasis will most likely also the latent state of 
the provirus. 
Additionally, a single publication states that diminazene inhibits SSAT, leading to increased 
putrescine and reduced AMD1 levels in primary fibroblasts from rheumatoid arthritis patients 
(Neidhart et al., 2014). Despite the differential target, the results are comparable to the            
above-mentioned examples. Also, ODC inhibition by its specific inhibitor, i.e. α-D,L-
difluoromethylornithine hydrochloride (DFMO), led to the described results, including changed 
DNA methylation, halted cell proliferation (Mamont et al., 1976) and apoptosis induction via 
the mitochondrial pathway (Mandal et al., 2015).  
 
Figure 48: Simplified scheme on the influence of polyamines. Polyamines participate in various 
processes and interact with a wide range of cellular molecules; due to this polyamines affect cellular 
proliferation and apoptosis. In addition, polyamines homeostasis can be differently affected by viral 
infections. Adapted from Mounce et al., 2017. 
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4.2.6 Diminazene conclusion and outlook 
Diminazene was identified to have a positive effect on latency reversal in J-Lat cells when 
applied in combination with different LRAs, with the effect being most prominent with TNFα or 
prostratin. U1 cells on the other hand did not recapitulate this effect. There are several literature 
reports linking diminazene to the polyamine synthesis/catabolism, specifically to AMD1, 
whereas no evidence exists that link diminazene and the thioredoxin system, i.e. the proposed 
target of auranofin. Therefore one could assume that auranofin and diminazene do not target 
the same pathway and that the observed reversal of latency is induced by mechanisms 
different from the proposed inhibition of the thioredoxin system. On the other hand, one could 
argue that diminazene’s effect on polyamine content leads as a secondary effect to an 
imbalance in the overall redox state of the cell, as depleted/non-converted polyamines could 
not serve as direct ROS scavengers. This in turn could have a wide range of effects and would 
link the polyamine system to the redox state of the cell, which could serve as possible 
explanation for the comparable effect of auranofin and diminazene on latency reversal. On the 
other hand, polyamines are essential for the cell and participate in many more cellular 
processes than just as ROS scavenger. It is therefore likely that the effect of diminazene 
cannot be only linked to its potential influence on redox state. But that the effect on latency 
reversal might be also evoked by a potential destabilization of DNA and RNA, by an influence 
on protein translation, or by effects on the chromatin state. Whether latency reversal is evoked 
by disturbance of one of the mentioned examples or by the accumulation of cellular 
pertubations derived from various mechanisms need to be experimentally tested. The usage 
of other known specific inhibitors of the polyamine synthesis and catabolism will help to verify 
diminazene’s target (pathway). 
Even though the target (pathway) of diminazene still needs to be fully elucidated, we found 
robust reversal of latency in the J-Lat cell system. This effect has never been documented so 
far while diminazene’s proposed influence on the polyamine synthesis is seizable. Therefore 
polyamine synthesis and catabolism might present a yet underinvestigated target pathway in 
regard to latency, in which polyamine disturbances lead to cellular pertubations affecting also 
the the provirus  
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4.2.7 Primary human results 
In order to test auranofin’s and diminazene’s potential effect on latency reversal in primary 
cells, overall CD4+ T cells or non-activated CD4+ T cells were isolated from HIV-1 positive 
patient blood. The isolation of CD4+ T cells (overall and non-activated) was successfully 
established and the optimal compound (and LRA) concentration for a 3-day treatment was 
determined. Reversal of latency, though, could not be successfully confirmed, except for one 
donor out of 13 tested. This example supports the general experimental setup but does not 
allow overall conclusions for the tested compounds. Further, testing and fine-tuning would be 
needed to definitely allow a conclusion of auranofin’s and diminazene’s action on latency 
reversal.  
A major limitation of the primary experiments was the overall time limitation, i.e. as primary 
experiments were conducted at the Robert Koch Institute for a period of 2.5 months. The initial 
experimental duration was reduced from six days to three days (graphical overview on the 
initial experimental setup Figure 36). This, on the one hand, shortened the assay duration and 
allowed for acceptable cell viability results (see Figure 40). But this shortening, on the other 
hand, might have also taken time needed to produce sufficient levels of progeny viruses to a 
detectable level in the supernatant. So further experiments might be conducted with the initially 
planned duration, while retitrating compounds and LRA concentrations to allow for cell survival. 
Another aspect to consider was the overall low cell numbers isolated, which were due to the 
low amount of starting material provided. A greater quantity of patient blood would allow to 
isolate higher numbers of resting cells and therefore to test all experimental conditions initially 
planned and also allow for an increase in cell number per experimental condition, since higher 
cell numbers would also increase the probability of isolating cells carrying a replication-
competent provirus. Considering the overall cell needs due to the low numbers of cells 
harboring a provirus (assumed one resting cells out of one million cells (Eriksson et al., 2013)), 
leukapheresis might be the best suitable option to guarantee enough cells. Further, the 
implementation of a qVOA, which is considered the gold standard to measure reactivation of 
latent primary cells, could be considered, as it would allow an amplification of the p24 signal 
due to propagation of the of reactivated virus, which in turn could facilitate the read-out.  
Despite the difficulties mentioned, it would be of interest to continue testing both compounds 
in a primary setting and to elucidate whether I) auranofin has an effect on latency reversal or 
evokes its effect primarily by the higher sensitivity of resting cells and further II) whether 
diminazene application proves advantageous for latency reversal. 
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4.3 Overall conclusion 
HTS have been proven a valuable tool for accelerated hit identification for various research 
areas, and so has also the validation of the primary hits from a genome-wide siRNA screen 
performed in HIVluc HEK293T cells involved in HIV-1 latency, as assayed in this scientific 
work, led to interesting results and pointed towards the involvement of so far                           
under-investigated pathways. Following two differential approaches to choose and validate 
primary hits, the chromatin-binding protein TRRAP (= approach I) as well as the compounds 
auranofin and diminazene (= approach II) were identified and tested. While TRRAP knockdown 
recapitulated the results of the genome-wide siRNA screen, a latency involvement could not 
be definitely defined. Further, the compounds auranofin and diminazene were identified and 
successfully tested in J-Lat cells, even though their effect was different and cell line specific. 
The proposed initial target, i.e. PRDX5 and upstream pathway, could not be absolutely verified. 
Interestingly, there is a huge discrepancy between publications and databases considering the 
cellular targets of compounds, which needs to be kept in mind while working with those 
databases as DrugBank (Law et al., 2014). According to literature it is highly likely that 
auranofin evokes its effect via the inhibition of the thioredoxin system, while diminazene evokes 
its effect via its influence on the polyamine homeostasis. Though, the host factors associated 
with the two systems, namely TXNRD and TRX for auranofin and AMD1 (and potentially SSAT) 
for diminazene have not been identified as primary hit. Nevertheless, both systems are of 
crucial importance for the cell and have been implied in HIV-1 infection (Couret and Chang, 
2016; Jin et al., 2015; Porter and Sutliff, 2012; Schäfer et al., 2006), but have not been 
recognized for their importance in HIV-1 latency. Further experiments are needed to determine 
the cellular target(s) of those compounds and to prove their involvement in HIV-1 latency. 
In summary, the choice of primary hits to follow-up on had led to the identification of two 
compounds, which proved supportive in latency reversal, whereas their mechanism of action 
and their targets remain to be determined. The proposed influence of those compounds on 
either the redox or the polyamine system, as well as a possible interconnection of those 
systems, needs to be experimentally tested. It is possible that resting cells are more sensitive 
for disturbances of those systems and that application of those compounds might support 
reversal of latency. Those compounds could then support the ‘shock step’ in the ‘shock and 
kill’ approach. Further, it is also possible that the application of those compounds leads to a 
depletion of the viral reservoir by inducing apoptosis without reversing latency. If this possibility 
proves true, specific depletion of resting cells could support an HIV-1 cure by depleting the 
4.3 Overall conclusion 
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more sensitize resting cells along with the latent reservoir without the need to first induce 
proviral transcription followed by killing of the virus producing cell. 
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6 Abbreviations  
abbreviation full name 
°C Celisius degrees 
AbeAdo 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine 
ACE2 angiotensin converting enzyme 2 
activ. activation 
AIDS acquired immunodeficiency syndrome 
AMD1 adenosylmethionine decarboxylase 
AP-1 activator protein 1 
APAO acetylpolyamine oxidase 
APC antigen presenting cell 
applic.  application  
ASK-1 apoptosis signal-regulating kinase 1 
ASXL3 additional sex combs like 3 (Drosophila) 
AZT 3′-Azido-3′-deoxythymidine 
b.d. below detection 
BRD4 bromodomain containing protein 4 
bromo bromodomain 
BSA bovine serum albumin 
CAR chimeric antigen receptor 
CBX6 chromobox homolog 6 
CCR5 C-C chemokine receptor type 5 
CD cluster of differentiation 
CDK9 cyclin dependent kinase 9 
chromo chromodomain 
conju.  conjugate  
CpG 5'cytosine-phosphate-guanine3' (nucleotide sequence) 
CTL cytotoxic T lymphocytes 
CXCR4 C-X-C chemokine receptor type 4 
CXXC1 CXXC finger protein 1 
CYLD Cylindromatosis 
DAO diamine oxidase, a.k.a AOC1 
dcSAM decarboxylated S-adenosylmethioninamine 
DFMO difluoromethylornithine hydrochloride (ODC inhibitor) 
DMEM Dulbeccos modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNMT DNA methyltransferases 
DSIF DRB sensitivity factor 
e.g. Latin: exempli gratia, English: for example 
EDTA ethylenediaminetetraacetic acid 
eIF5A eukaryotic translation initiation factor 5A 
ELISA enzyme-linked immuno assay 
env envelope gene (HIV) 
FACS fluorescence-activated cell sorting 
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abbreviation full name 
FC  flow cytometry 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FITC  fluorescein isothiocyanate  
fw forward (primer) 
g gram 
Gag group specific antigen (HIV) 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
gDNA genomic DNA 
GFP green fluorescent protein 
GPX glutathione peroxidase 
GRX glutaredoxin 
h hours 
HAART highly active antiretroviral therapy 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV human immunodeficiency virus 
HIV-1 M group HIV-1 major group  
HIVluc HIV-1 derived reporter virus, expressing luciferase instead of nef, env deleted 
HLA-DR human leukocyte antigen – DR isotype 
HMT histone methyltransferase 
HRP horseradish peroxidase 
HTS high throughput screening 
i.e. Latin: id est, English: that is 
IkB inhibitor of κB 
IKK complex IκB kinase  
iso. isolation  
IUPM infectious units per million cells  
IκB inhibitor of kappa B 
KAT6B lysine acetyltransferase 6B 
kb kilobase 
kDNA kinetoplast DNA 
LB  lysogeny broth 
LPS lipopolysaccharides 
LRA latency reversing agent 
LTR long terminal repeat (HIV) 
MAPK mitogen-activated protein kinases 
mc  monoclonal 
MGBG methylglyoxal-bis-guanylhydrazone (inhibitor AMD1) 
min minutes 
ml mililiter 
MOPS 3-(N-morpholino) propanesulfonic acid 
mRNA messenger RNA 
MSH6 mutS homolog 6 
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abbreviation full name 
n.t. not tested 
NADP+ nicotinamide adenine dinucleotide phosphate 
NADPH reduced form of nicotinamide adenine dinucleotide phosphate 
nef negative regulatory factor 
NELF negative elongation factors  
NFAT nuclear factor of activated T-cell 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells  
NGS normal goat serum 
NHP non-human primate 
NLS nuclear localization signal 
NMS normal mouse serum 
ox oxidized 
p50/p65 NFκB heterodimer 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
pc  polyclonal  
PE phycoerythrin 
PEI Paul-Ehrlich-Institut 
PFA paraformaldehyde 
PHA phytohaemagglutinin 
PHD  plant homeodomain 
PKC protein kinase C 
PRDX peroxiredoxin 
P-TEFb postive transcriptional elongation factor b (complex) 
PWWP proline-tryptophan-tryptophan-proline containing domain 
qPCR quantitative PCR 
qVOA quantitative viral outgrowth assay 
red reduced 
rev reverse (primer) 
RNA ribonucleic acid 
RNA Pol II RNA polymerase II  
RNAi RNA interference 
ROS reactive oxygen species 
RPL13A 60S ribosomal protein L13a 
RPMI Roswell Park Memorial Institute medium 
RPS11 40S ribosomal protein S11 
RPS27a 40S ribosomal protein S27a 
RT-qPCR reverse transcriptase qPCR 
s seconds 
SAHA Suberanilohydroxamic acid (a.k.a Vorinostat) 
SAM S-adenosylmethionine decarboxylase adenosyl methionine 
SDS-PAGE SDS polyacrylamide gel electrophoresis  
seq sequencing 
SETD3 SET domain containing 3 
shRNA smal-hairpin RNA 
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abbreviation full name 
SIV simian immunodeficiency virus 
SIV cpz SIV chimpanzee 
SIV smm SIV sooty mangabey 
SMYD2 SET and MYND domain containing 2 
SOC medium super optimal broth with catabolite repression medium 
sod.but. sodium butyrate 
SSAT spermidine/spermine-N1-acetyltransferase 
STAT signal transducer and activator of transcription 
TAE buffer Tris-Acetate-EDTA buffer 
TAR trans-activating response element (HIV) 
Tat transactivator of transcription (HIV) 
TBS-T Tris-buffered saline with Tween 20 
TCM  central memory T cell 
TCR T-cell receptor 
TE buffer Tris-EDTA buffer 
TEM effector memory T cell 
TNFα tumor necrosis factor alpha  
TRRAP transformation/transcription domain-associated protein 
TRX thioredoxin 
TTM  transitional memory T cell  
TXNRD thioredoxin reductase 
USP22 ubiquitin specific peptidase 22 
UV ultraviolet 
Vif viral infectivity factor (HIV) 
Vpr viral protein r (HIV) 
Vpu viral protein u (HIV) 
VSV-G vesicular stomatitis Indiana virus glycoprotein 
WB Western blot 
∆ delta 
µ micro 
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Table S1: Primary screening hits derived from a genome-wide siRNA screen performed in HIVluc 
HEK293T cells, listed by their increasing Z-score. 
OfficialSymbol Z-Score LocusLink NCBI-Official Full Name 
PRKCH -3.2606 5583 protein kinase C, eta 
PHYH -3.2591 5264 phytanoyl-CoA 2-hydroxylase 
RGS13 -3.1137 6003 regulator of G-protein signaling 13 
STYX -3.0499 6815 serine/threonine/tyrosine interacting protein 
KRTCAP2 -3.0184 200185 keratinocyte associated protein 2 
SLC22A18AS -2.9664 5003 solute carrier family 22 (organic cation transporter), 
member 18 antisense 
PGAM5 -2.933 192111 phosphoglycerate mutase family member 5 
POLR2B -2.9059 5431 polymerase (RNA) II (DNA directed) polypeptide B, 
140kDa 
MPV17L2 -2.8822 84769 MPV17 mitochondrial membrane protein-like 2 
CNTRL -2.8675 11064 centriolin 
ACSM3 -2.7645 6296 acyl-CoA synthetase medium-chain family member 3 
GREB1 -2.7446 9687 growth regulation by estrogen in breast cancer 1 
POLR2E -2.7021 5434 polymerase (RNA) II (DNA directed) polypeptide E, 
25kDa 
MED21 -2.6844 9412 mediator complex subunit 21 
VGLL2 -2.6539 245806 vestigial like 2 (Drosophila) 
LINC00652 -2.6432 29075 long intergenic non-protein coding RNA 652 
SF3B1 -2.6389 23451 splicing factor 3b, subunit 1, 155kDa 
SH3BP5L -2.6267 80851 SH3-binding domain protein 5-like 
SLC24A1 -2.6241 9187 solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 1 
SYNE4 -2.6114 163183 spectrin repeat containing, nuclear envelope family 
member 4 
SF3B2 -2.5996 10992 splicing factor 3b, subunit 2, 145kDa 
GGT7 -2.5881 2686 gamma-glutamyltransferase 7 
ZNF157 -2.5813 7712 zinc finger protein 157 
EEF1A2 -2.569 1917 eukaryotic translation elongation factor 1 alpha 2 
RMND5B -2.5303 64777 required for meiotic nuclear division 5 homolog B (S. 
cerevisiae) 
RBM25 -2.5074 58517 RNA binding motif protein 25 
SLC13A2 -2.5056 9058 solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 2 
NTN1 -2.496 9423 netrin 1 
BUD31 -2.4837 8896 BUD31 homolog (S. cerevisiae) 
ZNF205 -2.4826 7755 zinc finger protein 205 
GTF3C4 -2.4821 9329 general transcription factor IIIC, polypeptide 4, 90kDa 
KCTD18 -2.4668 130535 potassium channel tetramerization domain containing 
18 
HK2 -2.4252 3099 hexokinase 2 
POLR2H -2.4224 5437 polymerase (RNA) II (DNA directed) polypeptide H 
ANXA13 -2.4188 312 annexin A13 
POLR2I -2.4173 5438 polymerase (RNA) II (DNA directed) polypeptide I, 
14.5kDa 
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OfficialSymbol Z-Score LocusLink NCBI-Official Full Name 
SSPN -2.4089 8082 sarcospan 
ZNF599 -2.4022 148103 zinc finger protein 599 
BCAS2 -2.385 10286 breast carcinoma amplified sequence 2 
TMEM97 -2.385 27346 transmembrane protein 97 
MED14 -2.3846 9282 mediator complex subunit 14 
MZB1 -2.3711 51237 marginal zone B and B1 cell-specific protein 
ST3GAL1 -2.3705 6482 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
POLR2A -2.3677 5430 polymerase (RNA) II (DNA directed) polypeptide A, 
220kDa 
IRF7 -2.3629 3665 interferon regulatory factor 7 
SEC13 -2.3575 6396 SEC13 homolog (S. cerevisiae) 
MYL3 -2.3574 4634 myosin, light chain 3, alkali; ventricular, skeletal, slow 
SMAD4 -2.354 4089 SMAD family member 4 
TMEM246 -2.3492 84302 transmembrane protein 246 
PLEKHA5 -2.3482 54477 pleckstrin homology domain containing, family A 
member 5 
KRT40 -2.348 125115 keratin 40 
CAMKMT -2.3474 79823 calmodulin-lysine N-methyltransferase 
SERP1 -2.3398 27230 stress-associated endoplasmic reticulum protein 1 
POMP -2.3384 51371 proteasome maturation protein 
POLR2K -2.3372 5440 polymerase (RNA) II (DNA directed) polypeptide K, 
7.0kDa 
THOP1 -2.3269 7064 thimet oligopeptidase 1 
PTMS -2.3254 5763 parathymosin 
SESN1 -2.3141 27244 sestrin 1 
POLR2C -2.3116 5432 polymerase (RNA) II (DNA directed) polypeptide C, 
33kDa 
KIAA2013 -2.3047 90231 KIAA2013 
TPGS1 -2.3011 91978 tubulin polyglutamylase complex subunit 1 
KIAA1109 -2.2765 84162 KIAA1109 
PDZD4 -2.2734 57595 PDZ domain containing 4 
SPRR2B -2.2686 6701 small proline-rich protein 2B 
PCNX -2.2547 22990 pecanex homolog (Drosophila) 
EFNB1 -2.2482 1947 ephrin-B1 
PELI1 -2.245 57162 pellino E3 ubiquitin protein ligase 1 
ADAM20 -2.2408 8748 ADAM metallopeptidase domain 20 
LEPREL1 -2.2333 55214 leprecan-like 1 
C16orf67 -2.2324 79014 chromosome 16 open reading frame 67 
TMEM144 -2.2241 55314 transmembrane protein 144 
WDR53 -2.2238 348793 WD repeat domain 53 
C19orf48 -2.218 84798 chromosome 19 open reading frame 48 
POLR2D -2.2174 5433 polymerase (RNA) II (DNA directed) polypeptide D 
CREBBP -2.2101 1387 CREB binding protein 
CCDC108 -2.209 255101 coiled-coil domain containing 108 
LOC200213 -2.206 200213 hypothetical protein LOC200213 
KIF19 -2.1759 124602 kinesin family member 19 
PSME4 -2.1666 23198 proteasome (prosome, macropain) activator subunit 4 
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OfficialSymbol Z-Score LocusLink NCBI-Official Full Name 
KLRF1 -2.1604 51348 killer cell lectin-like receptor subfamily F, member 1 
MGAT5B -2.1569 146664 mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, isozyme B 
ILF3 -2.1539 3609 interleukin enhancer binding factor 3, 90kDa 
MAEL -2.1528 84944 maelstrom spermatogenic transposon silencer 
MYF6 -2.1511 4618 myogenic factor 6 (herculin) 
CDH15 -2.1499 1013 cadherin 15, type 1, M-cadherin (myotubule) 
C1orf51 -2.1411 148523 chromosome 1 open reading frame 51 
RPL23 -2.1399 9349 ribosomal protein L23 
SLC25A25 -2.1363 114789 solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 25 
C16orf71 -2.1279 146562 chromosome 16 open reading frame 71 
NME7 -2.1256 29922 NME/NM23 family member 7 
SLC39A14 -2.1249 23516 solute carrier family 39 (zinc transporter), member 14 
PSMC4 -2.1211 5704 proteasome (prosome, macropain) 26S subunit, 
ATPase, 4 
LOC257396 -2.1165 257396 uncharacterized LOC257396 
FAM167B -2.1159 84734 family with sequence similarity 167, member B 
NUDT14 -2.113 256281 nudix (nucleoside diphosphate linked moiety X)-type 
motif 14 
SEMA3A -2.1126 10371 sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3A 
CD68 -2.1069 968 CD68 molecule 
POLR2L -2.1005 5441 polymerase (RNA) II (DNA directed) polypeptide L, 
7.6kDa 
XAGE2 -2.0994 9502 X antigen family, member 2 
TMED1 -2.0991 11018 transmembrane emp24 protein transport domain 
containing 1 
NFIX -2.0985 4784 nuclear factor I/X (CCAAT-binding transcription factor) 
NEK6 -2.0961 10783 NIMA-related kinase 6 
POLB -2.0955 5423 polymerase (DNA directed), beta 
ICAM1 -2.0947 3383 intercellular adhesion molecule 1 
PTRH2 -2.0895 51651 peptidyl-tRNA hydrolase 2 
RRP15 -2.0862 51018 ribosomal RNA processing 15 homolog (S. cerevisiae) 
SEMG1 -2.0832 6406 semenogelin I 
C11orf40 -2.081 143501 chromosome 11 open reading frame 40 
FKSG83 -2.0802 83954 FKSG83 
OSBPL6 -2.0782 114880 oxysterol binding protein-like 6 
IKBIP -2.0757 121457 IKBKB interacting protein 
RRAGB -2.0743 10325 Ras-related GTP binding B 
POLL -2.0728 27343 polymerase (DNA directed), lambda 
NCKAP1 -2.0723 10787 NCK-associated protein 1 
RAN -2.0703 5901 RAN, member RAS oncogene family 
SCARB2 -2.0656 950 scavenger receptor class B, member 2 
RIIAD1 -2.0597 284485 regulatory subunit of type II PKA R-subunit (RIIa) 
domain containing 1 
GDPD2 -2.059 54857 glycerophosphodiester phosphodiesterase domain 
containing 2 
DIRAS2 -2.0587 54769 DIRAS family, GTP-binding RAS-like 2 
12 Appendix 
190 
OfficialSymbol Z-Score LocusLink NCBI-Official Full Name 
RHOH -2.0546 399 ras homolog family member H 
TMEM256 -2.0533 254863 transmembrane protein 256 
ZNF304 -2.048 57343 zinc finger protein 304 
MS4A6E -2.0464 245802 membrane-spanning 4-domains, subfamily A, member 
6E 
ELOVL3 -2.0415 83401 ELOVL fatty acid elongase 3 
LOC129020 -2.0401 129020 hypothetical protein similar to topoisomerase (DNA) III 
beta (H. sapiens) 
ZZEF1 -2.0386 23140 zinc finger, ZZ-type with EF-hand domain 1 
RARRES1 -2.0363 5918 retinoic acid receptor responder (tazarotene induced) 1 
XKR8 -2.0333 55113 XK, Kell blood group complex subunit-related family, 
member 8 
ZNF2 -2.0315 7549 zinc finger protein 2 
KPNB1 -2.027 3837 karyopherin (importin) beta 1 
YWHAEP7 -2.0268 284100 tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon 
pseudogene 7 
PDAP1 -2.0237 11333 PDGFA associated protein 1 
RRAS -2.0165 6237 related RAS viral (r-ras) oncogene homolog 
LRRC4B -2.014 94030 leucine rich repeat containing 4B 
ZNF700 -2.0137 90592 zinc finger protein 700 
NPEPPS -2.0122 9520 aminopeptidase puromycin sensitive 
DDOST -2.0117 1650 dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit (non-catalytic) 
POF1B -2.0086 79983 premature ovarian failure, 1B 
MED31 -2.0078 51003 mediator complex subunit 31 
CMC1 -2.0078 152100 C-x(9)-C motif containing 1 
ACD -2.0051 65057 adrenocortical dysplasia homolog (mouse) 
DNAJB12 -2.0031 54788 DnaJ (Hsp40) homolog, subfamily B, member 12 
ZSCAN10 -2.0029 84891 zinc finger and SCAN domain containing 10 
NXF1 -2.0028 10482 nuclear RNA export factor 1 
SLC12A1 -2 6557 solute carrier family 12 (sodium/potassium/chloride 
transporter), member 1 
ENTPD8 2.0014 377841 ectonucleoside triphosphate diphosphohydrolase 8 
TTC28 2.0027 23331 tetratricopeptide repeat domain 28 
RUNX1T1 2.0046 862 runt-related transcription factor 1; translocated to, 1 
(cyclin D-related) 
NFKBIE 2.0086 4794 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, epsilon 
C10orf88 2.0118 80007 chromosome 10 open reading frame 88 
TGOLN2 2.0121 10618 trans-golgi network protein 2 
NXF5 2.0129 55998 nuclear RNA export factor 5 
EML3 2.0144 256364 echinoderm microtubule associated protein like 3 
ZNF557 2.0154 79230 zinc finger protein 557 
SRF 2.0182 6722 serum response factor (c-fos serum response element-
binding transcription factor) 
CARF 2.0189 79800 calcium responsive transcription factor 
C12orf10 2.0194 60314 chromosome 12 open reading frame 10 
TLCD1 2.0195 116238 TLC domain containing 1 
PLSCR4 2.0209 57088 phospholipid scramblase 4 
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LAMB1 2.0226 3912 laminin, beta 1 
GOLT1A 2.0227 127845 golgi transport 1A 
PEX26 2.0241 55670 peroxisomal biogenesis factor 26 
TMC6 2.0245 11322 transmembrane channel-like 6 
CBLN1 2.0246 869 cerebellin 1 precursor 
HOXC13 2.0257 3229 homeobox C13 
C7orf62 2.0257 219557 chromosome 7 open reading frame 62 
USP22 2.0267 23326 ubiquitin specific peptidase 22 
SRRM2 2.0282 23524 serine/arginine repetitive matrix 2 
C12orf5 2.0331 57103 chromosome 12 open reading frame 5 
SLC25A29 2.0338 123096 solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine carrier), member 29 
FAM212B 2.035 55924 family with sequence similarity 212, member B 
OMP 2.0415 4975 olfactory marker protein 
ARMC12 2.0416 221481 armadillo repeat containing 12 
ZCCHC13 2.0432 389874 zinc finger, CCHC domain containing 13 
CRISPLD2 2.0465 83716 cysteine-rich secretory protein LCCL domain containing 
2 
SRD5A3 2.0482 79644 steroid 5 alpha-reductase 3 
POU6F1 2.0545 5463 POU class 6 homeobox 1 
ZYG11B 2.0549 79699 zyg-11 family member B, cell cycle regulator 
ASXL3 2.058 80816 additional sex combs like 3 (Drosophila) 
IL2RA 2.0608 3559 interleukin 2 receptor, alpha 
KCNT1 2.0632 57582 potassium channel, subfamily T, member 1 
FATE1 2.0634 89885 fetal and adult testis expressed 1 
C6orf47 2.0688 57827 chromosome 6 open reading frame 47 
LIN54 2.0704 132660 lin-54 homolog (C. elegans) 
TNIP2 2.0712 79155 TNFAIP3 interacting protein 2 
TM4SF18 2.0727 116441 transmembrane 4 L six family member 18 
TSG101 2.0733 7251 tumor susceptibility 101 
CDRT1 2.0761 374286 CMT1A duplicated region transcript 1 
ZNF543 2.0768 125919 zinc finger protein 543 
FAM129A 2.0777 116496 family with sequence similarity 129, member A 
ZNF331 2.0786 55422 zinc finger protein 331 
IFNA1 2.0815 3439 interferon, alpha 1 
LNX1 2.0818 84708 ligand of numb-protein X 1, E3 ubiquitin protein ligase 
DGCR2 2.0838 9993 DiGeorge syndrome critical region gene 2 
CFHR3 2.0838 10878 complement factor H-related 3 
INTS1 2.0838 26173 integrator complex subunit 1 
RIMKLA 2.0847 284716 ribosomal modification protein rimK-like family member 
A 
SDF4 2.088 51150 stromal cell derived factor 4 
HYAL2 2.0949 8692 hyaluronoglucosaminidase 2 
TAPBP 2.0952 6892 TAP binding protein (tapasin) 
SCGB1A1 2.0968 7356 secretoglobin, family 1A, member 1 (uteroglobin) 
C15orf41 2.0977 84529 chromosome 15 open reading frame 41 
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SGCG 2.1035 6445 sarcoglycan, gamma (35kDa dystrophin-associated 
glycoprotein) 
PPAPDC2 2.1054 403313 phosphatidic acid phosphatase type 2 domain 
containing 2 
AK9 2.1055 221264 adenylate kinase 9 
DLG1 2.1096 1739 discs, large homolog 1 (Drosophila) 
GABRA4 2.1142 2557 gamma-aminobutyric acid (GABA) A receptor, alpha 4 
DIS3L2 2.1142 129563 DIS3 mitotic control homolog (S. cerevisiae)-like 2 
UBXN8 2.1154 7993 UBX domain protein 8 
CHM 2.1158 1121 choroideremia (Rab escort protein 1) 
LY6G5C 2.119 80741 lymphocyte antigen 6 complex, locus G5C 
PCBD1 2.1206 5092 pterin-4 alpha-carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha 
CATSPERB 2.1234 79820 catsper channel auxiliary subunit beta 
ZFP36 2.1263 7538 ZFP36 ring finger protein 
MBOAT2 2.1273 129642 membrane bound O-acyltransferase domain containing 
2 
HNRNPC 2.1285 3183 heterogeneous nuclear ribonucleoprotein C (C1/C2) 
CBFA2T3 2.1292 863 core-binding factor, runt domain, alpha subunit 2; 
translocated to, 3 
SNRPE 2.1333 6635 small nuclear ribonucleoprotein polypeptide E 
BMPER 2.134 168667 BMP binding endothelial regulator 
BRCTD1 2.1342 345499 BRCT domain containing 1 
C9orf169 2.1372 375791 chromosome 9 open reading frame 169 
TMEM184C 2.1432 55751 transmembrane protein 184C 
YEATS4 2.1445 8089 YEATS domain containing 4 
KAT6B 2.1472 23522 K(lysine) acetyltransferase 6B 
ZNF415 2.148 55786 zinc finger protein 415 
KIAA1715 2.1511 80856 KIAA1715 
PAK1 2.1518 5058 p21 protein (Cdc42/Rac)-activated kinase 1 
LOC257054 2.152 257054 similar to D-2-hydroxyglutarate dehydrogenase 
REV1 2.1533 51455 REV1, polymerase (DNA directed) 
ADAM32 2.1539 203102 ADAM metallopeptidase domain 32 
MGC18216 2.1601 145815 hypothetical protein MGC18216 
SNCA 2.1632 6622 synuclein, alpha (non A4 component of amyloid 
precursor) 
NAP1L2 2.1649 4674 nucleosome assembly protein 1-like 2 
ADAMTS5 2.1651 11096 ADAM metallopeptidase with thrombospondin type 1 
motif, 5 
SYT1 2.1659 6857 synaptotagmin I 
APP 2.1673 351 amyloid beta (A4) precursor protein 
SAFB 2.168 6294 scaffold attachment factor B 
LMOD1 2.168 25802 leiomodin 1 (smooth muscle) 
TNNT3 2.1699 7140 troponin T type 3 (skeletal, fast) 
SLC25A15 2.1722 10166 solute carrier family 25 (mitochondrial carrier; ornithine 
transporter) member 15 
MS4A2 2.1732 2206 membrane-spanning 4-domains, subfamily A, member 
2 
ADCK4 2.1775 79934 aarF domain containing kinase 4 
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EXOSC3 2.1786 51010 exosome component 3 
SMG6 2.1793 23293 SMG6 nonsense mediated mRNA decay factor 
HSPC047 2.1794 29060 HSPC047 protein 
OR2C1 2.1798 4993 olfactory receptor, family 2, subfamily C, member 1 
LINC00323 2.1833 284835 long intergenic non-protein coding RNA 323 
N4BP1 2.1834 9683 NEDD4 binding protein 1 
SNUPN 2.1861 10073 snurportin 1 
METTL21A 2.1884 151194 methyltransferase like 21A 
TMEM9B 2.1887 56674 TMEM9 domain family, member B 
HNRNPL 2.1888 3191 heterogeneous nuclear ribonucleoprotein L 
USP45 2.1916 85015 ubiquitin specific peptidase 45 
CIDEA 2.1949 1149 cell death-inducing DFFA-like effector a 
ZC3H10 2.1962 84872 zinc finger CCCH-type containing 10 
CCSER2 2.197 54462 coiled-coil serine-rich protein 2 
ZNF830 2.2 91603 zinc finger protein 830 
MILR1 2.2036 284021 mast cell immunoglobulin-like receptor 1 
KCNE3 2.204 10008 potassium voltage-gated channel, Isk-related family, 
member 3 
MAP2 2.2052 4133 microtubule-associated protein 2 
SAGE1 2.2064 55511 sarcoma antigen 1 
FLJ31821 2.2064 146268 hypothetical protein FLJ31821 
APCS 2.2075 325 amyloid P component, serum 
RABGAP1L 2.2081 9910 RAB GTPase activating protein 1-like 
C1orf74 2.2095 148304 chromosome 1 open reading frame 74 
DUSP15 2.2129 128853 dual specificity phosphatase 15 
ARID5B 2.2132 84159 AT rich interactive domain 5B (MRF1-like) 
F8A1 2.215 8263 coagulation factor VIII-associated 1 
BEND5 2.2171 79656 BEN domain containing 5 
CCNG2 2.2206 901 cyclin G2 
PRPF38A 2.2208 84950 pre-mRNA processing factor 38A 
BCO2 2.2225 83875 beta-carotene oxygenase 2 
KIAA1456 2.2231 57604 KIAA1456 
FLNB 2.2259 2317 filamin B, beta 
PPRC1 2.2286 23082 peroxisome proliferator-activated receptor gamma, 
coactivator-related 1 
MADCAM1 2.2327 8174 mucosal vascular addressin cell adhesion molecule 1 
GDF9 2.2337 2661 growth differentiation factor 9 
FAF1 2.2349 11124 Fas (TNFRSF6) associated factor 1 
MRPS34 2.2351 65993 mitochondrial ribosomal protein S34 
FBXO22 2.2365 26263 F-box protein 22 
MMP10 2.2384 4319 matrix metallopeptidase 10 (stromelysin 2) 
PCDH12 2.2407 51294 protocadherin 12 
NDUFS4 2.2548 4724 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 
18kDa (NADH-coenzyme Q reductase) 
PXK 2.2556 54899 PX domain containing serine/threonine kinase 
DES 2.256 1674 desmin 
C6orf57 2.2582 135154 chromosome 6 open reading frame 57 
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PAF1 2.259 54623 Paf1, RNA polymerase II associated factor, homolog 
(S. cerevisiae) 
TCP11 2.2619 6954 t-complex 11, testis-specific 
NR6A1 2.2625 2649 nuclear receptor subfamily 6, group A, member 1 
CBX6 2.2635 23466 chromobox homolog 6 
SLC9A6 2.2662 10479 solute carrier family 9, subfamily A (NHE6, cation 
proton antiporter 6), member 6 
RLTPR 2.2708 146206 RGD motif, leucine rich repeats, tropomodulin domain 
and proline-rich containing 
USP5 2.2722 8078 ubiquitin specific peptidase 5 (isopeptidase T) 
UGGT2 2.2751 55757 UDP-glucose glycoprotein glucosyltransferase 2 
GAS2L1 2.2763 10634 growth arrest-specific 2 like 1 
SLC25A23 2.2776 79085 solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 23 
KIAA1644 2.2776 85352 KIAA1644 
CERS1 2.2832 10715 ceramide synthase 1 
CCBL1 2.2865 883 cysteine conjugate-beta lyase, cytoplasmic 
C4orf17 2.2928 84103 chromosome 4 open reading frame 17 
FLJ32154 2.2947 149650 uncharacterized protein FLJ32154 
SDE2 2.2952 163859 SDE2 telomere maintenance homolog (S. pombe) 
KIAA0492 2.2998 57238 KIAA0492 protein 
BEX1 2.3004 55859 brain expressed, X-linked 1 
TGIF2LX 2.3004 90316 TGFB-induced factor homeobox 2-like, X-linked 
ATP8A2 2.3025 51761 ATPase, aminophospholipid transporter, class I, type 
8A, member 2 
NUDT10 2.3025 170685 nudix (nucleoside diphosphate linked moiety X)-type 
motif 10 
MACF1 2.3034 23499 microtubule-actin crosslinking factor 1 
STXBP4 2.3045 252983 syntaxin binding protein 4 
CXXC1 2.3053 30827 CXXC finger protein 1 
KCNQ2 2.3054 3785 potassium voltage-gated channel, KQT-like subfamily, 
member 2 
NAA38 2.3146 51691 N(alpha)-acetyltransferase 38, NatC auxiliary subunit 
UTS2 2.3165 10911 urotensin 2 
FOXP2 2.3174 93986 forkhead box P2 
SHMT1 2.3182 6470 serine hydroxymethyltransferase 1 (soluble) 
DANCR 2.3221 57291 differentiation antagonizing non-protein coding RNA 
SLC25A22 2.3228 79751 solute carrier family 25 (mitochondrial carrier: 
glutamate), member 22 
CALU 2.3231 813 calumenin 
C3orf52 2.3248 79669 chromosome 3 open reading frame 52 
CITED2 2.3255 10370 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
LMCD1 2.3286 29995 LIM and cysteine-rich domains 1 
TMEM120A 2.3307 83862 transmembrane protein 120A 
TCF7 2.3338 6932 transcription factor 7 (T-cell specific, HMG-box) 
GALNTL5 2.3381 168391 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 5 
PANX2 2.3384 56666 pannexin 2 
PRDX4 2.3386 10549 peroxiredoxin 4 
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RFESD 2.3403 317671 Rieske (Fe-S) domain containing 
FAM65B 2.3427 9750 family with sequence similarity 65, member B 
GCDH 2.3437 2639 glutaryl-CoA dehydrogenase 
RNF41 2.3467 10193 ring finger protein 41 
GCNT2 2.3492 2651 glucosaminyl (N-acetyl) transferase 2, I-branching 
enzyme (I blood group) 
DENND5A 2.3547 23258 DENN/MADD domain containing 5A 
ELMO3 2.3566 79767 engulfment and cell motility 3 
EMC1 2.3595 23065 ER membrane protein complex subunit 1 
PCID2 2.3637 55795 PCI domain containing 2 
MEF2D 2.3742 4209 myocyte enhancer factor 2D 
RHPN1-AS1 2.3762 78998 RHPN1 antisense RNA 1 (head to head) 
SYCP3 2.3774 50511 synaptonemal complex protein 3 
DZIP3 2.3778 9666 DAZ interacting zinc finger protein 3 
BIRC5 2.3787 332 baculoviral IAP repeat containing 5 
FAM73A 2.3794 374986 family with sequence similarity 73, member A 
IL17A 2.383 3605 interleukin 17A 
PCYT1A 2.3882 5130 phosphate cytidylyltransferase 1, choline, alpha 
ARL6IP4 2.3968 51329 ADP-ribosylation-like factor 6 interacting protein 4 
CSRP2 2.3992 1466 cysteine and glycine-rich protein 2 
SCAND2P 2.4068 54581 SCAN domain containing 2 pseudogene 
PFN4 2.4088 375189 profilin family, member 4 
MTMR6 2.4129 9107 myotubularin related protein 6 
NEDD4L 2.4129 23327 neural precursor cell expressed, developmentally 
down-regulated 4-like, E3 ubiquitin protein ligase 
ANXA9 2.4149 8416 annexin A9 
DHRS1 2.4151 115817 dehydrogenase/reductase (SDR family) member 1 
CTTNBP2NL 2.4157 55917 CTTNBP2 N-terminal like 
ZFP2 2.4157 80108 ZFP2 zinc finger protein 
MCM2 2.4175 4171 minichromosome maintenance complex component 2 
SMC5 2.4228 23137 structural maintenance of chromosomes 5 
NDUFAF7 2.4231 55471 NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 7 
UPRT 2.4259 139596 uracil phosphoribosyltransferase (FUR1) homolog (S. 
cerevisiae) 
ZNF593 2.427 51042 zinc finger protein 593 
SENP3 2.4275 26168 SUMO1/sentrin/SMT3 specific peptidase 3 
MAGEH1 2.4314 28986 melanoma antigen family H, 1 
LOC113230 2.4322 113230 uncharacterized LOC113230 
LNX2 2.4325 222484 ligand of numb-protein X 2 
STARD3 2.4335 10948 StAR-related lipid transfer (START) domain containing 
3 
PRDX5 2.4355 25824 peroxiredoxin 5 
LINC00342 2.4371 150759 long intergenic non-protein coding RNA 342 
GP6 2.4386 51206 glycoprotein VI (platelet) 
TRRAP 2.4388 8295 transformation/transcription domain-associated protein 
LZTS1 2.4396 11178 leucine zipper, putative tumor suppressor 1 
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SLC25A14 2.4484 9016 solute carrier family 25 (mitochondrial carrier, brain), 
member 14 
DEPDC7 2.451 91614 DEP domain containing 7 
REXO1 2.4529 57455 REX1, RNA exonuclease 1 homolog (S. cerevisiae) 
SLC25A46 2.4611 91137 solute carrier family 25, member 46 
GABPA 2.4668 2551 GA binding protein transcription factor, alpha subunit 
60kDa 
KY 2.4715 339855 kyphoscoliosis peptidase 
AP2A2 2.4722 161 adaptor-related protein complex 2, alpha 2 subunit 
ANXA5 2.4742 308 annexin A5 
KIAA1731 2.4745 85459 KIAA1731 
LINC00310 2.4773 114036 long intergenic non-protein coding RNA 310 
ARHGEF39 2.4796 84904 Rho guanine nucleotide exchange factor (GEF) 39 
CAMSAP2 2.483 23271 calmodulin regulated spectrin-associated protein 
family, member 2 
A1BG 2.4844 1 alpha-1-B glycoprotein 
ZNF321P 2.489 399669 zinc finger protein 321, pseudogene 
PAQR8 2.4907 85315 progestin and adipoQ receptor family member VIII 
TMEM121 2.4998 80757 transmembrane protein 121 
NT5DC3 2.5001 51559 5'-nucleotidase domain containing 3 
MGC45922 2.5008 284365 uncharacterized LOC284365 
INCENP 2.5077 3619 inner centromere protein antigens 135/155kDa 
SLC25A3 2.5095 5250 solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 3 
NFKBIA 2.5114 4792 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 
RNF183 2.512 138065 ring finger protein 183 
FSCN3 2.5124 29999 fascin homolog 3, actin-bundling protein, testicular 
(Strongylocentrotus purpuratus) 
TNFRSF10C 2.5136 8794 tumor necrosis factor receptor superfamily, member 
10c, decoy without an intracellular domain 
LARP4B 2.5172 23185 La ribonucleoprotein domain family, member 4B 
NMI 2.5205 9111 N-myc (and STAT) interactor 
CAPN2 2.5252 824 calpain 2, (m/II) large subunit 
EXOSC8 2.5265 11340 exosome component 8 
TRIM5 2.5268 85363 tripartite motif containing 5 
USP39 2.5295 10713 ubiquitin specific peptidase 39 
SAMD1 2.5317 90378 sterile alpha motif domain containing 1 
LRRC9 2.5325 341883 leucine rich repeat containing 9 
MGAT4B 2.5349 11282 mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 
SLC19A2 2.5366 10560 solute carrier family 19 (thiamine transporter), member 
2 
BBOX1 2.5376 8424 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 
(gamma-butyrobetaine hydroxylase) 1 
SERINC2 2.5406 347735 serine incorporator 2 
LPXN 2.5505 9404 leupaxin 
FIGNL1 2.5519 63979 fidgetin-like 1 
ZNF259 2.5524 8882 zinc finger protein 259 
WDR5B 2.5526 54554 WD repeat domain 5B 
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DNAH3 2.5529 55567 dynein, axonemal, heavy chain 3 
LRP12 2.5568 29967 low density lipoprotein receptor-related protein 12 
TMEM184A 2.5577 202915 transmembrane protein 184A 
CLDN11 2.5617 5010 claudin 11 
NUS1 2.566 116150 nuclear undecaprenyl pyrophosphate synthase 1 
homolog (S. cerevisiae) 
PHLDB3 2.5701 284345 pleckstrin homology-like domain, family B, member 3 
CCNYL1 2.5722 151195 cyclin Y-like 1 
EPS8L3 2.5798 79574 EPS8-like 3 
DDX39A 2.58 10212 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 
USP29 2.5858 57663 ubiquitin specific peptidase 29 
INHBE 2.5866 83729 inhibin, beta E 
SEMA5B 2.5968 54437 sema domain, seven thrombospondin repeats (type 1 
and type 1-like), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 5B 
TSPAN4 2.5979 7106 tetraspanin 4 
SAMD3 2.5995 154075 sterile alpha motif domain containing 3 
CTTN 2.6018 2017 cortactin 
LSP1 2.6031 4046 lymphocyte-specific protein 1 
ZNF383 2.6071 163087 zinc finger protein 383 
RWDD4 2.6148 201965 RWD domain containing 4 
GAL 2.6289 51083 galanin/GMAP prepropeptide 
SAP18 2.6355 10284 Sin3A-associated protein, 18kDa 
TFEB 2.6366 7942 transcription factor EB 
GYPB 2.6404 2994 glycophorin B (MNS blood group) 
ANO6 2.6448 196527 anoctamin 6 
VCAM1 2.6462 7412 vascular cell adhesion molecule 1 
SLC35A3 2.6462 23443 solute carrier family 35 (UDP-N-acetylglucosamine 
(UDP-GlcNAc) transporter), member A3 
FAHD2B 2.6464 151313 fumarylacetoacetate hydrolase domain containing 2B 
STX11 2.6491 8676 syntaxin 11 
KIF20A 2.6537 10112 kinesin family member 20A 
PPP6R2 2.6561 9701 protein phosphatase 6, regulatory subunit 2 
SACS 2.6562 26278 spastic ataxia of Charlevoix-Saguenay (sacsin) 
DICER1 2.6584 23405 dicer 1, ribonuclease type III 
ANKRD31 2.6585 256006 ankyrin repeat domain 31 
IKZF2 2.662 22807 IKAROS family zinc finger 2 (Helios) 
TRAIP 2.6681 10293 TRAF interacting protein 
HMGB2 2.67 3148 high mobility group box 2 
STX12 2.6742 23673 syntaxin 12 
TAMM41 2.6774 132001 TAM41, mitochondrial translocator assembly and 
maintenance protein, homolog (S. cerevisiae) 
IRS1 2.6796 3667 insulin receptor substrate 1 
ZSWIM1 2.6819 90204 zinc finger, SWIM-type containing 1 
ATOX1 2.685 475 antioxidant 1 copper chaperone 
MAMDC4 2.6883 158056 MAM domain containing 4 
MTSS1 2.6958 9788 metastasis suppressor 1 
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NCR3 2.7002 259197 natural cytotoxicity triggering receptor 3 
E4F1 2.7053 1877 E4F transcription factor 1 
NLE1 2.7073 54475 notchless homolog 1 (Drosophila) 
KLF4 2.7084 9314 Kruppel-like factor 4 (gut) 
UBE2E1 2.7088 7324 ubiquitin-conjugating enzyme E2E 1 
UBL4A 2.7123 8266 ubiquitin-like 4A 
PDGFA 2.7181 5154 platelet-derived growth factor alpha polypeptide 
SEC31B 2.7198 25956 SEC31 homolog B (S. cerevisiae) 
SLC47A2 2.7206 146802 solute carrier family 47 (multidrug and toxin extrusion), 
member 2 
EIF1AX 2.7209 1964 eukaryotic translation initiation factor 1A, X-linked 
CACNG2 2.7279 10369 calcium channel, voltage-dependent, gamma subunit 2 
ZC3HAV1 2.7352 56829 zinc finger CCCH-type, antiviral 1 
MRPL21 2.7403 219927 mitochondrial ribosomal protein L21 
RAPGEFL1 2.7468 51195 Rap guanine nucleotide exchange factor (GEF)-like 1 
TBRG1 2.7508 84897 transforming growth factor beta regulator 1 
CNRIP1 2.7539 25927 cannabinoid receptor interacting protein 1 
LMNA 2.7563 4000 lamin A/C 
TIMP4 2.7571 7079 TIMP metallopeptidase inhibitor 4 
DPCR1 2.7642 135656 diffuse panbronchiolitis critical region 1 
DUS1L 2.7778 64118 dihydrouridine synthase 1-like (S. cerevisiae) 
RARRES2 2.7791 5919 retinoic acid receptor responder (tazarotene induced) 2 
FAM3D 2.7804 131177 family with sequence similarity 3, member D 
C5orf17 2.7859 285685 chromosome 5 open reading frame 17 
NCF2 2.7875 4688 neutrophil cytosolic factor 2 
SIRPB1 2.7889 10326 signal-regulatory protein beta 1 
MUC3B 2.7928 57876 mucin 3B, cell surface associated 
FAM219B 2.7941 57184 family with sequence similarity 219, member B 
PRG2 2.8016 5553 proteoglycan 2, bone marrow (natural killer cell 
activator, eosinophil granule major basic protein) 
INADL 2.8032 10207 InaD-like (Drosophila) 
KIAA1549L 2.8124 25758 KIAA1549-like 
TTC3 2.8156 7267 tetratricopeptide repeat domain 3 
DMRTC1 2.8175 63947 DMRT-like family C1 
CEP55 2.8244 55165 centrosomal protein 55kDa 
SETD3 2.8281 84193 SET domain containing 3 
BCMO1 2.8322 53630 beta-carotene 15,15'-monooxygenase 1 
CYLD 2.8376 1540 cylindromatosis (turban tumor syndrome) 
RCVRN 2.8384 5957 recoverin 
PEX12 2.8414 5193 peroxisomal biogenesis factor 12 
KLK3 2.8482 354 kallikrein-related peptidase 3 
C16orf54 2.8485 283897 chromosome 16 open reading frame 54 
RASAL3 2.8519 64926 RAS protein activator like 3 
TTC27 2.8735 55622 tetratricopeptide repeat domain 27 
DMTF1 2.8782 9988 cyclin D binding myb-like transcription factor 1 
ZNF526 2.8789 116115 zinc finger protein 526 
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DCK 2.8848 1633 deoxycytidine kinase 
RIC8A 2.887 60626 RIC8 guanine nucleotide exchange factor A 
CIAO1 2.891 9391 cytosolic iron-sulfur protein assembly 1 
LOC100499484
-C9ORF174 
2.8923 57653 LOC100499484-C9orf174 readthrough 
PLIN1 2.8942 5346 perilipin 1 
WDR4 2.8973 10785 WD repeat domain 4 
ST8SIA5 2.9029 29906 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 5 
TOR2A 2.908 27433 torsin family 2, member A 
GLUD2 2.9103 2747 glutamate dehydrogenase 2 
ACO2 2.9115 50 aconitase 2, mitochondrial 
MYBL2 2.9225 4605 v-myb avian myeloblastosis viral oncogene homolog-
like 2 
FABP2 2.9235 2169 fatty acid binding protein 2, intestinal 
APIP 2.9259 51074 APAF1 interacting protein 
TMEM180 2.9331 79847 transmembrane protein 180 
TAF7L 2.9355 54457 TAF7-like RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 50kDa 
WDR89 2.9459 112840 WD repeat domain 89 
C7orf71 2.9535 285941 chromosome 7 open reading frame 71 
CABYR 2.9556 26256 calcium binding tyrosine-(Y)-phosphorylation regulated 
FNDC4 2.9563 64838 fibronectin type III domain containing 4 
KHDRBS3 2.9631 10656 KH domain containing, RNA binding, signal 
transduction associated 3 
ARHGEF7 2.9673 8874 Rho guanine nucleotide exchange factor (GEF) 7 
CREB3L3 2.9704 84699 cAMP responsive element binding protein 3-like 3 
DACT3 2.982 147906 dishevelled-binding antagonist of beta-catenin 3 
ACCS 2.9857 84680 1-aminocyclopropane-1-carboxylate synthase homolog 
(Arabidopsis)(non-functional) 
QPRT 2.9871 23475 quinolinate phosphoribosyltransferase 
SLITRK5 2.9917 26050 SLIT and NTRK-like family, member 5 
KCNIP1 2.9971 30820 Kv channel interacting protein 1 
FCGRT 3.0032 2217 Fc fragment of IgG, receptor, transporter, alpha 
KIF3B 3.0058 9371 kinesin family member 3B 
CCDC138 3.012 165055 coiled-coil domain containing 138 
SLC25A1 3.0145 6576 solute carrier family 25 (mitochondrial carrier; citrate 
transporter), member 1 
FAM216B 3.0248 144809 family with sequence similarity 216, member B 
WDR75 3.0271 84128 WD repeat domain 75 
EBLN2 3.0374 55096 endogenous Bornavirus-like nucleoprotein 2 
TSGA10IP 3.041 254187 testis specific, 10 interacting protein 
CLP1 3.0458 10978 cleavage and polyadenylation factor I subunit 1 
BLVRA 3.049 644 biliverdin reductase A 
CUL4A 3.0663 8451 cullin 4A 
LRBA 3.0702 987 LPS-responsive vesicle trafficking, beach and anchor 
containing 
KIAA0513 3.0757 9764 KIAA0513 
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RALA 3.0797 5898 v-ral simian leukemia viral oncogene homolog A (ras 
related) 
SLC25A45 3.0874 283130 solute carrier family 25, member 45 
PRO0297 3.0901 29000 PRO0297 protein 
ZNF578 3.0904 147660 zinc finger protein 578 
PACSIN2 3.0942 11252 protein kinase C and casein kinase substrate in 
neurons 2 
ABCC13 3.0987 150000 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 13, pseudogene 
SLC9B2 3.1094 133308 solute carrier family 9, subfamily B (NHA2, cation 
proton antiporter 2), member 2 
NEDD9 3.1106 4739 neural precursor cell expressed, developmentally 
down-regulated 9 
KIAA0226L 3.1123 80183 KIAA0226-like 
DCN 3.121 1634 decorin 
ATP6V1G2 3.1248 534 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit 
G2 
ARMC10 3.1394 83787 armadillo repeat containing 10 
FGFBP3 3.1427 143282 fibroblast growth factor binding protein 3 
ABO 3.1502 28 ABO blood group (transferase A, alpha 1-3-N-
acetylgalactosaminyltransferase; transferase B, alpha 
1-3-galactosyltransferase) 
UBXN6 3.1506 80700 UBX domain protein 6 
C20orf24 3.1578 55969 chromosome 20 open reading frame 24 
LRRC34 3.1586 151827 leucine rich repeat containing 34 
JSRP1 3.1591 126306 junctional sarcoplasmic reticulum protein 1 
PDCD11 3.1741 22984 programmed cell death 11 
RFTN2 3.1792 130132 raftlin family member 2 
TCTN2 3.1897 79867 tectonic family member 2 
DNASE1L3 3.1914 1776 deoxyribonuclease I-like 3 
FAM192A 3.1924 80011 family with sequence similarity 192, member A 
STAT4 3.202 6775 signal transducer and activator of transcription 4 
MMP7 3.2094 4316 matrix metallopeptidase 7 (matrilysin, uterine) 
DMKN 3.2165 93099 dermokine 
C19orf54 3.2174 284325 chromosome 19 open reading frame 54 
MBOAT7 3.2262 79143 membrane bound O-acyltransferase domain containing 
7 
WDR1 3.2412 9948 WD repeat domain 1 
USH1G 3.2433 124590 Usher syndrome 1G (autosomal recessive) 
TGIF2 3.2446 60436 TGFB-induced factor homeobox 2 
SLC30A5 3.2459 64924 solute carrier family 30 (zinc transporter), member 5 
SRL 3.2612 6345 sarcalumenin 
MRPL32 3.2795 64983 mitochondrial ribosomal protein L32 
PYCR1 3.289 5831 pyrroline-5-carboxylate reductase 1 
PHLDB1 3.2914 23187 pleckstrin homology-like domain, family B, member 1 
CFHR5 3.2959 81494 complement factor H-related 5 
SLC8B1 3.3316 80024 solute carrier family 8 (sodium/lithium/calcium 
exchanger), member B1 
OTUD7A 3.3601 161725 OTU domain containing 7A 
ZNF418 3.3632 147686 zinc finger protein 418 
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DAZL 3.366 1618 deleted in azoospermia-like 
MMP12 3.3677 4321 matrix metallopeptidase 12 (macrophage elastase) 
GTF3A 3.3899 2971 general transcription factor IIIA 
TSNARE1 3.3917 203062 t-SNARE domain containing 1 
PTBP2 3.4024 58155 polypyrimidine tract binding protein 2 
ARFGAP3 3.4107 26286 ADP-ribosylation factor GTPase activating protein 3 
HELB 3.4188 92797 helicase (DNA) B 
C1orf173 3.4332 127254 chromosome 1 open reading frame 173 
PEX3 3.4424 8504 peroxisomal biogenesis factor 3 
TMEM261 3.451 90871 transmembrane protein 261 
RGPD5 3.4586 84220 RANBP2-like and GRIP domain containing 5 
CNOT11 3.4613 55571 CCR4-NOT transcription complex, subunit 11 
GH2 3.4654 2689 growth hormone 2 
GALNT14 3.4668 79623 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 
CISD3 3.4681 284106 CDGSH iron sulfur domain 3 
NDUFA5 3.4782 4698 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 5 
DSN1 3.489 79980 DSN1, MIS12 kinetochore complex component 
PEX11B 3.4946 8799 peroxisomal biogenesis factor 11 beta 
MUL1 3.5017 79594 mitochondrial E3 ubiquitin protein ligase 1 
KRT24 3.5183 192666 keratin 24 
CAMSAP1 3.5343 157922 calmodulin regulated spectrin-associated protein 1 
INTU 3.5432 27152 inturned planar cell polarity protein 
CENPO 3.5473 79172 centromere protein O 
CSRNP3 3.5501 80034 cysteine-serine-rich nuclear protein 3 
CSNK1E 3.5735 1454 casein kinase 1, epsilon 
PUS7L 3.5768 83448 pseudouridylate synthase 7 homolog (S. cerevisiae)-
like 
PPP1R3B 3.5929 79660 protein phosphatase 1, regulatory subunit 3B 
SLFN12 3.5983 55106 schlafen family member 12 
MYEOV 3.5999 26579 myeloma overexpressed 
KLRC4 3.6062 8302 killer cell lectin-like receptor subfamily C, member 4 
ITGA2 3.6073 3673 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor) 
ZNF473 3.6115 25888 zinc finger protein 473 
PRPF31 3.6131 26121 pre-mRNA processing factor 31 
NRIP3 3.6247 56675 nuclear receptor interacting protein 3 
COMMD5 3.6276 28991 COMM domain containing 5 
KIAA1239 3.6362 57495 KIAA1239 
GALM 3.6366 130589 galactose mutarotase (aldose 1-epimerase) 
KRI1 3.6472 65095 KRI1 homolog (S. cerevisiae) 
S100A7A 3.6549 338324 S100 calcium binding protein A7A 
KRT86 3.6612 3892 keratin 86 
HEATR4 3.6952 399671 HEAT repeat containing 4 
HSPA2 3.6964 3306 heat shock 70kDa protein 2 
ZNF11B 3.6964 7558 zinc finger protein 11B 
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FAM178B 3.7261 51252 family with sequence similarity 178, member B 
YIPF1 3.7402 54432 Yip1 domain family, member 1 
ASPRV1 3.7537 151516 aspartic peptidase, retroviral-like 1 
C14orf178 3.7782 283579 chromosome 14 open reading frame 178 
MMP23B 3.8209 8510 matrix metallopeptidase 23B 
NANS 3.8261 54187 N-acetylneuraminic acid synthase 
TOB1 3.85 10140 transducer of ERBB2, 1 
FIBIN 3.8696 387758 fin bud initiation factor homolog (zebrafish) 
TMEM86A 3.9272 144110 transmembrane protein 86A 
GAS2L2 3.9373 246176 growth arrest-specific 2 like 2 
RLBP1 3.9969 6017 retinaldehyde binding protein 1 
CYP2C9 4.034 1559 cytochrome P450, family 2, subfamily C, polypeptide 9 
FAM200B 4.0377 285550 family with sequence similarity 200, member B 
SYNE1 4.0379 23345 spectrin repeat containing, nuclear envelope 1 
CORO1B 4.039 57175 coronin, actin binding protein, 1B 
WDR47 4.0722 22911 WD repeat domain 47 
C2orf48 4.077 348738 chromosome 2 open reading frame 48 
ETV7 4.0865 51513 ets variant 7 
KIF3C 4.0909 3797 kinesin family member 3C 
PLOD1 4.0922 5351 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 
ATP2A1 4.1042 487 ATPase, Ca++ transporting, cardiac muscle, fast twitch 
1 
ZNF253 4.1083 56242 zinc finger protein 253 
PEX19 4.1134 5824 peroxisomal biogenesis factor 19 
SCN11A 4.1307 11280 sodium channel, voltage-gated, type XI, alpha subunit 
KLHDC10 4.1618 23008 kelch domain containing 10 
PGAP3 4.1642 93210 post-GPI attachment to proteins 3 
RUVBL2 4.1801 10856 RuvB-like AAA ATPase 2 
C14orf119 4.1862 55017 chromosome 14 open reading frame 119 
SH2B3 4.2096 10019 SH2B adaptor protein 3 
SMYD2 4.2379 56950 SET and MYND domain containing 2 
EDDM3A 4.2572 10876 epididymal protein 3A 
ST3GAL4 4.2852 6484 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
HSPB2 4.2885 3316 heat shock 27kDa protein 2 
WNK2 4.3026 65268 WNK lysine deficient protein kinase 2 
KCNJ8 4.3405 3764 potassium inwardly-rectifying channel, subfamily J, 
member 8 
MEG3 4.3407 55384 maternally expressed 3 (non-protein coding) 
ST6GAL2 4.3672 84620 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 
PREB 4.3798 10113 prolactin regulatory element binding 
C1orf131 4.3955 128061 chromosome 1 open reading frame 131 
COMMD3 4.4093 23412 COMM domain containing 3 
MSH6 4.4118 2956 mutS homolog 6 
KCNK13 4.4143 56659 potassium channel, subfamily K, member 13 
NELFCD 4.4289 51497 negative elongation factor complex member C/D 
WDR17 4.4423 116966 WD repeat domain 17 
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GKN2 4.5036 200504 gastrokine 2 
PYCARD 4.5416 29108 PYD and CARD domain containing 
PPP1R21 4.5452 129285 protein phosphatase 1, regulatory subunit 21 
DCTN2 4.5876 10540 dynactin 2 (p50) 
BRD4 4.588 23476 bromodomain containing 4 
KCNQ1DN 4.6621 55539 KCNQ1 downstream neighbor (non-protein coding) 
RRN3 4.6878 54700 RRN3 RNA polymerase I transcription factor homolog 
(S. cerevisiae) 
FAM120B 4.7001 84498 family with sequence similarity 120B 
ZC3H13 4.708 23091 zinc finger CCCH-type containing 13 
ZDHHC2 4.7192 51201 zinc finger, DHHC-type containing 2 
DMRTB1 4.7524 63948 DMRT-like family B with proline-rich C-terminal, 1 
NAA15 4.7604 80155 N(alpha)-acetyltransferase 15, NatA auxiliary subunit 
MMP26 4.7838 56547 matrix metallopeptidase 26 
UTP6 4.8308 55813 UTP6, small subunit (SSU) processome component, 
homolog (yeast) 
LOC285733 4.8759 285733 hypothetical LOC285733 
CRYBB2 4.8773 1415 crystallin, beta B2 
ANPEP 4.943 290 alanyl (membrane) aminopeptidase 
SLC22A18 4.951 5002 solute carrier family 22, member 18 
NCSTN 4.9557 23385 nicastrin 
TMEM125 5.025 128218 transmembrane protein 125 
SNTA1 5.0916 6640 syntrophin, alpha 1 
TNP1 5.1668 7141 transition protein 1 (during histone to protamine 
replacement) 
RBM6 5.2019 10180 RNA binding motif protein 6 
ITPKB 5.3147 3707 inositol-trisphosphate 3-kinase B 
MDH2 5.3526 4191 malate dehydrogenase 2, NAD (mitochondrial) 
PRKRIR 5.3715 5612 protein-kinase, interferon-inducible double stranded 
RNA dependent inhibitor, repressor of (P58 repressor) 
TOX3 5.5324 27324 TOX high mobility group box family member 3 
ZNF256 5.5416 10172 zinc finger protein 256 
COL6A5 5.6382 256076 collagen, type VI, alpha 5 
OVOL2 5.6559 58495 ovo-like zinc finger 2 
VWC2 5.6948 375567 von Willebrand factor C domain containing 2 
CMTM4 5.8988 146223 CKLF-like MARVEL transmembrane domain containing 
4 
WWC1 5.9123 23286 WW and C2 domain containing 1 
MESP1 6.1065 55897 mesoderm posterior 1 homolog (mouse) 
ATF7IP2 6.1733 80063 activating transcription factor 7 interacting protein 2 
EFCAB5 6.3777 374786 EF-hand calcium binding domain 5 
THSD7B 6.4392 80731 thrombospondin, type I, domain containing 7B 
ANTXR2 6.4397 118429 anthrax toxin receptor 2 
MDGA1 6.4535 266727 MAM domain containing glycosylphosphatidylinositol     
anchor 1 
TUG1 6.8214 55000 taurine up-regulated 1 (non-protein coding) 
ND3 6.906 4537 NADH dehydrogenase, subunit 3 (complex I) 
GOLGA2P5 7.837 55592 golgin A2 pseudogene 5 
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DNAJC12 8.2913 56521 DnaJ (Hsp40) homolog, subfamily C, member 12 
SUSD1 9.5587 64420 sushi domain containing 1 
HYOU1 14.1959 10525 hypoxia up-regulated 1 
 
  
  
 
